An exploration of the factors that associate with psychological outcomes in chronic illness and Inflammatory Bowel Disease populations

By: Katie Boden

A thesis submitted in partial fulfilment of the requirements for the Doctorate in Clinical Psychology

Faculty of Science
Clinical Psychology Unit, Department of Psychology
The University of Sheffield

Submission date: June 2020
This page is intentionally left blank
This form must be completed and returned to Research Services prior to the award of your degree

**SECTION 1: STUDENT DETAILS**

<table>
<thead>
<tr>
<th>Family Name</th>
<th>Boden</th>
<th>First Name</th>
<th>Katie</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration Number</td>
<td>150.17</td>
<td>Department</td>
<td>Clinical Psychology</td>
</tr>
<tr>
<td>Thesis Title</td>
<td>An exploration of the factors that associate with psychological outcomes in chronic illness and Inflammatory Bowel Disease populations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SECTION 2: THESIS SUBMISSION DETAILS – PLEASE SELECT ONE OF THE FOLLOWING OPTIONS**

- [ ] I am submitting in print format only for deposit in the University Library *(Note: this option only applies to students who initially registered prior to 2008)*
- [x] I am submitting an eThesis only to the White Rose eTheses Online server. I confirm that the eThesis is a complete version of my thesis and no content has been removed
- [ ] I am submitting an eThesis to the White Rose eTheses Online server and also submitting in print format because I have removed some content from my eThesis

**SECTION 3: EMBARGO DETAILS – PLEASE SELECT FROM THE FOLLOWING OPTIONS**

Requests for embargoes that exceed 12 months will require Faculty approval. If you wish to request a longer embargo, please also complete the extended embargo request form, available at: [www.sheffield.ac.uk/rs/code/embargoes](http://www.sheffield.ac.uk/rs/code/embargoes) and return it to pgr-enquiries@sheffield.ac.uk

If no boxes are ticked, you will be deemed to have consented to your thesis being made available immediately without any embargo.

<table>
<thead>
<tr>
<th>Should the thesis be embargoed? If ‘Yes’, please specify the length of embargo requested (in years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Print Thesis (where applicable)</td>
</tr>
<tr>
<td>eThesis</td>
</tr>
</tbody>
</table>

Reason for the embargo (please select from the following options):

- [ ] Third party copyright
- [ ] Contains personal data
- [ ] Could endanger health and safety
- [x] Planned publication
- [ ] Commercial confidentiality
- [ ] Could prejudice national security
- [ ] Exempt under another category listed in the FOI Act 2000
- [ ] Other (please specify)

**SECTION 4: COPYRIGHT LICENCE OPTIONS – PLEASE SELECT ONE OF THE FOLLOWING**
This thesis is protected by the Copyright Design and Patents Act 1988. No reproduction is permitted without consent of the author. It is recommended that you make your thesis available using a Creative Commons Licence https://creativecommons.org/share-your-work/. This Licence protects you as the author of the work and also clarifies the uses that others may make of your work.

<table>
<thead>
<tr>
<th>Creative Commons Attribution-Non-Commercial-No-derivatives (recommended)</th>
<th>Creative Commons Attribution-Non-Commercial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creative Commons Attribution</td>
<td>Creative Commons Attribution-No-derivative-Works</td>
</tr>
<tr>
<td>Creative Commons Attribution-Non-Commercial-Share Alike</td>
<td>Other/Do not apply a Licence</td>
</tr>
</tbody>
</table>
### SECTION 5: THESIS DEPOSIT AGREEMENT – STUDENT

1. I, the author, confirm that the Thesis is my own work, and that where materials owned by a third party have been used, copyright clearance has been obtained. I am aware of the University’s *Guidance on the Use of Unfair Means* ([www.sheffield.ac.uk/ssid/exams/plagiarism](http://www.sheffield.ac.uk/ssid/exams/plagiarism)).

2. I confirm that all copies of the Thesis submitted to the University, whether in print or electronic format, are identical in content and correspond with the version of the Thesis upon which the examiners based their recommendation for the award of the degree (unless edited as indicated above).

3. I agree to the named Thesis being made available in accordance with the conditions specified above.

4. I give permission to the University of Sheffield to reproduce the print Thesis (where applicable) in digital format, in whole or part, in order to supply single copies for the purpose of research or private study for a non-commercial purpose. I agree that a copy of the eThesis may be supplied to the British Library for inclusion on EThOS and WREO, if the thesis is not subject to an embargo, or if the embargo has been lifted or expired.

5. I agree that the University of Sheffield’s eThesis repository (currently WREO) will make my eThesis (where applicable) available over the internet via an entirely non-exclusive agreement and that, without changing content, WREO and/or the British Library may convert my eThesis to any medium or format for the purpose of future preservation and accessibility.

6. I agree that the metadata relating to the eThesis (where applicable) will normally appear on both the University’s eThesis server (WREO) and the British Library’s EThOS service, even if the eThesis is subject to an embargo.

| Student’s name (PLEASE PRINT): KATIE BODEN | Signature: | Date 19/06/2020 |

### SECTION 6: THESIS DEPOSIT AGREEMENT – SUPERVISOR

I, the supervisor, agree to the named Thesis being made available in accordance with the conditions specified above.

| Supervisor’s name (PLEASE PRINT): Dr Georgina Rowse Dr Rebecca Yeates Dr Fuschia Sirois | Signature: | Date: 19/06/2020 |
Declaration

This thesis has not been submitted for any other qualification at the University of Sheffield or any other institution
Structure and word counts

Section 1: Literature review

Excluding references and tables
7981

Including references and tables
13,712

Section 2: Research report

Excluding references and tables
7999

Including references and tables
12,670

Total word count

Excluding references and tables
15,980

Including references and tables
26,382
This page is intentionally left blank
Overall abstract

Chronic illnesses, including Inflammatory Bowel Disease (IBD), present individuals with an array of physical and psychological challenges. To successfully address psychological distress or foster resilience in those living with chronic illness, it is important to understand the factors that underpin such outcomes. This research aimed to: 1) understand the association between illness uncertainty and psychological distress in those with chronic illness, and; 2) develop a theoretical and empirically informed understanding of resilience in those with IBD.

A systematic review and narrative synthesis examined the association between illness uncertainty and psychological distress in people with chronic illnesses. A systematic search of three electronic databases yielded 23 studies. Specific inclusion/exclusion criteria were applied. All studies used self-report measures and all but one study, employed a cross-sectional design. Overall, low to moderate levels of illness uncertainty were present across the study samples. The synthesis illuminated the association between illness uncertainty and psychological distress (measured as depression, anxiety, negative mood states and trauma symptoms). This association remained regardless of individual or contextual factors, time across the illness trajectory; and when confounding variables were controlled for. Appraisals of illness uncertainty need further exploration, but studies have begun examining control-beliefs and intolerance of uncertainty. Limitations of the studies are discussed and further recommendations for future research are presented.

Recent research in the IBD field has begun exploring beliefs about illness and disease-related variables and their association with resilience and other outcomes. This exploratory research employed a cross-sectional, sequential mixed methods design. Therefore, findings from a scoping literature search and qualitative phase, eliciting
personal, voiced resilience experiences via interviews, informed a quantitative examination of factors and their association with resilience, using an online survey. Those over 18 years and with self-reported IBD diagnoses participated in the study. Five people participated in interviews. Potential factors comprising an important part of resilience were identified from the scoping review. The thematic analysis of the interview data supported these and the construct of grit additionally emerged (perseverance towards long-term goals). Next, eighty-five participants completed an online survey to test measures of social support, coping-efficacy and illness-acceptance (illness cognitions and coping resources); control-beliefs and intolerance of uncertainty (beliefs related to controllability); grit; time since diagnosis, disease activity and disease subtype (disease related variables); and their association with resilience (dependent variable).

Correlational analyses and a hierarchical regression analysis were conducted. Disease activity, illness-acceptance, social support, coping efficacy, control-beliefs and intolerance of uncertainty contributed 67.1% of the variance in resilience. Non-significant associations were found between grit, time since diagnosis and resilience. Daily persistence and endurance may be more characteristic of resilience in those with IBD. Limitations of the study are acknowledged, and recommendations for future clinical practice and research are discussed.
Acknowledgements

Thank-you to those who gave their time to participate in this research and to my research supervisors Dr Georgina Rowse, Dr Rebecca Yeates and Dr Fuschia Sirois for your guidance, expertise and steering me back on track when I lost my way.

My thanks also go to my family and friends. Not only did your encouragement and unwavering belief in me drive me to undertake clinical training under much less than favourable circumstances, but your emotional and practical support made the challenges and emotional rollercoaster of clinical training possible. To my life long best friends, my sisters; Anna, my academia guru; Claire, my guru in many other challenging life matters; you’re both inspirational; my parents- for so much support, for being you, and wonderful grandparents; my friends - my chosen family, for so much, for being Sienna’s extended family and for the much needed fun times; to Sandra for keeping me healthy and Charalene, because ashtanga yoga has kept me physically and emotionally grounded. Combined, you are my resilience and without you all this would not have been possible.

Lastly for my daughter, Sienna, for reminding me of what really matters, for helping me compartmentalise so that this work did not consume me, for your boundless love, joy, acceptance, and making sure there has never been a dull moment. This was for us.
Contents

Overall abstract..........................................................................................vii-viii
Acknowledgements....................................................................................ix

Section One: Literature review

How does illness uncertainty relate to psychological distress in chronic illness
populations: A systematic narrative review

Abstract.....................................................................................................2-3

Introduction...............................................................................................4

Illness uncertainty: An overview of definitions and models......................4-5

Mishel’s (1981) uncertainty in illness concept and theoretical
underpinnings...........................................................................................5-6

Empirical support for Mishel’s (1981) uncertainty in illness theory...........6-7

Chronic Illnesses.......................................................................................7-8

Psychological distress ............................................................................8

The current review.....................................................................................8-9

Method.....................................................................................................10

Design.......................................................................................................10

Search strategy..........................................................................................10-11

Inclusion/exclusion criteria........................................................................11-12

Measures of illness uncertainty using Mishel’s conceptualisation of IU....12

Data extraction..........................................................................................13

Quality appraisal.......................................................................................13-14

Results.....................................................................................................14-24
Study characteristics............................................................... 25
Clinical characteristics........................................................... 25
Demographics......................................................................... 25
Chronic illnesses.................................................................... 25-26
Methodological quality............................................................ 26
Synthesis of review findings.................................................... 26-27

1. What do the studies suggest about the commonality of illness uncertainty in those with chronic illnesses and its association with psychological distress?............................................................................................................. 27-28

2. Are there differences in the association between illness uncertainty and psychological distress according to the care-context?................................................................. 28-30

3. Are there differences in associations between illness uncertainty and psychological distress according to the type of measurement of psychological distress?......................................................................................................................... 30-34

Measures of depression and associated mood states.............. 30-31
Measures of anxiety................................................................. 31
Measures of psychological distress......................................... 32-33

4. Are there differences in associations between illness uncertainty and psychological distress according to chronic illness type?............................................................. 33-34

5. What is known about other variables in relation to illness uncertainty?................................................................................................................................. 34

Gender.................................................................................... 34-35
Illness intrusiveness............................................................... 35
Grit......................................................................................... 35
Coping styles........................................................................... 35
Locus of control...................................................................... 35-36
Disease-related variables....................................................... 36
Symptom severity.................................................................... 37-38
Illness duration ................................................................. 37-38

Discussion ............................................................................. 38

Theoretical frameworks ......................................................... 39-40

Limitations of the review ....................................................... 42-43

Clinical implications ............................................................. 43

Conclusions ............................................................................ 44

References ............................................................................. 45-63

Literature review Appendices

Appendix A: Search strategy: search terms .............................. 64-65
Appendix B: Search strategy: Inclusion/exclusion criteria ............ 66-67
Appendix C: Psychometric properties of MUIS measures ............ 68-69
Appendix D: Quality appraisal tool ........................................... 70-73
Appendix E: Quality appraisal of all studies ............................... 74-79
Appendix F: Illness uncertainty scores ...................................... 80-81
Appendix G: Time since diagnosis/illness duration figures ......... 82-83
Appendix H: PRISMA checklist ................................................. 84-87

Section 2: Research report

Factors that associate with resilience in people with IBD

Abstract ............................................................................. 2-3

Introduction ........................................................................... 4

Resilience factors in chronic illness and IBD ............................. 5

Disease-specific factors .......................................................... 8-9

xiii
Study aims...........................................................................................................9

Clinical implications.......................................................................................10

Methods...........................................................................................................10

Design............................................................................................................10

Epistemological position...............................................................................10-11

Ethics................................................................................................................11

Phase A: Qualitative enquiry..........................................................................11

Recruitment....................................................................................................11

Participants....................................................................................................12

Procedure.......................................................................................................12

Qualitative analytic method..........................................................................13

Reflexivity........................................................................................................13

Results:............................................................................................................13

Themes...........................................................................................................15

1. Superordinate theme: Intrapersonal ambivalence, grit.........................15-16

1.1 “I quite like the control”.........................................................................16

1.2 “An invisible illness”..............................................................................16-17

1.3. “Carry on regardless”...........................................................................17-18

2. Superordinate theme: Interpersonal ambivalence, social support.........18-19

2.1. “The support really helps”.................................................................19

2.2. “Nobody really understood“.............................................................19-20

2.3. “Brave face”......................................................................................20-21

Data analysis summary..................................................................................21

Phase B: Quantitative enquiry.......................................................................21

Recruitment and procedures.......................................................................21-22
Quantitative measures.................................................................................................................22
Screening and demographics information.................................................................22
Connor-Davidson Resilience Scale (CD-RISC, Connor & Davidson, 2003)..................................................................................................................................................22
Short Health Scale (SHS, Hjortswang et al., 2006, in Mcdermott et al., 2013)..................................................................................................................................................22-23
Illness Cognition Questionnaire......................................................................................23
Coping Efficacy Scale (CES, Gignac et al., 2000)..................................................................23
Duke-UNC Functional Social Support Questionnaire (FSSQ, Broadhead et al., 1988)..................................................................................................................................................23-24
Control Beliefs Inventory (CBI, Sirois, 2002.).................................................................24
The Intolerance of Uncertainty Scale-Short Form (IU-SF, Carleton et al., 2007)..................................................................................................................................................24
The Short Grit Scale (SGS, Duckworth & Quinn, 2009)......................................................................24-25
Sample characteristics.........................................................................................................25

Results ........................................................................................................................................25
Data analytic plan..................................................................................................................25-26
Missing data..........................................................................................................................26
Descriptive data....................................................................................................................26-28
Descriptive analyses.............................................................................................................29
Correlational analyses..........................................................................................................29-30
Regression analyses.............................................................................................................31-32

Discussion................................................................................................................................33
Resilience and disease variables.......................................................................................36

xv
Study limitations........................................................................................................37
Implications for clinical practice.............................................................................38
Conclusions.............................................................................................................39
References...............................................................................................................40

Research Report Appendices

Appendix A: Participant survey comments.............................................................61
Appendix B: Ethics approval and research governance sponsor letter...............62-63
Appendix C: Information sheets (focus group and interviews).............................64-69
Appendix D: Consent form (focus group)...............................................................70-71
Appendix E: Interview schedule used for focus group and individual interviews...72-73
Appendix F: Braun and Clarke (2006) thematic analysis steps............................74-80
Appendix G: Illustrative quotes for each theme......................................................81-90
Appendix H: All online advertisements.................................................................91-93
Appendix I: Online survey information and consent..........................................94-96
Appendix J: Copy of all measures........................................................................97-107
Appendix K: Normality tests..............................................................................108-121
Section 1: Literature review

How does illness uncertainty relate to psychological distress in chronic illness populations? A systematic narrative review
Abstract

Objectives

Illness uncertainty (IU) arises when illness related events have indeterminable meaning and adequate cognitive schema cannot be formed to interpret the meaning of such phenomena. IU has been associated with negative outcomes. This review aimed to synthesise papers examining the IU/psychological distress association in chronic illness populations; to understand it in relation to care-context, chronic illness type or form of psychological distress. This intended to draw conclusions to inform future research and clinical practice.

Method

Three electronic databases were systematically searched for studies that met pre-defined inclusion criteria, including use of an IU measure based on Mishel’s conceptualisation. The ‘Observational Cohort and Cross-sectional Studies’ tool was employed to assist quality appraisal and papers were narratively synthesised.

Results

The search yielded 23 papers (total participants, N=3126). Twenty-one studies demonstrated positive and significant associations between IU and psychological distress irrespective of gender, care-context, time across the illness trajectory, chronic illness type or form of psychological distress. The ambiguity element of Mishel’s IU conceptualisation yielded more significant associations and larger effect sizes than other facets of IU (complexity, inconsistency, and unpredictability). There was a tendency for greater IU to associate with subjective rather than objective illness severity. Intolerance of uncertainty and control beliefs as appraisal processes associated with IU and psychological distress.
Conclusions

IU associates with psychological distress regardless of individual or contextual differences. It is inferred from existing theoretical frameworks that appraisals mediate the association, but research is needed to explore causal pathways and specific appraisal processes linked with IU in chronic illness populations.

Practitioner points

- The presence of IU is ubiquitous in chronic illness populations and should be routinely assessed and normalised.
- Healthcare professionals should assess and target the different facets of IU using Mishel’s original measure and varying manifestations of psychological distress in those with chronic illnesses.
- Healthcare professionals should follow current National Institute for Health and Care Excellence guidance on the psychological treatment of emotional disorders (cognitive behavioural therapy) but assess for appraisal processes associated with IU.

Limitations

- The cross-sectional designs employed meant that causal associations could not be determined.
- Findings were not generalisable to all chronic illness populations and 65.2% of studies were conducted in the United States of America, limiting the cross-cultural validity of the findings.
- Few studies conducted power analyses; thus, it was difficult to determine if studies were sufficiently powered to avoid type 1 or II errors. Therefore, findings should be interpreted with caution.
Illness uncertainty: An overview of definitions and models

Uncertainty has been defined as a complex cognitive stressor and perceptual state or attitude of doubt or not knowing that changes over time (Mast, 1995; Wiener & Dodd, 1993). It is an ubiquitous human experience but is particularly poignant for those living with chronic illness (CI, Hilton, 1994; Mishel, 1990), because they present individuals with prolonged physical and psychological challenges. One potential challenge is IU which occurs when “adequate cognitive schema cannot be formed with which to interpret the meaning of illness-related events” (Mishel, 1997, p.225). Insufficient coping to buffer negative emotional responses can lead to protracted or unresolved psychological distress which can precede the need for clinical services. It is thus the focus of this review to develop an understanding of the association between IU and psychological distress in those living with CI.

IU has been conceptualised in many ways. One such conceptualisation suggests its synonymy to emotions evoked by illness-related events that can be positive or threatening (Hilton, 1994). Conversely, in the uncertainty in illness theory (UIT, Mishel, 1981), IU is proposed to be a “neutral cognitive state” (Mishel, 1997, p.58) distinct from its emotional outcomes (McCormick, 2002). The UIT has become the most established and researched framework and differing versions of measures based upon Mishel’s conceptualisation have been cited as the most widely used (Wright et al., 2009). The original Mishel Uncertainty in Illness Scale-Acute (MUIS-A, Mishel, 1981) captures four facets of IU. These include ambiguity; meaning information (symptoms or causes) can be vague and interpretable in several ways: complexity; uncertainty about treatment and the medical system; inconsistency; the symptom pattern presenting as variable and in discord with the disease process: and unpredictability, the inability to predict future course; such as about relapsing/remitting symptoms or prognosis (Mishel, 1988).
Contentions underpin the presumed causes and influencing factors of IU. Hilton (1992) suggested that lack of information underlies uncertainty, whereas Mishel (1997) placed emphasis on indeterminable meaning which comprises a multitude of factors, acknowledging IU is a multifaceted concept (McCormick, 2002). Four major components of IU are proposed, including: antecedents generating uncertainty; the appraisal of uncertainty, coping and affect control strategies; and adaptation to the illness. Poor cognitive abilities, low education levels and limited social support have also been associated with high levels of IU in CI populations (Liao et al., 2008; Lien et al., 2009; Mast, 1998). Thus, contextual, and individual factors influence IU.

*Mishel’s (1981) uncertainty in illness concept and theoretical underpinnings.*

The UIT drew upon Lazarus and Folkman’s (1984) stress and coping model, which illuminated the importance of the appraisal generated from uncertainty. Appraisal processes and the ways in which individuals cope with IU are variable (Alschuler & Beier, 2015). IU is not necessarily aversive until negatively appraised. Negative appraisals include thoughts related to danger (a threat to well-being) or hopelessness (Mishel, 1990). Mishel (1981, 1984) postulates that adaptive, promising outcomes are borne out of positive appraisals, such as that illness experiences provide opportunity (Mishel, 1981; Mishel, 1984). Conversely negative appraisals lead to the adoption of maladaptive coping strategies to manage affect, leading to outcomes of psychological distress (Mishel, 1988).

The UIT was originally applied to acute illness experiences (Mishel, 1988), but reconceptualised to address the phenomenology of continuous uncertainty in those with CI (Mishel, 1990). Within the theory it is suggested that living with IU chronically, destabilises pre-existing cognitive models of life as predictable and controllable, and thus IU becomes accepted as part of reality (Alligood, 2014). There is henceforth a shift
of perspective from danger to opportunity which may lead to positive psychological changes (Mishel, 1990). However, this has been critiqued because how meaning is assigned to IU and transformed to opportunity appraisals is an idiosyncratic process that lacks empirical backing (Alligood, 2014). Furthermore, Bailey and Neilson (1993) found no association between illness duration (mean duration was 17 years), IU, and its appraisal in those with rheumatoid arthritis.

The UIT shares the conceptual underpinnings of Beck’s (1967) cognitive theory of emotional disorders arguing that appraisals (about self, world, and future) are pertinent to the development of psychopathology; thoughts/appraisals impact on emotions which influence coping behaviours. Hence, appraisals of uncertainty in the context of a CI, may lead to undesirable outcomes. Intolerance of uncertainty which is defined as negative reactions to uncertainty on emotional, cognitive, and behavioural levels (Buhr & Dugas, 2009) has been extensively researched. Intolerance of uncertainty has been conceptually and empirically linked with generalised anxiety disorder (Dugas et al., 1998; Dugas & Robichaud, 2007; Freeston et al., 1994) and other emotional disorders (Gentes & Ruscio, 2011).

*Empirical support for Mishel’s (1981) uncertainty in illness theory.*

It has been argued that much of the research supporting the UIT dedicated its focus to the association between IU and psychosocial outcomes rather than the mediating roles of appraisals (McCormick, 2004). Hence, only extant research scaffolds the IU, appraisal link. For example, higher uncertainty associates with danger appraisal (Bailey & Neilson 1993). The extensive research on IU and outcomes has been conducted with varying populations, including paediatrics (Fortier et al, 2013) and chronic pain (Wright et al., 2009). A large tranche of empirical research on acute and CI populations, links IU with reduced Quality of Life (QOL, Chen et al., 2018; Fedele...
et al., 2009; Padilla, 1992), lower adjustment (Christman, 1990; Mishel & Baden, 1987), negative mood states (Christman et al., 1988; Lin et al., 2013; Lutze & Archenholtz, 2007; Wineman, 1990; Wineman et al., 2003), poorer emotional well-being and depressive symptoms (Bailey et al., 2009; Bang et al., 2013; Hoth et al., 2013; Mishel, 1981; Wang et al., 2014). Accordingly, higher levels of certainty have correlated with better QOL and psychosocial adaptation (McNulty et al., 2004; Niv et al., 2017).

Some internal resources have been found to mediate between IU and outcomes, including optimism (Christman, 1990; Mishel et al., 1984; Mishel & Sorenson, 1991), hope (Christman, 1990; Hilton, 1994), mastery (Mishel et al., 1991) and learned resourcefulness (Rosenbaum, 1983). Furthermore ‘grit’, or persistence despite challenge (Duckworth et al., 2007), has been linked with lower IU and thus decreased distress (Sharkey et al., 2017).

**Chronic Illnesses**

The Department of Health (DOH, 2017) defines CIs as “complex… multiple causes… generally long-term and persistent, and often lead to a gradual deterioration of health and loss of independence. While not usually immediately life threatening, chronic conditions are the most common and leading cause of premature mortality” (p.6). Moreover, they are not passed from person and person and are of long duration with generally slow progression (World Health Organisation, WHO, 2016). CIs range from medication-controlled asthma or diabetes; to neurodegenerative diseases such as Multiple Sclerosis or Parkinson’s disease which present individuals with significant experiences of pain and the threat of unpredictable but gradual decline. Though distinct CI’s vary in their clinical profile, they share common characteristics, including uncertain aetiology, symptom ambiguity, uncontrollable or fluctuating trajectories and
uncertain prognosis. Uncertainty can be exacerbated by the ever-present potential for decline in health functionality (Mishel, 1990).

**Psychological distress**

Psychological distress is frequently referenced in health-care literature, but as a distinct concept, it has not been clearly defined and articulated (Ridder, 2004). It is conceptually linked with stress and distress, considered the “unique discomforting, emotional state experienced by an individual in response to a specific stressor” (Ridder, 2004, p.539). It has also been characterised by symptoms of depression and anxiety (Drapeau et al., 2012), which have been named as leading causes of morbidity and disability (Prince et al., 2011). Those with CI’s have higher rates of depression and anxiety than physically healthy controls and approximately 20% of those with a CI have depression (NICE, 2010). Existing systematic reviews have measured psychological distress multidimensionally (Gong et al., 2016; Kuswanto et al., 2018), capturing depression, anxiety, trauma symptomatology, mood states and perceived stress symptoms. Research included in this review captures these wider measures of psychological distress.

**The current review**

Existing reviews have focused on IU and outcomes in specific populations; including caregiver and paediatric uncertainty in relation to young people with CI (Szulczewski et al., 2017) and chronic pain (Wright et al., 2009). Szulczewski et al. (2017) conducted a meta-analysis and found associations between child and caregiver uncertainty and outcomes of depression, anxiety, and psychological distress in young people, with medium effect sizes. Wright et al.’s. (2009) concept review was not systematically conducted which may have introduced several biases. However, they found IU to be associated with maladaptive coping and higher psychological distress. A
plethora of individual quantitative studies that have examined the IU and psychological distress association in adult CI populations exist, however no study has synthesised findings.

This timely review carries clinical and empirical importance. A synthesis offers a nuanced understanding of the association between IU and psychological distress according to CI-type and care-context. Furthermore, the NICE (2010, guideline 91) recommended cognitive behaviour therapy treatment of depression is based on a standardised manual, rather than being tailored to addressing the psychological processes associated with CI. A nuanced understanding of IU, psychological distress and associated variables could facilitate an understanding of what psychological processes health care professionals (HCP’s) might assess and target in CI populations; and highlight those more vulnerable to moving towards a trajectory of negative outcomes. This could be valuable for those working in primary care, hospital settings, health, and psychology departments and psychological therapists.

The review question was developed using the PICO (population, intervention, comparator, and outcome) framework (Moher et al., 2015), culminating in the final review question: How does illness uncertainty relate to psychological distress in chronic illness populations?

This review had five aims: 1) Examine the commonality of IU and the general trend across all studies examining the association between IU and psychological distress across CI populations; 2) consider the association between IU and psychological distress across differing care-contexts; 3) examine the association between IU and varying types of psychological distress; 4) elucidate how this association might differentiate across CI types; 5) identify other variables that have been examined in relation to IU.
Method

Design

The review protocol was registered with the international Prospective Register of Systematic Reviews (PROSPERO, Registration number: CRD42020166475). This review followed the ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses’ (PRISMA; Moher et al., 2009) guidance. Systematic narrative reviews involve methodically selecting, summarising and critically appraising available research (Moher et al., 2009). In line with narrative synthesis guidance (Popay et al., 2006) a preliminary synthesis of study findings was conducted, and patterns elicited. Next the studies were summarised, and consideration given to the direction and magnitudes of effects. Subsequently, exploration of the similarities, differences and relationships within the data was undertaken, accounting for quality appraisal (Lisy & Poritt, 2016).

Search strategy

Three electronic databases, Scopus, Psycinfo and MEDLINE (all titles, abstracts, keywords) were searched on 20th February 2020, from database inception, with no date restrictions. This enabled the search to capture and synthesise all available research. Only English language papers were included. Search concepts were developed using PICO (Moher et al., 2015); no search concepts were included regarding comparator or study design. Search terms were developed (See Appendix A) from preliminary scans of the literature, thesaurus searching the key constructs and informed by previous reviews studying CI populations (Amo-Setien et al., 2019; Cal et al., 2015; Snippen et al., 2019; Szulczewski et al., 2017). Search-terms included “chronic* ill*”, “illness uncertainty”, “Mishel* illness uncertainty scale” and “psychological distress*”. 

10
Boolean operators were utilised to connect terms and combine specificity and sensitivity to yield eligible studies (meeting the inclusion/exclusion criteria).

A PRISMA diagram is presented in figure 1 and provides a summary of the search and selection process (Moher et al., 2009). Where full text articles were not accessible, main authors were contacted which enabled all papers to be successfully obtained. To enable a comprehensive search, reference lists of identified papers elicited by the above systematic search were hand searched; one additional paper was identified and included in the final review using this method (Detprapon et al., 2004). A forward and backward citation search was conducted on all included papers; two papers were identified which were unavailable in English language and thus excluded. Screening resulted in duplicates being removed initially and eligibility subsequently being ascertained by title, and then abstract inspection. If it was unclear if papers met inclusion/exclusion criteria, full articles were inspected.

**Inclusion/exclusion criteria**

Papers were included according to inclusion and exclusion criteria (see Appendix B). Papers needed to include a CI or form of psychological distress cohering with the definitions discussed in this review (DOH, 2017; Ridder, 2004; WHO, 2016). They were also required to employ an IU measure based on Mishel’s conceptualisation so that there was some homogeneity pertaining to what constituted IU in terms of definition and measurement (e.g. Hagen et al., 2015; Mishel 1981; Mishel, 1986).

Where it was unclear if a paper met inclusion, this was reconciled through discussions with research supervisors, with consideration of the papers content and relevance to the review question. Illustratively, two papers were included studying survivors of childhood cancer (Lee, 2006; Santacroce & Lee, 2006). The key rationale for inclusion was that recurrent disease has been found to be 4.4%, 5.6%, and 6.2% at
10, 15, and 20 years post-paediatric cancer survival respectively (Wasilewski-Masker et al., 2009); survivor death rates have been found to exceed age-matched controls, with death from subsequent cancer being the most frequent cause (Mertens et al., 2015).

Exclusion-criteria included IU measurement pre-post major surgery or drug trial participation as this was deemed to capture something phenomenologically distinct. However, papers were included for those with a CI undergoing protracted treatments such as haemodialysis (e.g. B. Kim & J. Kim, 2019) or chemotherapy (e.g. Kurita et al., 2013).

Measures of illness uncertainty using Mishel’s conceptualisation of IU

Mishel (1983) advocated the development of measures for specific illness and diagnostic groups. Hence several versions have been developed since the original 33-item MUIS-A (Mishel, 1981). The measures employed by papers in this review are described. All measures have demonstrated robust psychometric properties (See Appendix C for psychometric properties).

The MUIS-A measures all facets of IU thus containing subscales of ambiguity, complexity, inconsistency, and unpredictability. It includes questions related to acute illness and hospitalisation. A 28-item two factor MUIS version (Mishel, 1997) including subscales ambiguity (16 items) and complexity (12 items) was subsequently developed. The 23-item Mishel Uncertainty in Illness Scale-Community (MUIS-C, Mishel, 1991) was adapted from the MUIS-A and thus contains similar items. However, those items related to hospitalisation of acutely ill patients were removed; it was designed for community-dwelling individuals, unlikely to be undergoing medical interventions and differed in its use of a unidimensional scale. B. Kim & J. Kim (2019) used the Korean translation (Jung et al., 2005). The 5-item Mishel Uncertainty in Illness Scale-Short
Form (MUIS-SF, Hagen et al., 2015) captures ambiguity about and controllability of the illness; and complexity of treatment/system of care as a unitary construct.

**Data extraction**

The following data were extracted and tabulated (see Table 1): author(s), publication year, country of publication, sample characteristics (CI, sample size, percentage female, age ranges, mean age), recruitment setting, study design, sampling method, measures of IU and psychological distress adopted by each study, and finally the correlation coefficients (r) between the IU and psychological distress measure; which indicated the effect size (Ellis, 2010). Effects sizes were interpreted according to Cohen’s (1988) guidelines; \( r=0.10 \) to 0.29 (small), \( r=0.30 \) to 0.49 (medium) and \( r=0.50 \) to 1.00 (large). Where r-square value was used Cohen’s (1992) guidance was followed; \(<0.12\) (low association with outcome), 0.13 to 0.25 (medium); and \( >0.26 \) (large).

In papers where the association between IU and psychological distress was not the predominant focus, bivariate correlational findings (with correlation coefficients) were extrapolated. Where possible, partial correlations were also reported.

**Quality appraisal**

The quality of papers included in a review can impact on the validity of its results (Centre for Reviews & Dissemination, 2008). Assessment of study quality was conducted using the 14-item Observational Cohort and Cross-sectional Studies tool (National Institutes of Health, 2014, see Appendix D for items). A checklist is provided allowing for analysis of transparency, consistency, and validity; enabling papers to be rated as ‘poor’, ‘fair’, or ‘good’. Items are rated as ‘yes’, ‘no’, ‘cannot-determine’, ‘not reported’ or ‘non-applicable’. No guidelines offer categorisation of numerical ratings and some items were not applicable to the study design. Thus, for the purpose of this review, non-applicable items were excluded from the scoring and a percentage rating
was calculated to facilitate comparisons of study quality (total score/applicable items x 100). The author applied the principles that <50% = poor; 50%-70% = fair and >70% = good. Table 1 presents percentage and quality ratings.

An independent final-year clinical psychology doctoral trainee with experience of quality appraisal and who was blind to the main author’s ratings, rated 5 randomly selected papers. This intended to confirm inter-rater reliability of the quality assessment. Any disparities in ratings were discussed until a consensus was reached (the final agreed ratings are presented in Table 1). Overall, the quality of the studies included in this review was deemed fair (N=15) or good (N=8) (see Appendix E). No studies received a ‘poor’ rating. Discussion of individual aspects of study quality are additionally embedded within the review findings.

Results

In total the systematic search culminated in the inclusion of 23 studies (see figure 1). Table 1 summarises the key study characteristics and extracted data from the reviewed studies.
Figure 2

PRISMA diagram (PRISMA; Moher et al., 2009)

Records identified through database searching: n=3851

Additional records identified through other sources: n=3

Total papers: n=3854

Duplicates removed n=146

Titles screened n=3708

Papers excluded n=3551

Abstracts assessed for eligibility n=157

Papers excluded: n=115
a) Before/after major treatment=30
b) Age of participants=14
c) Excluded on the basis of outcomes=37
d) Proxy measures of IU used=10
e) Participant sample diagnoses of exclusion/acute conditions=15
f) Non-peer reviewed articles=3
g) Qualitative methodology= 4
h) Did not use a version of Mishel’s IU scale=2

Full text articles assessed for eligibility n=42

Papers excluded: n=19
a) Before/after major treatment=4
b) No direct statistical examination of IU and psychological/distress=4
c) Excluded on the basis of outcomes=4
d) Did not use a version of Mishel’s IU scale=2
e) Article not written in English=4
f) Age of participants=1

Articles included in the review n=23
<table>
<thead>
<tr>
<th>Author (year) Country</th>
<th>Chronic Illness</th>
<th>Sample characteristics</th>
<th>Study design</th>
<th>Outcome variables (and measure used)</th>
<th>MUIS Measure</th>
<th>Correlation coefficient</th>
<th>Significant association</th>
<th>Quality score (%) and rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahn et al. (2017) South Korea</td>
<td>Parkinson’s disease Outpatient</td>
<td>120 participants from a neurology outpatient department Mean age= 65.01 (9.08) Female= 49.2%</td>
<td>Cross-sectional</td>
<td>Depression (SF-GDS)</td>
<td>MUIS-A (Korean version, 33 items)</td>
<td>Bivariate r=0.46***</td>
<td>Y</td>
<td>70 Good</td>
</tr>
<tr>
<td>Bailey et al. (2009) England</td>
<td>Hepatitis C Outpatient</td>
<td>126 patients undergoing watchful, waiting protocol-medical centre Mean age = 53.1 (9.4) Range= 27-78 Female= 50.8%</td>
<td>Cross-sectional</td>
<td>Depression (CES-D)</td>
<td>MUIS-A (33-item)</td>
<td>Bivariate: Ambiguity: r=0.51** Complexity: r=0.23* Inconsistency: r=0.39** Unpredictability: r=0.06 Partial: r=0.36** (ambiguity subscale only)</td>
<td>Y</td>
<td>72.7 Good</td>
</tr>
<tr>
<td>Barberis et al. (2019) Italy</td>
<td>Chronic kidney disease Inpatient</td>
<td>50 patients enrolled at the unit of nephrology of a hospital Female= 26%</td>
<td>Cross-sectional</td>
<td>Depression and anxiety (HADS)</td>
<td>MUIS-A (33-item)</td>
<td>Bivariate Depression r=0.40*** Anxiety r=0.54***</td>
<td>Y</td>
<td>54.5 Fair</td>
</tr>
<tr>
<td>Author (year)</td>
<td>Chronic Illness</td>
<td>Sample characteristics</td>
<td>Study design</td>
<td>Outcome variables</td>
<td>MUIS Measure</td>
<td>Correlation coefficients</td>
<td>Significant association</td>
<td>Quality score (%) and rating</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>-------------------</td>
<td>--------------</td>
<td>--------------------------</td>
<td>------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Carpentier et al. (2007).</td>
<td>Childhood onset asthma</td>
<td>America 121 college students from a large midwestern public university Mean age = 19.7(1.62) Range=18-22 Female= 62.8% 121 healthy control subjects</td>
<td>Cross-sectional</td>
<td>Psychological distress/anxiety and depression (BSI) Illness-induced interference (IIRS)</td>
<td>MUIS-C</td>
<td>Hierarchical regression analysis IU significantly predicted depression, anxiety and full BSI (p&lt;0.001)</td>
<td>Y</td>
<td>80 Good</td>
</tr>
<tr>
<td>Colagreco et al. (2014).</td>
<td>Chronic Hepatitis C</td>
<td>America Outpatients 92 participants recruited from a single centre, following watchful waiting protocol. Mean age=56.10(7.40) Range=24-74 Female= 35.9%</td>
<td>Cross-sectional</td>
<td>Depression (CES-D) MUIS-A (33-item)</td>
<td>Bivariate: Total MUIS: r=0.49** Ambiguity: r=0.51** Inconsistency: r=0.36** Complexity: r=-0.07 Unpredictability: r=0.01 Bivariate r=0.82***</td>
<td>Y</td>
<td>50 Fair</td>
<td></td>
</tr>
<tr>
<td>Detprapon et al. (2009)</td>
<td>Head and neck cancer</td>
<td>Thailand Outpatients 240 head and neck cancer patients recruited from an outpatient clinic Mean age=55.17 Range= 19-89 Female=29.6%</td>
<td>Cross-sectional</td>
<td>Depression (CES-D) MUIS-C</td>
<td>Symptom experience (MSES)</td>
<td></td>
<td></td>
<td>55.6 Fair</td>
</tr>
<tr>
<td>Author (year) Country</td>
<td>Chronic illness</td>
<td>Sample characteristics</td>
<td>Study design</td>
<td>Outcome variables (and measures)</td>
<td>MUIS Measure</td>
<td>Correlation coefficient</td>
<td>Significant association</td>
<td>Quality score (%) and rating</td>
</tr>
<tr>
<td>----------------------</td>
<td>----------------</td>
<td>-------------------------</td>
<td>-------------</td>
<td>----------------------------------</td>
<td>-------------</td>
<td>------------------------</td>
<td>--------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Hommel et al. (2003) America</td>
<td>Childhood onset asthma Community</td>
<td>56 participants were recruited from undergraduate classes at a large midwestern university.</td>
<td>Cross sectional</td>
<td>Depression (IDD) Anxiety (BAI) Illness severity (Illness severity assessment)</td>
<td>MUIS-C</td>
<td>Bivariate Depression r=0.48** Anxiety r=0.56**</td>
<td>Y</td>
<td>75 Fair</td>
</tr>
<tr>
<td>Hoth et al. (2013) America</td>
<td>COPD Outpatients</td>
<td>407 people with alpha-1 antitrypsin deficiency-associated COPD (From Alpha-1 Foundation Research Registry)</td>
<td>Prospective correlational</td>
<td>Depression and anxiety (HADS)</td>
<td>MUIS-A (28-item, measuring ambiguity and complexity)</td>
<td>Linear mixed models, controlling for demographic and illness related variables.</td>
<td>Ambiguity: b=0.13*** Complexity: b=-0.01</td>
<td>54.5 Fair</td>
</tr>
<tr>
<td>B. Kim &amp; J. Kim (2019) Korea</td>
<td>End-stage renal disease Inpatients</td>
<td>152 patients receiving hemodialysis across 5 hospitals</td>
<td>Cross-sectional</td>
<td>Depression (PHQ-9) Perceived social support (MSPSS)</td>
<td>MUIS-A (33-item) Korean version</td>
<td>Bivariate r=0.31***</td>
<td>Y</td>
<td>60 Fair</td>
</tr>
<tr>
<td>Author (year)</td>
<td>Chronic illness</td>
<td>Sample characteristics</td>
<td>Study design</td>
<td>Outcome variables (and measures)</td>
<td>MUIS Measure</td>
<td>Correlation coefficient</td>
<td>Significant association</td>
<td>Quality score (%) and rating</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>----------------------------------</td>
<td>--------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Kurita et al. (2013)</td>
<td>Lung cancer</td>
<td>49 participants diagnosed with lung cancer at least 6 months prior to enrolment</td>
<td>Cross-sectional</td>
<td>Depression (CES-D)</td>
<td>Intolerance of uncertainty (IUS)</td>
<td>Bivariate b=0.18</td>
<td>N</td>
<td>70</td>
</tr>
<tr>
<td>America</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age=64.2(11.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range=37-86</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female=71.4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee (2006)</td>
<td>Childhood survivors of cancer</td>
<td>45 participants from a pediatrics department database</td>
<td>Cross-sectional</td>
<td>Post-traumatic stress symptoms (PTSDI)</td>
<td>MUIS-C</td>
<td>Bivariate r=0.40*</td>
<td>Y</td>
<td>60</td>
</tr>
<tr>
<td>Taiwan</td>
<td>Community</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age=27.4(5.54)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lemaire (2004)</td>
<td>Endometriosis</td>
<td>Female=62.25% 298 women attending an endometriosis conference</td>
<td>Cross-sectional</td>
<td>Emotional distress (FARS)</td>
<td>MUIS-C</td>
<td>Bivariate r=0.48**</td>
<td>Y</td>
<td>60</td>
</tr>
<tr>
<td>America</td>
<td>Community</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age=34(7.10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female=100%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author (year)</td>
<td>Chronic illness</td>
<td>Sample characteristics</td>
<td>Study design</td>
<td>Outcome variables (and measures)</td>
<td>MUIS Measure</td>
<td>Correlation coefficient</td>
<td>Significant association</td>
<td>Quality score (%) and rating</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>---------------------------------------------</td>
<td>--------------</td>
<td>-------------------------</td>
<td>--------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Lin et al. (2013)</td>
<td>Primary brain tumours (PBT’s)</td>
<td>186 patients with PBT’s from a cancer centre and brain and spine Centre Clinic</td>
<td>Cross-sectional</td>
<td>Mood states (POMS-SF)</td>
<td>MUIS-BT</td>
<td>Bivariate</td>
<td>Y</td>
<td>63.6 Fair</td>
</tr>
<tr>
<td>America</td>
<td>Outpatients</td>
<td>Mean age=44.2 Range=19-80 Female=46.8%</td>
<td></td>
<td>Presence and severity of symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Confusion subscale</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Depression subscale</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fatigue subscale</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tension subscale</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mullins et al. (2000)</td>
<td>Childhood onset asthma</td>
<td>40 college students from two midwestern universities with diagnosed childhood asthma.</td>
<td>Cross-sectional</td>
<td>Depression (IDD)</td>
<td>MUIS-C</td>
<td>Partial correlations</td>
<td></td>
<td>66.7 Fair</td>
</tr>
<tr>
<td>America</td>
<td>Community</td>
<td>Mean age=19.67(1.77) Range=18-25 Female=55%</td>
<td></td>
<td>Illness intrusiveness (IIRS)</td>
<td></td>
<td>(controlling for age and socioeconomic background)</td>
<td>r=0.63***</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mullins et al. (2001)</td>
<td>Multiple Sclerosis</td>
<td>78 participants from regional support groups and local neurologists</td>
<td>Cross-sectional</td>
<td>Psychological distress (SCL-90-R)</td>
<td>MUIS-C</td>
<td>Bivariate full scale</td>
<td></td>
<td>70 Good</td>
</tr>
<tr>
<td>America</td>
<td>Outpatients</td>
<td>Mean age=46.3(9.1) Range=30-73 Female=70.5%</td>
<td></td>
<td>Illness intrusiveness (IIRS)</td>
<td></td>
<td>Global PD</td>
<td>β=0.47**</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hierarchical regression analysis</td>
<td>β=0.29*</td>
<td></td>
</tr>
<tr>
<td>Author (year) Country</td>
<td>Chronic illness</td>
<td>Sample characteristics</td>
<td>Study design</td>
<td>Outcome variables (and measures)</td>
<td>MUIS measure</td>
<td>Correlation coefficient</td>
<td>Significant association</td>
<td>Quality score (%) and rating</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>----------------------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>--------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Mullins et al. (2017) America</td>
<td>Allergies, asthma Other chronic illnesses (type 1 diabetes cystic fibrosis, epilepsy, sickle cell disease, migraines, IBD, obesity)</td>
<td>364 college students with self-reported allergies and/or asthma Mean age=19.62(2.09) Range=18-26 Female=65.1%</td>
<td>Cross-sectional</td>
<td>Depression (CES-D)</td>
<td>MUIS-C</td>
<td>Bivariate</td>
<td>Depression Asthma/allergies β=0.36*** Y</td>
<td>60 Fair</td>
</tr>
<tr>
<td>Community</td>
<td></td>
<td></td>
<td></td>
<td>Anxiety (SAS)</td>
<td></td>
<td></td>
<td>Other CI’s β=0.25** Y</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Illness intrusiveness (IIRS)</td>
<td></td>
<td></td>
<td>Anxiety Asthma/allergies β=0.46*** Y</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other CI’s β=0.27** Y</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>148 college students with self-reported other chronic illnesses Mean age =20.38(1.70) Female=69.6%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pahlevan (2017a) Malaysia</td>
<td>Breast cancer Outpatients</td>
<td>918 Malaysian women with breast cancer from a private hospital Mean age =50.95(9.35) Female=100%</td>
<td>Cross-sectional</td>
<td>Depression and anxiety (HADS) Locus of control (Locus of control scale -short form)</td>
<td>SF-MUIS</td>
<td>Partial correlation (controlling for age, cancer stage, time since diagnosis and education)</td>
<td>Depression r=0.32** Y</td>
<td>80 Good</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Anxiety r=0.29** Y</td>
<td></td>
</tr>
<tr>
<td>Author (year)</td>
<td>Chronic illness</td>
<td>Sample characteristics</td>
<td>Study design</td>
<td>Outcome variables (and measures)</td>
<td>MUIS measure</td>
<td>Correlation coefficient</td>
<td>Significant association</td>
<td>Quality score (%) and rating</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>-----------------------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>--------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Pahlevan et al. (2017b)</td>
<td>Breast cancer</td>
<td>135 Malaysian women with breast cancer from a medical centre</td>
<td>Cross-sectional</td>
<td>Depression and anxiety (HADS)</td>
<td>MUIS-SF</td>
<td>Partial correlation (controlling for age, cancer stage, time since diagnosis and education)</td>
<td>Y</td>
<td>60 Fair</td>
</tr>
<tr>
<td></td>
<td>Outpatients</td>
<td>Mean age =51.18(9.48) Female=100%</td>
<td></td>
<td>Coping strategies (Brief COPE)</td>
<td></td>
<td>Depression r=0.32**</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female=100%</td>
<td></td>
<td></td>
<td></td>
<td>Anxiety r=0.27**</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>November 2015 to January 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanders-Dewey et al. (2001)</td>
<td>Parkinson’s disease</td>
<td>44 participants 66 years (SD = 7.9 years) Mean age = 72.8 (7.2) Female=29.5%</td>
<td>Cross-sectional</td>
<td>Psychological Distress (90-SCL-R) Depression and anxiety subscales</td>
<td>MUIS-C</td>
<td>Bivariate Depression r=0.21 Anxiety r=0.20 GSI r=0.14 Multiple regression analysis IU no significant variance to global distress</td>
<td>N</td>
<td>70 Good</td>
</tr>
<tr>
<td></td>
<td>Outpatients</td>
<td>Mean age = 72.8 (7.2) Female=29.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Santacroce &amp; Lee (2006)</td>
<td>Young adult survivors of childhood cancer</td>
<td>45 participants: a clinical database of a childhood cancer long-term follow up programme</td>
<td>Cross-sectional</td>
<td>Post traumatic symptoms (PTSDI)</td>
<td>MUIS -C</td>
<td>Bivariate r=0.40*</td>
<td>Y</td>
<td>60 Fair</td>
</tr>
<tr>
<td></td>
<td>Community</td>
<td>Mean age=24.5(5.5) Range=22-40 Female=62.2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author (year)</td>
<td>Chronic illness</td>
<td>Sample characteristics</td>
<td>Study design</td>
<td>Outcome variables (and measures)</td>
<td>MUIS measure</td>
<td>Correlation coefficient</td>
<td>Significant association</td>
<td>Quality score (%) and rating</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>----------------------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Sharkey et al. (2018)</td>
<td>Chronic conditions (including asthma, allergies, inflammatory bowel disease, type 1 diabetes, epilepsy, obesity, juvenile rheumatoid arthritis)</td>
<td>120 college students</td>
<td>Cross-sectional</td>
<td>Depression (CES-D)</td>
<td>MUIS-C</td>
<td>r=0.57***</td>
<td>Y</td>
<td>60 Fair</td>
</tr>
<tr>
<td></td>
<td>America</td>
<td>Mean age =21.13(5.45)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female=73.3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Community</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Anxiet (SAS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grit (SGS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Illness intrusiveness (IIRS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small &amp; Graydon (1992)</td>
<td>COPD</td>
<td>26 participants from five large teaching hospitals</td>
<td>Cross-sectional</td>
<td>Transient mood states (negative mood)</td>
<td>MUIS-A (28-item)</td>
<td>r=0.37</td>
<td>N</td>
<td>70 Good</td>
</tr>
<tr>
<td></td>
<td>Canada</td>
<td>Mean age=69(8.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Range=53-86</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female=42.3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Physical symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Somatic scale Emphysema symptom checklist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hierarchical regression analysis (controlling for physical symptoms) IU accounted for 9% of variance (and prediction not significant)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author (year)</td>
<td>Chronic illness</td>
<td>Sample characteristics</td>
<td>Study design</td>
<td>Outcome variables (and measures)</td>
<td>MUIS measure</td>
<td>Correlation coefficient</td>
<td>Significant association</td>
<td>Quality score (%) and rating</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>---------------------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>--------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Wolfe-Cristensen et al. (2008)</td>
<td>Childhood onset asthma Community</td>
<td>102 young adult college students recruited from undergraduate psychology and marketing classes at a major Midwestern university</td>
<td>Cross-sectional</td>
<td>Psychological distress (BSI)</td>
<td>MUIS-C</td>
<td>Global severity index of BSI (all nine scales)</td>
<td>Bivariate correlation</td>
<td>r=0.53**</td>
</tr>
</tbody>
</table>

Mean age=19.70(1.25)
Range=18-22
Female=63.7%

Note. BAI=Beck Anxiety Inventory (Beck et al., 1988), Brief COPE, (Carver et al., 1989), BSI=Brief Symptom Inventory (Derogatis, 1993), CES-D=Centre for Epidemiological Studies-Depression (Radloff, 1977), et al., 1997), FARS=Feelings and Reactions Scale (Lemaire, 2004), HADS=Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983), IDD=Inventory to Diagnose Depression (Zimmerman & Coryell, 1987), IIRS=Illness Intrusiveness Ratings Scale (Devins et al., 1983), IUS=Intolerance of Uncertainty Scale (Carleton et al., 2007), Locus of control scale-short form (Levenson, 1974), MAX-PC=Memorial Anxiety Scale for Prostate Cancer (Roth et al., 2003), MUIS-A=Mishel Uncertainty In Illness-Acute (Mishel, 1981), MUIS-C=Mishel Uncertainty In Illness-Community (Mishel, 1986), MSES=Modified Symptom Experience Scale (Detprapon et al., 2009), MSPSS=Multidimensional Scale of Perceived Social Support (Zimet et al., 1988), PHQ-9=Patient Health Questionnaire (Kroenke et al., 2001), POMS=Profile of Mood State (Biehl & Landauer, 1975), PTSDI=Post Traumatic Stress Disorder Index (Pynoos et al., 1998, cited in Santacroce & Lee, 2007), SCL-90-R=Symptom Checklist-90-Revised (Derogatis, 1992), SAS=Zung Self-rating Anxiety Scale (Zung, 1971), SF-GDS=Short Form-Geriatric Depression Scale (Cho et al., 1999), SGS=Short Grit Scale (Duckworth & Quinn, 2009). *p = < 0.05; **p = < 0.01; ***p = < 0.001
Study characteristics

Most of the studies were conducted in the United States of America (N=15). Others took place in Canada (N=1), England (N=1), Italy (N=1), Malaysia (N=2), South Korea (N=1), Taiwan (N=1) and Thailand (N=1). Three studies recruited participants from inpatient settings and the remaining studies from outpatient departments (N=11) or community settings (N=9).

Twenty-two studies employed a cross-sectional design. One employed a prospective longitudinal design (Hoth et al., 2013) measuring variables across 2-years. All studies used self-report measures. Two studies recruited participants from the same medical centre but across different time frames (Pahlevan, 2017a; Pahlevan et al., 2017b), therefore no overlapping datasets were identified.

Clinical characteristics

Demographics

There was a combined total of 3162 participants across studies and a large variation in sample-size (26 to 407, median=118). Mean ages ranged from 19.1 to 65.1 years with 1919 females and 1243 males. Females constituted 60.7% of the overall sample.

Chronic illnesses

Twenty-one studies included one CI and 14 CI’s in total were researched across the studies, including: childhood onset asthma (Carpentier et al., 2007; Hommel et al., 2003; Mullins et al., 2017; Mullins et al., 2000; Sharkey et al., 2018; Wolfe-Christensen et al., 2008); breast cancer (Pahlevan, 2017a; Pahlevan et al., 2017b), head and neck cancer (Detprapon et al., 2009); lung cancer (Kurita et al., 2013); brain tumours (Lin et al., 2013); chronic renal patients (Barberis et al., 2019), end-stage renal disease (B.
Kim & J. Kim, 2019); chronic lung disease or COPD (Hoth et al., 2013; Small & Graydon, 1992), endometriosis (Lemaire, 2004); hepatitis C (Bailey et al., 2009; Colagreco et al., 2014), Multiple sclerosis (Mullins et al., 2001), Parkinson’s Disease (Ahn et al., 2017; Sanders-Dewey et al., 2002) and young adult survivors of childhood cancer (Lee, 2006; Santacroce & Lee, 2006). Two studies researched mixed CI populations (see Table 1, Mullins et al., 2017; Sharkey et al., 2018). Mullins et al. (2017) compared asthma/allergies, mixed CI, and non-CI groups.

**Methodological quality**

All the studies clearly defined their research question, objectives, hypotheses, sample population and inclusion/exclusion criteria. Across all studies, independent and dependent variables, and their corresponding measures, were clearly defined and accompanied by clear reporting of their psychometric properties. The main critique pertained to the cross-sectional design (N=22) and limitations associated with this such as the inability to make causal inferences and the unmeasurable influence of confounding variables on findings. Furthermore, it was only possible to determine that >50% of the source population were recruited in 8/23 studies (34.8%). Therefore, for most studies, samples were not representative of the source populations. Convenience sampling also introduced risks pertaining to self-selection bias amongst the studies. Only seven studies (30.4%) reported a power analysis calculation. Therefore, despite most studies recruiting large samples, it was difficult to determine if they were sufficiently powered to avoid type 1 or II errors.

**Synthesis of review findings**

Studies used a heterogeneous array of measures based on Mishel’s conceptualisation of IU, measures of psychological distress; and recruited participants across various care-contexts and CI types. To synthesise findings, consideration was
given firstly to the overall levels of IU; the general trends across studies of the association between IU and psychological distress: and next according to care-context; measures of psychological distress; CI types; and ‘other’ variables researched in relation to IU. Table 1 presents the correlation coefficients for all the included studies and will be used to facilitate comparisons amongst the measures and groups. Tables 3-5 present means and effect size ranges of the groups or measures to further facilitate comparison of findings.

1. What do the studies suggest about the commonality of illness uncertainty in those with chronic illnesses and its association with psychological distress?

Table 2 presents descriptive statistics for IU scores.

**Table 2.**

*The means, standard deviations (SD) and ranges of scores for studies reporting the most used MUIS-C and MUIS-A*

<table>
<thead>
<tr>
<th>Measure</th>
<th>Mean (SD)</th>
<th>Minimum/maximum score range</th>
</tr>
</thead>
<tbody>
<tr>
<td>MUIS-C (possible range)</td>
<td>56.14(7.9)</td>
<td>45.95-70.60</td>
</tr>
<tr>
<td></td>
<td>23-115</td>
<td></td>
</tr>
<tr>
<td>MUIS-A (possible range)</td>
<td>88.9(6.39)</td>
<td>81.78-99.03</td>
</tr>
<tr>
<td></td>
<td>33-165</td>
<td></td>
</tr>
</tbody>
</table>

*Note.* Nine out of twelve studies using the MUIS-C reported mean IU scores for their samples and all five studies using the original 33-item MUIS-A (or variation of) reported their samples’ mean scores. No MUIS measure provides categorical cut-off scores.
Totalled mean scores across the study samples were subjectively interpreted and deemed low to moderate. Raw scores from the remaining studies using alternate measures (see Appendix F) mirror these findings, suggesting that low to moderate levels of IU are consistent across studies.

Twenty-one studies (91.3%) found statistical significance between IU (or a facet of IU) and form of psychological distress in a positive direction, thus the greater the IU, the greater the psychological distress. Effect sizes were wide-ranging (r = 0.14-0.82).

2. Are there differences in the association between illness uncertainty and psychological distress according to the care-context?

The IU measure used reflected the care-context. Illustratively the MUIS-C (Mishel, 1991) was used predominantly with community (N=9) and outpatient samples (N=2). The MUIS-A (Mishel, 1981) was used in inpatient (N=3) and outpatient samples (N=5).

All nine studies researching community samples found significant associations between IU and a form of psychological distress. These studies researched CI’s ranging from childhood onset asthma (N=4), endometriosis (N=1), childhood cancer survivors (N=2) and mixed CI’s (N=2) (see Table 1). Across studies varying forms of psychological distress were researched, including depression (N=8), anxiety (N=5), general psychological distress (N=5) and post-traumatic stress symptoms (N=2).

Carpentier et al. (2009) conducted hierarchical regression analyses and found that IU significantly predicted depression, anxiety, and psychological distress (p<0.001). Their study was rated as ‘good’ and included a largely representative population of college students (92% participant rate) who rated their asthma severity as relatively mild and somewhat controllable. From examination of bivariate correlations alone in community samples, effects sizes were either medium (Lemaire, 2004; Lee,
2006; Mullin et al., 2017; Santacroce & Lee, 2006), or large (Hommel et al., 2003; Sharkey et al., 2018; Wolfe-Christensen et al., 2009). These studies shared the limitation of not controlling for confounding variables in their examination of the association, however for those who conducted partial correlations (Hommel et al., 2003; Mullins et al., 2000) significant associations remained.

There was a similar trend towards a significant association between IU and psychological distress for inpatient samples using the MUIS-A. Those researching chronic end of life renal disease (Barberis et al., 2019; B. Kim. & J. Kim., 2019) both found medium effect sizes. Conversely, Small and Graydon (1992) found that IU accounted for only 9% of the variance (non-significant) of negative mood in a sample with COPD. The authors postulated that the mean length of time since diagnosis (10.6 years) led to the development of coping, however length since diagnosis was comparable to other studies within this review where significant associations were found (see Appendix G). However, they used a small sample and did not report a power calculation. Thus, the study might have lacked sufficient power to detect an association (type 1 or 11 error).

Outpatients samples (N=11) included those living in the community but receiving treatment from a medical centre (inclusive of Parkinson’s disease, multiple sclerosis, types of cancers, COPD and Hepatitis C). There was a similar trend towards a significant association between IU and psychological distress. Of the significant associations found across outpatient samples, the effect sizes were wide-ranging (0.13-0.82). Two studies found non-significant associations (Kurita et al., 2014; Sanders-Dewey et al., 2002). However, in Sanders-Dewey et al’s. (2002) study with individuals with Parkinson’s disease, the MUIS-C was found to have low internal consistency calling into question the applicability of this measure for their Parkinson’s disease.
population and thus validity of their findings. Table 3 presents the mean effects sizes for all population groups to further aid comparisons. Mean effect sizes for all care-contexts fell within the medium range.

Table 3.

Effect size ranges, means and standard deviations (SD’s) for the association between IU according to care context

<table>
<thead>
<tr>
<th>Sample</th>
<th>Number of studies</th>
<th>Mean effect size (SD)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community</td>
<td>9</td>
<td>0.39 (0.20)</td>
<td>0.01-0.63</td>
</tr>
<tr>
<td>Outpatients</td>
<td>11</td>
<td>0.41(0.19)</td>
<td>0.07-0.82</td>
</tr>
<tr>
<td>Inpatients</td>
<td>3</td>
<td>0.36(0.46)</td>
<td>0.31-0.40</td>
</tr>
</tbody>
</table>

Note: Bivariate correlation coefficients were included in the calculations, however if a study only reported partial correlations these were included in the mean effect size calculation.

3. Are there differences in associations between illness uncertainty and psychological distress according to the type of measurement of psychological distress?

Depression was the most widely measured form of psychological distress (N=16). Within these studies the CES-D (Radloff, 1977, N=6) was the most widely used measure, containing frequency-based questions regarding an array of depressive symptoms. Others used subscales of the HADS (Zigmond & Snaith, 1983, N=4), containing items related to symptoms of anhedonia. See table 1 for other depression measures used.

Measures of depression and associated mood states. Across all 16 studies researching IU and depression there was a general trend towards significant and positive associations, with wide-ranging effect sizes (r=0.05-0.82). Several large effect sizes were found between IU and CES-D (Radloff, 1977) (Bailey et al., 2009; Colagreco et al., 2014; Detprapon et al., 2009; Sharkey et al., 2018).
Three of the studies researching depression used the MUIS-A which illuminated the elements of IU within Mishel’s conceptualisation more associated with the development of low mood. Ambiguity correlated with depression across several studies (Bailey et al., 2009; Colagreco et al., 2014; Hoth et al., 2013). A strength of Bailey et al.’s (2009) study was that they controlled for the other IU subscales. Conversely neither Bailey et al. (2009) nor Colagreco et al. (2014) controlled for confounding variables, meaning other unknown factors could have impacted the association between IU and depression. Hoth et al. (2013) also found in their longitudinal investigation that depression was associated with ambiguity across a 2-year time-period and not at any point in the illness trajectory. This indicates that IU plays a causal role. The authors also recruited a geographically diverse sample. Non-significant associations were found between the unpredictability subscale and depression in two studies researching people with Hepatitis C (Bailey et al., 2009; Colagreco et al., 2014).

All other studies using depression measures examined the relationship with MUIS-total scores. Positive and significant associations were consistent across CI types and care-contexts. This was synonymous for negative mood states (Lin et al., 2013), however this finding was not consistent (Small & Graydon, 1992). Hommel et al. (2003) found that once gender, age, subjective and objective illness severity (asthma) were controlled for, the association between IU and depression became non-significant.

Measures of anxiety. Eight studies measured anxiety using anxiety subscales of the HADS (Zigmond & Snaith, 1983, N=4), and BSI (Derogatis, 1993, N=2); the SAS (Zung, 1971, N=1), and BAI (Beck et al., 1988, N=1). Effect sizes ranged from small to large (0.01-0.56). Most of the studies found positive significant relationships between IU and anxiety. Anxiety also remained stable over a 2-year period and correlated with the ambiguity aspect of IU (Hoth et al., 2013), suggesting that anxiety about symptom
ambiguity/vagueness of symptom profile does not abate. In both Mullins et al.’s. (2017) and Carpentier et al.’s (2009) studies levels of anxiety were significantly higher in the CI groups compared with the healthy controls (no CI diagnosis).

Eight of these studies examined both anxiety and depression. Interestingly, of these eight studies, anxiety had larger correlation coefficients than depression in five studies (Barberis et al., 2019; Hommel et al., 2003; Hoth et al., 2013; Mullins et al., 2017; Sharkey et al., 2018). In Hommel et al.’s. (2003) study IU contributed significant variance to anxiety once gender, age, disease variables and depressive symptomatology were controlled for.

**Measures of psychological distress.** Synonymous with low mood and anxiety a positive significant association was found across six of the seven studies using measures of general distress. All these studies used the MUIS-C (Mishel, 1991) thus conclusions could not be drawn pertaining to individual facets of IU. The effect sizes ranged from small to large with a medium overall mean effect size (see Table 4). Two studies researched childhood survivors of cancer (Santacroce & Lee, 2006) assessing post-trauma symptomatology and found medium significant effect sizes. This supports that IU remains relevant and associated with trauma symptoms for those who are no longer actively unwell but live with an ongoing threat of re-occurrence. Table 4 presents the mean effect sizes for all forms of psychological distress. Overall, they all fell within the medium ranges.
Table 4.

*Effect size ranges and means for the association between IU and forms of psychological distress.*

<table>
<thead>
<tr>
<th>Psychological distress categories</th>
<th>Number of studies</th>
<th>Mean effect size (SD)</th>
<th>Effect size ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression</td>
<td>17</td>
<td>0.38 (0.17)</td>
<td>0.06-0.82</td>
</tr>
<tr>
<td>Anxiety</td>
<td>8</td>
<td>0.36 (0.2)</td>
<td>0.01-0.63</td>
</tr>
<tr>
<td>General psychological distress</td>
<td>5</td>
<td>0.33 (0.22)</td>
<td>0.04-0.53</td>
</tr>
<tr>
<td>Post-trauma symptoms</td>
<td>2</td>
<td>0.40 (0)</td>
<td>0.40</td>
</tr>
</tbody>
</table>

*Note:* Bivariate correlation coefficients were included in the calculations, however if a study only reported partial correlations these were included in the mean effect size calculation.

4. *Are there differences in associations between illness uncertainty and psychological distress according to chronic illness type?*

One study directly compared CI groups (see Table 1, Mullins et al., 2017). Their group with mixed CI’s had significantly higher levels of IU and anxiety than those with asthma/allergies or those with an absence of a CI diagnosis. Four studies researched childhood onset asthma (Carpentier et al., 2007; Hommel et al., 2003; Mullins et al., 2000; Wolf-Christensen et al., 2009); and two additional studies researched mixed asthma/allergy samples (Mullins et al., 2017; Sharkey et al., 2018). All six of these studies recruited young adult college students limiting generalisability to other populations. Nevertheless, borderline large or large effect sizes were found in most of the studies researching solely asthma or medium or large effect sizes were observed for those including mixed asthma/allergy samples. The only study that researched endometriosis found IU to be associated with emotional distress with a medium effect size (Lemaire, 2004).
Positive significant associations were consistently found for those with cancers, with at least medium effect sizes (0.27-0.82). The largest effect size was observed for those with head and neck cancer, an illness that threatens parts of the body that are visibly prominent and serve important communicative functions. One out of three studies researching degenerative conditions (Sander-Dewey et al., 2002) found a non-significant association. It was possible that those individuals were clearer about their prognosis and impending outcome. However more studies are needed on IU and degenerative conditions so that robust conclusions can be drawn.

Table 5 presents the mean effect sizes across CI groups. The mean effect size was slightly larger for those with cancers overall, which may reflect the threatening nature of the condition and corresponding treatments. However, all groups fell within the medium effect size range.

**Table 5.**

*Effect size ranges, means and standard deviations (SD’S) for the association between IU according to CI types.*

<table>
<thead>
<tr>
<th>Sample</th>
<th>Number of studies</th>
<th>Mean effect size (SD)</th>
<th>Effect size ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancers</td>
<td>6</td>
<td>0.43 (0.17)</td>
<td>0.18-0.82</td>
</tr>
<tr>
<td>Childhood onset asthma/allergies</td>
<td>6</td>
<td>0.36 (0.23)</td>
<td>0.01-0.63</td>
</tr>
<tr>
<td>Degenerative conditions</td>
<td>3</td>
<td>0.30 (0.16)</td>
<td>0.14-0.47</td>
</tr>
</tbody>
</table>

*Note:* Bivariate correlation coefficients were included in the calculations, however if a study only reported partial correlations these were included in the mean effect size calculation.

5. **What is known about other variables in relation to illness uncertainty?**

**Gender.** Eighteen studies used mixed gender samples, and seven examined IU according to gender. Women reported significantly higher levels of IU in two studies on
participants with mixed CI’s and childhood onset asthma (Sharkey et al., 2018; Wolfe-Christensen et al., 2008). There was no significant difference in IU scores between genders in five studies (Ahn et al., 2017; Bailey et al., 2009; Carpentier et al., 2009; Kurita et al., 2013; Mullins et al., 2001).

**Illness intrusiveness.** Illness intrusiveness was assessed across five studies (Carpentier et al., 2007; Mullins et al., 2000; Mullins et al., 2001; Mullins et al., 2017; Sharkey et al., 2018). Only one study (Sharkey et al., 2018) found that IU and illness intrusiveness combined influenced anxious and depressive symptomatology. The other studies found that IU and illness intrusiveness independently predicted depressive and anxious symptomatology (Mullins et al., 2000; Mullins et al., 2001; Mullins et al., 2017). Illness intrusiveness did not mediate the relationship (Mullins et al., 2000). Mullins et al. (2017) found greater effects sizes for IU than illness intrusiveness for both depressive ($\beta=0.36$, $p < .001$) and anxiety symptoms ($\beta=0.46$, $p < .001$).

**Grit.** Sharkey et al. (2018) found an inverse relationship between grit and IU ($\beta= -0.21$, $p< .05$). Their overall path-analysis demonstrated that IU mediated the relationship between grit and outcomes of anxiety and depression. Thus, grit was associated with reduced IU which in turn was related to decreased distress.

**Coping styles.** Pahlevan et al. (2017b) found a significant positive relationship between IU and avoidant coping ($r = 0.218$, $p < 0.05$), and the inverse for active emotional coping ($r = -0.297$, $p < 0.01$). Kurita et al. (2013) examined avoidance (e.g. of uncertain situations threatening images or thoughts) and its relationship with intolerance of uncertainty. Avoidance was found to mediate between intolerance of uncertainty and non-somatic depressive symptoms.

**Locus of control.** Pahlevan (2017a) examined LOC and found that individuals with breast cancer with higher internal LOC (ILOC, and lower external LOC)
experienced lower anxiety (-0.374, p<0.01) and depression (-0.269, p<0.01).

Uncertainty mediated the relationship between LOC and depression, but not anxiety.

**Disease-related variables**

**Symptom severity.** Subjective symptom severity was measured across seven studies and objective illness severity was additionally measured in three of those studies (see Table 5). The measures used to examine illness severity differed in accordance with differing clinical profiles. Overall, IU was more frequently positively associated with subjective ratings, thus the more one perceived their symptoms to be severe the greater the IU. A limitation of Wolfe-Christensen et al.’s (2008) study was there use of a single item created by the research team, thus calling into question the comprehensiveness and reliability of it.
Table 5.

*The Correlation coefficients (r) between subjective and objective illness severity and IU.*

<table>
<thead>
<tr>
<th>Study</th>
<th>Subjective illness severity rating</th>
<th>Objective illness severity rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carpentier et al. (2007)</td>
<td>0.01</td>
<td>-0.06</td>
</tr>
<tr>
<td>Detprapon et al. (2009)</td>
<td>0.69***</td>
<td></td>
</tr>
<tr>
<td>Hommel et al. (2003)</td>
<td>0.17</td>
<td>0.23</td>
</tr>
<tr>
<td>Mullins et al. (2000)</td>
<td>0.38*</td>
<td></td>
</tr>
<tr>
<td>Mullins et al. (2017)</td>
<td>0.106**</td>
<td></td>
</tr>
<tr>
<td>Lin et al. (2013)</td>
<td>Anger 0.26***</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tension 0.18*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Depression 0.24**</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fatigue 0.24***</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Confusion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-significant</td>
<td></td>
</tr>
<tr>
<td>Wolf-Christensen et al. (2008)</td>
<td>0.40**</td>
<td>0.07</td>
</tr>
</tbody>
</table>

*Note. *p = < 0.05; **p = <0.01; ***p = < 0.001

**Illness duration.** Illness durations varied greatly across studies and are tabulated in Appendix G. Three out of seven studies that examined illness duration found a non-significant association with IU. In two studies ‘time since diagnosis’ was used as a control and the significant relationship between IU and PD remained (Pahlevan, 2017a; Pahlevan et al., 2017b). In the only prospective study, ambiguity, and psychological distress were not impacted by number of years since diagnosis (Hoth et
al., 2013). Only one study found that an earlier point in the illness trajectory was associated with greater IU in those with brain tumours (Lin et al., 2013).

**Discussion**

This is the only systematic review to synthesise and examine the current state of quantitative research investigating the association between IU and psychological distress in adult CI populations. The review comprised 23 papers spanning almost three decades (1992 to 2019), with a total number of 3126 participants. Overall low to moderate levels of IU were observed across the included studies, confirming that IU is an integral aspect of the CI experience (Mishel, 1990).

This synthesis garners strong support for the association between IU and psychological distress, supported by 21 studies. While conclusions cannot be drawn regarding the direct or causal link between IU and psychological distress, findings suggest IU impacts on psychological distress in adults with CI. This is consistent with the meta-analytic evidence found in relation to paediatric IU in which medium effect sizes were observed between IU and outcomes of depression and anxiety (Szulxzewski et al., 2017).

IU was ubiquitously linked with psychological distress, regardless of gender, care-context, form of psychological distress or CI type. Some findings suggest that ambiguity; symptoms or causes that can be vague and interpretable in several ways, might be more pertinent to the development of psychological distress than other facets of IU. Furthermore, slightly higher associations were found overall for those with cancers, with at least medium effect sizes (0.27-.0.82). This might reflect the threat of mortality cancer poses (American Cancer Society, 2008). More research is needed researching inpatient samples.
This synthesis found that IU associated with diverse manifestations of distress. Depression and anxiety were frequently comorbid which reflects findings in the general population (Wu & Fang, 2014); and overall, they were consistently associated with IU. Clark and Watson’s (1991) tripartite model argues that anxiety and depression which are physiologically and phenomenologically distinct (anxiety is characterised by hyperarousal and depression by anhedonia), are both underpinned by negative affectivity. Comorbidity can complicate the clinical picture, leading to treatment resistance (Wu & Fang, 2014). However, these findings suggest that IU is an underlying transdiagnostic factor elevating negative affectivity in those with CI’s. Furthermore, trauma symptoms were observed to associate with IU in two childhood cancer survivor populations (Lee, 2006; Santacroce & Lee, 2003). Post trauma symptomatology has also been identified in a chronic heart disease population (Moreland & Santacroce, 2018), which suggests this finding is generalisable to other CI populations and underpinned by IU related challenges. However more research is needed assessing post trauma symptomatology in those with other CI’s.

**Theoretical frameworks**

Considering Mishel’s (1990) framework it can be inferred from these findings that negative appraisal and maladaptive coping strategies are employed in response to the experience of IU, leading to outcomes of psychological distress. Indeed, in Wright et al’s. (2009) review IU was found to associate with maladaptive coping strategies. Most of the studies did not assess appraisal processes connected to IU, mirroring a previous critique of the empirical literature guided by Mishel’s UIT (McCormick, 2004). However, research has begun exploring intolerance of uncertainty (Kurita et al., 2013) and ILOC (Pahlevan et al., 2017); the appraisal that one is responsible for the events that occur/perceptions of control. These are important areas of research because
how in control a person feels influences uncertainty (McCormick, 2002). Furthermore, ILOC has previously been found to inversely associate with anxiety, and depression (Fan et al., 2010; Park & Gaffey, 2007) and better health outcomes (Green & Murdock, 2013). A large body of research has studied intolerance of uncertainty as an influential transdiagnostic factor underlying anxiety disorders and depression (Boswell et al., 2013; Carleton et al., 2012). Hence, a fruitful area for future research pertains to the exploration of intolerance of uncertainty and ILOC as specific appraisal process in the context of CI and IU.

This synthesis indicates that IU correlates with psychological distress at any point in the illness trajectory and post recovery, into survivorship (Lee, 2006; Santacroce & Lee, 2006). This evidence and the longitudinal investigation (Hoth et al., 2013) refutes Mishel’s (1990) UIT reconceptualization that, over time, a perspective shift from a danger appraisal to opportunity may lead to positive psychological changes. However, psychological adaptation to CI and chronic IU is a complex, evolving and possibly cyclical process (Mishel, 1988, 1990). Qualitative research in this area would enrich the understanding of how IU is experienced and evolves over time.

The cognitive behavioural model can also be used to understand the association between IU and psychological distress. The theory argues that appraisals, emotions, and behaviours (such as maladaptive coping strategies) interact and influence each other. Pahlevan et al. (2017b) found that IU was positively associated with avoidant coping (such as denial or self-distraction), anxiety and depression, a finding that was consistent with previous findings in a sample with prostate cancer (Guan et al., 2020). Pahlevan et al. (2017b) adds the importance of IU in this association. The Cognitive Behavioural Therapy (CBT) model suggests that the ways in which one behaves (coping strategies) can perpetuate negative affect and appraisal. Thus, CBT advocates targeting coping
strategies, management of affect and cognitive reframing (Beck, 1976). A previous study demonstrated that applying CBT and shifting control-beliefs from external to internal (ILOC) led to positive outcomes in a CI population (Mehrtak et al., 2017).

**Limitations of the studies**

The limitations of the included studies restrict the validity and generalisability of the findings. The predominant limitation concerned the cross-sectional design which meant causality could not be deduced. Henceforth it was unclear whether IU contributed directly to psychological distress or whether those with higher psychological distress experienced greater IU. It might be that there is a reciprocal and mutually reinforcing relationship between these variables. Future longitudinal research should utilise designs that elucidate causation and explore the temporal relationships between variables.

A cross-sectional design also introduces risks pertaining to uncontrolled, confounding variables (Setia, 2016). IU and psychological distress are dynamic and likely to be confounded by external events. Therefore, caution should be exercised when attributing psychological distress solely to IU. Additionally, in relation to examination of the direct association between IU and psychological distress, only nine studies used statistical methods that allowed for known confounding variables to be controlled for. Finally, only six studies reported a power calculation, thus despite most studies recruiting large samples, it was difficult to determine if studies were sufficiently powered (Nayak, 2010).

The studies were also limited in terms of their generalisability. Most studies were conducted in the USA; thus, the cross-cultural validity of the findings is spurious. Additionally, convenience sampling was used across studies. This method can reduce sample bias by generating a more representative sample of the population of interest (Hulley et al., 2013), however, in half the studies less than 50% of the available sample
were recruited. Thus, in comparison to random sampling methods this design lacks rigour. Furthermore, all studies researching childhood asthma or mixed asthma/allergies samples used young adult college students and thus future research would need to diversify samples to generalise findings. As significant differences between asthma and allergy groups have been observed (Hullman et al., 2013), future research should delineate groups. Replicated studies of specific CI’s might add to the understanding of IU and psychological distress for each CI, which vary naturally in their challenges, particularly with regards to the condition’s controllability.

While a strength of the studies was that they utilised valid and reliable measures, Carleton et al. (2013) argued that the validity and psychometric properties of the CES-D have been questioned. For example, items assessing somatic concerns may artificially inflate scores for chronic pain populations. Considering that the phenomenology of many CI’s involves the experience of pain or other somatic complaints, it must be acknowledged that this may have conflated findings in the six studies in which it was employed in. Future research might consider the use of depression measures that do not include items related to somatic complaints. In general, the extensive use of self-report measures may have increased the chance of shared method variance which can lead to a higher probability of significant relationships between variables (Podsakoff et al., 2003). With further consideration of measurement, future studies should delineate MUIS subscales to assist understanding of which aspects may be a target for psychological intervention.

Limitations of the review

A narrative synthesis approach was chosen on the basis the studies were not homogenous enough to conduct a meta-analysis; it was deemed unfeasible to divide papers into homogenous clusters to conduct subgroup statistical analyses. Therefore,
this review did not use meta-analytic statistics to quantify associations and test moderators, however the narrative synthesis enabled examination of the IU, psychological distress association across settings, CI types and forms of psychological distress. The conclusions may have been undermined by publication bias meaning that quantitative studies that demonstrate significant findings are more likely to be published or those that did not are more likely to remain unpublished (Joober et al., 2012). Furthermore, the exclusion of grey literature and non-English language articles from the review may have increased this bias. Future reviews could include correspondence with experts in the field to pursue unpublished data (Rosenthal, 1979). Finally, mean effects sizes were used to supplement comparison of groups, however this simple statistically calculation does not calculate the precision of individual studies (Borenstein et al., 2007), thus these findings should be interpreted with caution.

Strengths of this review included the breadth of electronic databases searched, with no publication-date restrictions, enabling a comprehensive search of eligible studies. This increased the probability they were all retrieved. This review followed a systematic process and employed a critical appraisal tool, second-rated, which increased its robustness and would enable other reviewers to accurately replicate. Furthermore, the PRISMA (2009) checklist was used to facilitate quality and comprehensiveness (see Appendix H).

Clinical implications

This synthesised body of evidence does not refute current practices and guidance. An intervention employing cognitive-behavioural strategies in line with NICE (2010) guidance, suggests that IU can be modified by targeting a patient’s cognitions, knowledge, and coping skills and that this can have positive effects for those with a CI (Gil et al., 2006). These findings suggest that assessing and targeting IU as a
transdiagnostic factor underpinning many forms of psychological distress is relevant in diverse care settings, across genders, and at any time across the illness trajectory.

HCP’s should routinely assess for the presence of IU and forms of psychological distress at the point of diagnosis, throughout the illness trajectory and into survivorship (Decker et al., 2007). Use of the MUIS-A would enable assessment of the distinct aspects of IU, however when used in community samples, consideration ought to be taken with regards to non-applicable items. HCP’s should assess for the idiosyncratic meaning of IU, appraisals (including of intolerance of uncertainty and control beliefs) and coping strategies. Where psychological distress reaches a clinical level, the above assessment information can guide the development of a CBT case formulation (Jacqueline & Lisa, 2015) and guides target areas for intervention that account for IU. Given the prevalence of IU in CI populations and potential for negative appraisal or intolerance of uncertainty, the experience of IU should be normalised. In line with Mishel’s (1981) theory and the pertinence of ambiguity to psychological distress, HCP’s should endeavour to provide clear information and effective communication.

**Conclusions**

A synthesis of all available studies strongly suggests an association between IU and psychological distress, regardless of individual or contextual differences. Findings support current guidance recommending CBT to address psychological distress in those with CI. IU should be considered as a transdiagnostic factor, and appraisals processes targeted. HCP’s should normalise IU in those with CI’s at any point along the illness trajectory. Future research is needed to establish appraisal processes linked to IU, causal pathways and how to investigate how IU evolves over time.
References

* = included in this review


https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf


https://doi.org/10.1002/nur.4770110203.


https://doi:10.1097/PSY.0b013e318051542c.


Appendix A

Search strategy: search terms

*Search terms entered into all search engines Scopus, Psycinfo and MEDLINE*

<table>
<thead>
<tr>
<th>Population</th>
<th>Target variable</th>
<th>Psychological outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>“chronic* ill*” OR</td>
<td>“illness uncertainty” OR</td>
<td>“psychological distress*”</td>
</tr>
<tr>
<td>“chronic condition*” OR</td>
<td>“Mishel* illness” OR</td>
<td>“psychological stress”</td>
</tr>
<tr>
<td>“chronic* disease*” OR</td>
<td>uncertainty theory” OR</td>
<td>OR depression OR</td>
</tr>
<tr>
<td>“chronically critically ill”</td>
<td>“Mishel* illness”</td>
<td>“depressive symptom*”</td>
</tr>
<tr>
<td>OR “chronic patient*” OR</td>
<td>uncertainty scale” OR</td>
<td>OR “depressive disorder”</td>
</tr>
<tr>
<td>“noncommunicable”</td>
<td>MUIS OR uncertainty</td>
<td>OR “emotional distress”</td>
</tr>
<tr>
<td>disease*” OR NCD</td>
<td></td>
<td>OR “mood state*” OR</td>
</tr>
<tr>
<td>OR illness OR disease OR</td>
<td></td>
<td>“negative mood” OR</td>
</tr>
<tr>
<td>“disabled persons” OR</td>
<td></td>
<td>“negative affect” OR</td>
</tr>
<tr>
<td>LTC OR “long term” condition*” OR arthritis</td>
<td></td>
<td>anxiety OR anxious OR</td>
</tr>
<tr>
<td>OR asthma OR “brain injuries” OR cancer OR</td>
<td></td>
<td>loneliness OR PTSD OR</td>
</tr>
<tr>
<td>“cardiovascular disease*” OR</td>
<td></td>
<td>“posttraumatic stress disorder” OR distress OR</td>
</tr>
<tr>
<td>OR “chronic obstructive pulmonary disease*” OR</td>
<td></td>
<td>“psychological well-being” OR “psychosocial adjustment” OR</td>
</tr>
<tr>
<td>COPD OR CVD OR</td>
<td></td>
<td>“psychological adjustment” OR “common mental disorder”</td>
</tr>
<tr>
<td>“diabetes mellitus” OR diabetes OR epilepsy OR HIV OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hypercholesterolemia OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population</td>
<td>Target variable</td>
<td>Psychological outcome</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>hypertension OR</td>
<td>&quot;inflammatory bowel disease&quot; OR &quot;interstitial cystitis&quot; OR lupus OR &quot;musculoskeletal disorder&quot; OR &quot;multiple sclerosis&quot; OR &quot;parkinsons disease&quot; OR &quot;sickle cell disease&quot; OR stroke</td>
<td></td>
</tr>
</tbody>
</table>

*Note.* COPD=chronic obstructive pulmonary disease; CVD=cardiovascular disease; HIV=Human immunodeficiency virus; LTC=long term condition; MUIS=Mishel’s illness uncertainty scale; NCD=noncommunicable disease.
Appendix B
Search strategy: Inclusion/exclusion criteria

Table presenting inclusion and exclusion criteria

<table>
<thead>
<tr>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Over the age of 18 years and individuals with a diagnosed chronic health condition defined by DOH (2017) and WHO (2016) (and defined diagnostically by the medical profession)</td>
<td>Populations with conditions that do not fit the definition of a diagnosable chronic health condition, such as medically unexplained symptoms, chronic pain conditions or diagnoses of exclusion (e.g. fibromyalgia, chronic fatigue syndrome);</td>
</tr>
<tr>
<td>The paper includes the measurement of PD as defined in previous research as a broad concept (Gong et al., 2016; Kuswanto et al., 2018)</td>
<td>Papers that are studying an acute self-limiting condition, other non-chronic physical health illness or chronic mental illnesses</td>
</tr>
<tr>
<td>A Quantitative methodology was used including cross-sectional, correlational, prospective and longitudinal studies.</td>
<td>Papers studying participants under age 18 or where the data is not separate for the adult age group and the child/adolescent age group</td>
</tr>
<tr>
<td>The direct relationship between IU and PD is statistically examined.</td>
<td></td>
</tr>
<tr>
<td>Inclusion criteria</td>
<td>Exclusion criteria</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>The paper is published in a peer-reviewed journal.</td>
<td>The paper uses proxy measures of individual uncertainty (e.g. child illness uncertainty, parent uncertainty or carer uncertainty)</td>
</tr>
<tr>
<td>The paper is written in the English language.</td>
<td>Outcomes measures that do not constitute PD (see introduction)</td>
</tr>
<tr>
<td>IU is measured using a version of or subscale of the MUIS (e.g. Hagen et al., 2011; Mishel, 1981; Mishel, 1986)</td>
<td>Measurement of IU immediately before and/or after participants are undergoing a major medical procedure/surgery/drug trial.</td>
</tr>
<tr>
<td>The full-text paper is possible to obtain following reasonable means to obtain it</td>
<td>Non-peer reviewed papers such as grey literature, conference abstracts, case studies or unpublished theses</td>
</tr>
<tr>
<td></td>
<td>Studies employing a qualitative methodology</td>
</tr>
</tbody>
</table>
Appendix C

Psychometric properties of MUIS measures used in the studies included in this review


The MUIS-A which has been available since 1981 has undergone repeated psychometric evaluation (Bailey et al., 2009). Cronbach’s alphas of the four subscales, ambiguity (13 items), complexity (7 items), inconsistency (7 items) and unpredictability (5 items) were 0.86, 0.81, 0.78 or 0.65 respectively (Mishel, 1997); and a Cronbach’s alpha of 0.87 for the whole scale (Mishel, 1997). The full scale MUIS-A was found to be 0.90 in a study with those with Hepatitis C (Bailey et al., 2009). The Cronbach’s alpha was 0.84 in another study researching those with Hepatitis C (Colagreco et al., 2014. The Cronbach’s alpha was 0.86 in a study on a population of people with chronic renal disease (Barberis et al., 2019). The Cronbach’s alphas for the ambiguity and complexity subscales were 0.88 and 0.79 respectively in a study with individuals with chronic lung disease (Hoth et al., 2013).

The 33-item MUIS-brain tumour form (MUIS-BT, Lin et al., 2012).

Six out of 33 items in the original MUIS-A were modified to better suit the experience of people with primary brain tumours and uncertainty. Cronbach’s alphas of the four subscales, ambiguity/inconsistency, unpredictability of disease prognosis, unpredictability of symptoms and complexity were 0.90, 0.77, 0.75 and 0.65, respectively for those with brain tumours (Lin et al., 2012).

The 33-item Korean MUIS (Jung et al., 2005)

The Korean MUIS was found to have a Cronbach’s alpha on 0.91 in people with gynaecologic cancer patients (Jung et al., 2005) and 0.79 in a study researching people with chronic renal disease on haemodialysis (B. Kim & J. Kim, 2019).
MUIS-Community (MUIS-C, Mishel, 1997)

MUIS-C scores across 18 adult samples with CI’s (total n=1068) were examined and Cronbach’s alpha ranged from 0.53-0.92; values exceeded 0.85 in the majority of the samples (Mishel, 1997), comparable to the MUIS-A. Bailey et al. (2011) conducted a secondary analysis examining the reliability of the MUIS-C for use with men undergoing active surveillance for prostate cancer and the Cronbach’s alpha for the full MUIS-C was .908. The Cronbach’s alphas collected from 20 studies with people with CI’s (Mishel, 1997, cited in Carpentier et al., 2009) ranged from 0.74 to 0.92.

MUIS-short form (MUIS-SF, Hagen et al., 2015)

The 5-item MUIS-SF was found to have a Cronbach’s alpha of 0.70 in patients with breast cancer. In two studies researching women with breast cancer (Pahlevan, 2017a; Pahlevan et al., 2017b) the Cronbach’s alpha were found to be 0.50 and 0.56, respectively.
Appendix D
Quality appraisal tool

The Observational Cohort and Cross-sectional studies tool (National Institutes of Health (2014). Observational Cohort and Cross-sectional studies tool.

https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Yes</th>
<th>No</th>
<th>Other (CD, NR, NA)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Was the research question or objective in this paper clearly stated?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Was the study population clearly specified and defined?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Was the participation rate of eligible persons at least 50%?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Criteria</td>
<td>Yes</td>
<td>No</td>
<td>Other (CD, NR, NA)*</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-----</td>
<td>----</td>
<td>---------------------</td>
</tr>
<tr>
<td>5. Was a sample size justification, power description, or variance and effect estimates provided?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Was the exposure(s) assessed more than once over time?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Criteria</td>
<td>Yes</td>
<td>No</td>
<td>Other (CD, NR, NA)*</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-----</td>
<td>----</td>
<td>---------------------</td>
</tr>
<tr>
<td>11. Were the outcome measures (dependent variables) clearly defined,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>valid, reliable, and implemented consistently across all study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>participants?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Were the outcome assessors blinded to the exposure status of</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>participants?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Was loss to follow-up after baseline 20% or less?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Were key potential confounding variables measured and adjusted</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>statistically for their impact on the relationship between exposure(s)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and outcome(s)?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Quality Rating (Good, Fair, or Poor)**

Rater #1 initials:
<table>
<thead>
<tr>
<th>Quality Rating (Good, Fair, or Poor)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rater #2 initials:</td>
</tr>
<tr>
<td>Additional Comments (If POOR, please state why):</td>
</tr>
</tbody>
</table>

*CD, cannot determine; NA, not applicable; NR, not reported
### Appendix E

Quality appraisal of all studies

Table of Quality appraisal ratings for each item on the observational cohort and cross-sectional studies appraisal tool (items 1-14, see Appendix D).

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>Score (%) and rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahn et al.</td>
<td></td>
<td></td>
<td>CD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td>70% GOOD</td>
</tr>
<tr>
<td>(2017)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bailey et al.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td>72.7% GOOD</td>
</tr>
<tr>
<td>(2009)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>Score (%) and rating</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>-----</td>
<td>---------------------</td>
</tr>
<tr>
<td>Barberis et al. (2019)</td>
<td></td>
<td></td>
<td></td>
<td>NR</td>
<td>NR</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>54.5% FAIR</td>
<td></td>
</tr>
<tr>
<td>Carpentier et al. (2007)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>80% GOOD</td>
<td></td>
</tr>
<tr>
<td>Colagreco et al. (2014)</td>
<td></td>
<td></td>
<td>NR</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50% FAIR</td>
<td></td>
</tr>
<tr>
<td>Detprapon et al. (2009)</td>
<td></td>
<td></td>
<td></td>
<td>NR</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>55.6% FAIR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>Score (%) and rating</td>
</tr>
<tr>
<td>----------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Hoth et al. (2013)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>75%</td>
<td>GOOD</td>
</tr>
<tr>
<td><strong>Hommel et al. (2003)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60%</td>
</tr>
<tr>
<td><strong>B. Kim &amp; J. Kim (2019)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60%</td>
</tr>
<tr>
<td><strong>Kurita et al. (2013)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70%</td>
</tr>
<tr>
<td><strong>Lee (2006)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60%</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>Score (%) and rating</td>
</tr>
<tr>
<td>----------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----------------------</td>
</tr>
<tr>
<td>Lemaire (2004)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td>60% FAIR</td>
</tr>
<tr>
<td>Lin et al. (2013)</td>
<td>CD</td>
<td>CD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td>63.6% FAIR</td>
</tr>
<tr>
<td>Mullins et al. (2000)</td>
<td>CD</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td>66.7% FAIR</td>
</tr>
<tr>
<td>Mullins et al. (2001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td>NA</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td>70% GOOD</td>
</tr>
<tr>
<td>Mullins et al. (2017)</td>
<td>CD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td>60% Fair</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>Score (%) and rating</td>
</tr>
<tr>
<td>----------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----------------------</td>
</tr>
<tr>
<td>Pahlevan (2017a)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>80%</td>
<td>GOOD</td>
</tr>
<tr>
<td>Pahlevan et al. (2017b)</td>
<td></td>
<td></td>
<td></td>
<td>CD</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60%</td>
<td>FAIR</td>
</tr>
<tr>
<td>Santacroce &amp; Lee (2006)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70%</td>
<td>GOOD</td>
</tr>
<tr>
<td>Sanders-Dewey et al. (2002)</td>
<td></td>
<td></td>
<td></td>
<td>CD</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60%</td>
<td>FAIR</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>Score (%) and rating</td>
</tr>
<tr>
<td>----------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----------------------</td>
</tr>
<tr>
<td>Sharkey et al. (2018)</td>
<td></td>
<td>CD</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>60%</td>
<td>FAIR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small &amp; Graydon (1992)</td>
<td></td>
<td></td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>70%</td>
<td>GOOD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wolfe-Christensen et al. (2008)</td>
<td></td>
<td>CD</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>60%</td>
<td>FAIR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note.* Numbers 1 to 14 correspond to quality appraisal tool questions (see Appendix D); Green = Yes Red = No White = NA/NR/CD. A “good” study has the least risk of bias; the results are considered to be valid. “Fair” constitutes some susceptibility to bias but not sufficient to invalidate the result.

CD=cannot determine, NR= not reported NA=not applicable. In total Good=9, Fair=14, Poor=0
Appendix F

Illness uncertainty scores

Table presenting IU raw scores for each paper

<table>
<thead>
<tr>
<th>Study</th>
<th>MUIS-C (range 23-115)</th>
<th>MUIS-A (original 33 item) (range 33-165)</th>
<th>MUIS-A modified (28-item) (range 28-140)</th>
<th>“other” *SF-MUIS (range 5-25)</th>
<th>** BT-MUIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahn et al. (2017)</td>
<td>99.03 (13.04)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bailey et al. (2009)</td>
<td></td>
<td>87.30 (17.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barberis et al. (2019)</td>
<td></td>
<td>81.78 (16.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carpentier et al. (2007)</td>
<td></td>
<td></td>
<td></td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Colagreco et al. (2014)</td>
<td></td>
<td>86.45 (13.84)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detprapon et al. (2009)</td>
<td></td>
<td>53.9 (13.05)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hommel et al. (2003)</td>
<td></td>
<td>47.63 (12.19)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoth et al. (2013)</td>
<td></td>
<td></td>
<td>35.4 (10.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Kim &amp; J. Kim (2019)</td>
<td></td>
<td>90.00 (11.63)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kurita et al. (2013)</td>
<td></td>
<td></td>
<td></td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Lee (2006)</td>
<td></td>
<td>51.3 (14.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lemaire (2004)</td>
<td></td>
<td>65.03 (15.90)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>MUIS-C (range 23-115)</td>
<td>MUIS-A (original 33 item) (range 33-165)</td>
<td>MUIS-A modified (28-item) (range 28-140)</td>
<td>“other” *SF-MUIS (range 5-25) ** BT-MUIS</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------</td>
<td>-----------------------------------------</td>
<td>------------------------------------------</td>
<td>------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Lin et al. (2013)**</td>
<td></td>
<td></td>
<td></td>
<td>Ambiguity/inconsistency (range 16-66)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Score: 34.03 (10.84)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Unpredictability of disease prognosis (range, 7-32)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Score: 17.97</td>
<td></td>
</tr>
<tr>
<td>Mullins et al. (2000)</td>
<td>45.95(12.74)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mullins et al. (2001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mullins et al. (2017)</td>
<td></td>
<td>Asthma/allergies: 53.91(13.89)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other CI’s: 60.34 (15.26)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pahlevan (2017a)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pahlevan et al. (2017b)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanders-Dewey et al. (2001)</td>
<td>70.6(10.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Santacroce &amp; Lee (2006)</td>
<td>51.3(14.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sharkey et al. (2018)</td>
<td>61.45(8.14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small &amp; Graydon (1992)</td>
<td></td>
<td></td>
<td></td>
<td>77.23(13.89)</td>
<td></td>
</tr>
<tr>
<td>Wolf-Christensen et al. (2008)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*NR

*11.28

Note. NR = not reported
### Appendix G

**Time since diagnosis/illness duration figures**

Table presenting TSD figures reported from each paper

<table>
<thead>
<tr>
<th>Study</th>
<th>Time since diagnosis - mean (years) or related information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahn et al. (2017)</td>
<td>7.12</td>
</tr>
<tr>
<td>Bailey et al. (2009)</td>
<td>NR</td>
</tr>
<tr>
<td>Barberis et al. (2019)</td>
<td>NR</td>
</tr>
<tr>
<td>Carpentier et al. (2007)</td>
<td>6.8(SD=3.85).</td>
</tr>
<tr>
<td>Colagreco et al. (2014)</td>
<td>4.45(range 1.08–8.59)</td>
</tr>
<tr>
<td>Detprapon et al. (2009)</td>
<td>The authors reported: Almost half (42.5%) had been treated using a combination of surgery and radiotherapy for 1 - 12 months (mean = 5.27 months).</td>
</tr>
<tr>
<td>Hommel et al. (2003)</td>
<td>13.63(SD=3.65)</td>
</tr>
<tr>
<td>Hoth et al. (2013)</td>
<td>12.1(SD=7.5)</td>
</tr>
<tr>
<td>B. Kim &amp; J. Kim (2019)</td>
<td>NR</td>
</tr>
<tr>
<td>Kurita et al. (2013)</td>
<td>NR but inclusion “diagnosed for a minimum of 6 months with cancer of the lung”</td>
</tr>
<tr>
<td>Lee (2006)</td>
<td>The mean time since diagnosis was 16 (SD = 6.4) years; range 5-31 years</td>
</tr>
<tr>
<td>Lemaire (2004)</td>
<td>NR</td>
</tr>
<tr>
<td>Lin et al. (2013)</td>
<td>NR</td>
</tr>
<tr>
<td>Mullins et al. (2000)</td>
<td>The authors reported: Age range of participants (18-25, 19.67, SD = 1.77) – they received a diagnosis of asthma prior to 12 years of age</td>
</tr>
<tr>
<td>Mullins et al. (2001)</td>
<td>13.7(SD=7.3)</td>
</tr>
<tr>
<td>Study</td>
<td>Time since diagnosis - mean (years) or related information</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Mullins et al. (2017)</td>
<td>NR</td>
</tr>
<tr>
<td>Pahlevan (2017a)</td>
<td>Means NR</td>
</tr>
<tr>
<td>Pahlevan et al. (2017b)</td>
<td>Means NR</td>
</tr>
<tr>
<td>Sanders-Dewey et al. (2001)</td>
<td>6.5 years (SD = 3.8 years)</td>
</tr>
<tr>
<td>Santacroce &amp; Lee (2006)</td>
<td>14.2(SD=6.1) *time since treatment completion, childhood cancer survivors</td>
</tr>
<tr>
<td>Sharkey et al. (2018)</td>
<td>NR</td>
</tr>
<tr>
<td>Small &amp; Graydon (1992)</td>
<td>10.62(SD=12.02).</td>
</tr>
<tr>
<td>Wolfe-Christensen et al. (2008)</td>
<td>All participants received a diagnosis of asthma during childhood (age at diagnosis ranged from 1 to 12 years old) Mean age - 19.70 (SD= 1.25)</td>
</tr>
</tbody>
</table>

*Note. NR= not reported, SD=standard deviation*
Appendix H

Prisma checklist

The PRISMA checklist was retrieved from the weblink http://prisma-statement.org/prismastatement/Checklist.aspx
<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TITLE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review, meta-analysis, or both.</td>
<td>p.1</td>
</tr>
<tr>
<td><strong>ABSTRACT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structured summary</td>
<td>2</td>
<td>Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.</td>
<td>P’s. 2-3</td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>3</td>
<td>Describe the rationale for the review in the context of what is already known.</td>
<td>P’s 8-9</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).</td>
<td>p.9-10</td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol and registration</td>
<td>5</td>
<td>Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.</td>
<td>p.10</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>6</td>
<td>Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.</td>
<td>P’s.9-12</td>
</tr>
<tr>
<td>Information sources</td>
<td>7</td>
<td>Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.</td>
<td>p.10</td>
</tr>
<tr>
<td>Search</td>
<td>8</td>
<td>Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.</td>
<td>p.10(Appendix A)</td>
</tr>
<tr>
<td>Study selection</td>
<td>9</td>
<td>State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).</td>
<td>p.11 p.15</td>
</tr>
<tr>
<td>Data collection process</td>
<td>10</td>
<td>Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.</td>
<td>p.13</td>
</tr>
<tr>
<td>Section/topic</td>
<td>#</td>
<td>Checklist item</td>
<td>Reported on page #</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Data items</td>
<td>11</td>
<td>List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.</td>
<td>p.15</td>
</tr>
<tr>
<td>Risk of bias in individual studies</td>
<td>12</td>
<td>Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.</td>
<td>p.15 *quality appraisal for narrative synthesis</td>
</tr>
<tr>
<td>Summary measures</td>
<td>13</td>
<td>State the principal summary measures (e.g., risk ratio, difference in means).</td>
<td>P’s. 27-37</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>14</td>
<td>Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$) for each meta-analysis.</td>
<td>p.10 *narrative synthesis guidance</td>
</tr>
<tr>
<td>Risk of bias across studies</td>
<td>15</td>
<td>Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).</td>
<td>n/a *quality appraisal undertaken</td>
</tr>
<tr>
<td>Additional analyses</td>
<td>16</td>
<td>Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.</td>
<td>n/a</td>
</tr>
</tbody>
</table>

**RESULTS**

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study selection</td>
<td>17</td>
<td>Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.</td>
<td>p.14-.15 *PRISMA</td>
</tr>
<tr>
<td>Study characteristics</td>
<td>18</td>
<td>For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.</td>
<td>P’s. 14-25</td>
</tr>
<tr>
<td>Risk of bias within studies</td>
<td>19</td>
<td>Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).</td>
<td>P. 26</td>
</tr>
<tr>
<td>Results of individual studies</td>
<td>20</td>
<td>For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.</td>
<td>P’s. 26-39</td>
</tr>
<tr>
<td><strong>Synthesis of results</strong></td>
<td>21</td>
<td>Present results of each meta-analysis done, including confidence intervals and measures of consistency.</td>
<td>n/a</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>-----</td>
</tr>
<tr>
<td><strong>Risk of bias across studies</strong></td>
<td>22</td>
<td>Present results of any assessment of risk of bias across studies (see Item 15).</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>Additional analysis</strong></td>
<td>23</td>
<td>Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>DISCUSSION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Summary of evidence</strong></td>
<td>24</td>
<td>Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).</td>
<td>P’s. 38-44</td>
</tr>
<tr>
<td><strong>Limitations</strong></td>
<td>25</td>
<td>Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).</td>
<td>P’s. 41-43</td>
</tr>
<tr>
<td><strong>Conclusions</strong></td>
<td>26</td>
<td>Provide a general interpretation of the results in the context of other evidence, and implications for future research.</td>
<td>P’s. 43-44</td>
</tr>
<tr>
<td><strong>FUNDING</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Funding</strong></td>
<td>27</td>
<td>Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.</td>
<td></td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD

Section Two: Research Report

Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD

Abstract

Objectives

In response to an under-developed research field in relation to Inflammatory Bowel Disease (IBD) and resilience, this study aimed to develop a theoretical and empirically informed understanding of resilience in people with IBD by exploring the factors that associate with it.

Design

A sequential mixed-method cross-sectional design was employed.

Method

Participants over 18 years with self-reported IBD diagnoses were recruited via social media advertisements, a volunteer research database at the University of Sheffield, and the Crohn’s and Colitis UK website. Five participants were interviewed about their resilience experiences and data were thematically analysed. Eighty-five participants completed an online survey comprising measures of illness cognitions; social support, coping-efficacy, and illness-acceptance; control beliefs and intolerance of uncertainty; grit; time since diagnosis, IBD-subtype, disease activity and resilience.

Results

Grit was interpreted from the qualitative data, but correlation analyses revealed a non-significant association with resilience. Time since diagnosis and IBD-subtype also did not correlate with resilience. A hierarchical regression revealed that disease activity negatively predicted and explained 15.7% of the variance in resilience. Illness-
Factors that associate with resilience in people with IBD

acceptance, social support and coping-efficacy explained a further 54.1%. Control-beliefs and intolerance of uncertainty predicted a further 10.8% of the variance in resilience.

Conclusions

Illness cognitions and beliefs about controllability predict resilience over and above the negative influence of disease activity. Rather than perseverance towards long-term goals (grit), daily persistence or endurance might be more pertinent to resilience in those with IBD. Future research should examine causal pathways and the mediating influences of the constructs explored in this study between disease activity and resilience.

Practitioner points

- Targeting illness cognitions using cognitive behaviour therapy may foster resilience. Professional support could be particularly beneficial when disease-activity is high.
- Consideration could be taken to target intolerance of uncertainty and third-wave therapies could be considered to foster acceptance.

Limitations

- The qualitative phase comprised a homogenous sample limiting transferability of the findings.
- A cross-sectional design excludes causal explanations.
- The validity of the scales measuring control-beliefs and coping-efficacy were compromised and their findings should be interpreted with caution.

**Keywords:** Inflammatory Bowel Disease, illness-cognitions, control-beliefs, disease-activity, grit, mixed-methods.
Factors that associate with resilience in people with IBD

**Factors that associate with resilience in people with IBD**

IBD is a chronic illness (CI) and umbrella term for inflammatory conditions of the digestive system. Subtypes include Ulcerative Colitis (UC) and Crohn’s Disease (CD) which affect the large intestine and other parts of the digestive tract respectively (NICE, 2015). Indeterminate IBD is diagnosed where diagnostic tests are indicative of IBD, but when CD or UC are indistinguishable (Guindi & Riddell, 2004). An estimated 620,000 people in the UK (0.5-1%) have IBD (Molodecky et al., 2012) and 6.8 million globally (Global Burden Disease Collaborators [GBD], 2020). IBD is incurable and debilitating, presenting individuals with psychological challenges associated with unpredictable relapsing/remitting symptomatology (Moum et al., 1996). IBD subtypes share a similar symptom profile, including diarrhoea, faecal incontinence, fatigue, and abdominal pain (Bielefeldt et al., 2009; Larsson et al., 2008).

Research about people with IBD confirms it associates with negative psychopathological outcomes including depression and anxiety (Goodhand et al., 2012; Todorovic, 2012; Walker et al., 2008), psychological distress (Larsson et al., 2008; Nordin et al., 2002) and deleterious effects on quality of life (QOL, Bennebroek et al., 2012; Casellas et al., 2002). IBD is episodic in nature and is known to disrupt social activities, employment, relationships (Kemp et al., 2012; Restall et al., 2016), personal goals and functioning (Graff et al., 2009).

Resilience as a reported and desired state in those with IBD (Fourie et al., 2018; Luo et al., 2019) has been less researched (Luo et al., 2019; Sirois & Hirsch, 2017) and is under theorised in IBD populations. Research theorising resilience in the context of other CI’s has measured the construct as absence of psychopathology and preservation of QOL (Stanton et al., 2007; Stewart & Yuen, 2011). An IBD study by Kiebles et al.
Factors that associate with resilience in people with IBD

(2010) theorises resilience as retaining psychological/emotional functioning; but in this study a specific measure of resilience was not used. As a desired outcome at both an individual and clinical level, this research sought to empirically explore resilience factors in an IBD population to develop a theoretical understanding of resilience specific to IBD.

**Resilience factors in chronic illness and IBD**

Definitions of resilience vary substantially (Davydov et al., 2010), however, there is some consensus that it constitutes a return to pre-illness functioning (Gheshlagh et al., 2016; Carver, 1998). Carver’s (2010) generalised model of resilience in contexts of trauma and adversity distinguishes between deterioration (loss, depression), ‘bouncing back’ (a return to pre-illness functioning) and thriving (benefit and growth). A return to pre-illness functioning is influenced by illness cognitions (beliefs about illness and coping resources) that can mediate between the condition and individual well-being (Evers et al., 2001; Heijmans & De Ridder, 1998; Scharloo et al., 1998). One such illness cognition is self-efficacy and has been posited as one of four functions of resilience (Rutter, 1987). Pioneer of self-efficacy, Albert Bandura (1977; 1997) posited that it is one’s perception of their capability to execute the necessary behaviours to manage situations.

Other key psychological factors are identified as theoretically and empirically linked with resilience in the literature. Carver (1998) argued that those who thrive do so because they develop efficacious strategies for coping. Coping-efficacy which associates with thriving in those with arthritis and IBD (Sirois & Hirsch, 2013; Sirois & Hirsch, 2017) pertains to appraisals of how successfully one copes (Gignac et al., 2000). Furthermore, illness-acceptance; the recognition and willingness to adapt and tolerate
Factors that associate with resilience in people with IBD

the unpredictable, uncontrollable nature of the disease (Evers et al., 2001) is an illness cognition found to positively correlate with QOL (Kurpas et al., 2013; Lewko et al., 2012); adjustment and resilience in IBD populations (Kiebles et al., 2010; Sirois & Hirsch, 2017).

Irrespective of IBD’s association with a lower sense of control (Graff et al., 2009), research pertaining to control-beliefs, IBD and outcomes is limited. The locus of control (LOC) construct (Rotter, 1975) refers to the expectancy belief about control over an outcome (Green & Murdock, 2013). The belief in individual responsibility for events that occur is termed internal LOC (ILOC, Rotter, 1954). The modified social learning theory (Wallston, 1992) purports that health behaviour is contingent on one’s perceptions of control over health, synonymous to the construct of coping-efficacy. Bandura’s (1977) social cognitive theory additionally argues that one intrinsically seeks to exert control over their coping behaviour. ILOC has been linked to better psychological outcomes in those with health conditions (Lenze et al., 2008; Panagiotou et al., 2014) and decreased anxiety and depression (Fan et al., 2010; Park & Gaffey, 2007). Qualitative findings report control issues and powerlessness as central tenets of the IBD experience (Devlen et al., 2014; Dibley et al., 2017; Dudley-Brown, 1996; Pihl-Lesnovska et al., 2009).

How in control one feels also influences uncertainty (McCormick, 2002). Uncertainty is pertinent for those with IBD given its unknown aetiology, fluctuating and unpredictable symptomatology, thus the ability to tolerate uncertainty is an important factor. Intolerance of uncertainty (IOU) refers to the propensity to react negatively to uncertain situations (Buhr & Dugas, 2009) and has been conceptually and empirically linked to generalised anxiety disorder (GAD, Dugas et al., 1997) and lower
Factors that associate with resilience in people with IBD

psychological adjustment in those with lung cancer (Kurita et al., 2013). Higher perceived certainty has been linked to better QOL in one IBD study (Niv et al., 2017), however, the relationship between IOU and resilience has never been examined in an IBD population and thus is not understood.

Social support has been found to lead to positive outcomes in those with IBD. Received support is distinct from perceived support (Kamp et al., 2019), which is the realisation of being accepted and cared for (Strom & Egede, 2012); another illness cognition. The protective function of social support has been well documented (Ozbay et al., 2008). Theoretical models of social support acknowledge the importance of both emotional (receiving love and empathy) and practical components (Charney, 2004) through exerting positive effects on multiple neurobiological pathways and fostering effective coping (Ozbay et al., 2008). Social support also positively correlates with illness acceptance (Janowski et al., 2012) and self-efficacy (Wang et al., 2015).

In IBD populations, research demonstrates a link between increased social support, improved QOL (Janke et al., 2004; Katz et al., 2016); and adjustment in patients with IBD cross-sectionally (Gick & Sirois, 2010) and longitudinally (Oliveira et al., 2007). However, the relationship with outcomes in IBD is complex as tensions such as unwanted confrontation and undesirable reactions can occur (Palent & Himmel, 2019). This suggests more research is needed to understand the relationship between social support and resilience in those with IBD.

Setbacks are inherent within IBD population given its relapsing/remitting symptom profile. Hence, grit may be important to resilience in those with IBD, conceptualised as a dimension of resilience (Stoffel & Cain., 2018), which comprises perseverence towards long term goals with sustained commitment despite setback and
Factors that associate with resilience in people with IBD

adversity (Duckworth et al, 2007). Those individuals possessing grit approach
threatening situations with assurance they can exercise control over them (Duckworth et
al., 2007).

Disease-specific factors

Disease-specific factors also associate with resilience but research outcomes
present mixed findings. The relationship between IBD subtypes and psychological
functioning are variable (Graff et al., 2006; Rubin et al., 2004). Little is known about
what the impact of time following IBD diagnosis is on resilience, however the time-
period around diagnosis has been associated with higher rates of anxiety and depression
(Munkholm et al., 1995). Furthermore, distress levels fluctuate in parallel with disease
activity (Casellas et al., 2005; Porcelli et al., 1996). Greater illness severity has been
associated with poorer psychological adjustment (Voth & Sirois, 2009) which may link
to its influence on sense of mastery, the sense that one has control of one’s life (Graff et
al., 2009). Those in remission were found to have greater perceived control and
exhibited less depression (Gandhi et al., 2014). In a review of disease activity in CD, ten
studies revealed an inverse relationship between health related QOL and disease activity
(Vander-Have, 2014). Research suggests greater disease activity negatively affects
resilience in IBD populations, however more research is needed.

Despite constituting a relatively small field, the relationship between IBD and
resilience is supported by the literature. One IBD study using a small sample found that
illness-acceptance and coping associated with emotional and psychological functioning
(Kiebles et al., 2010). A recent study (Sirois & Hirsch, 2017) based on Carver’s (1998)
resilience framework measured loss, resilience, or thriving. Higher levels of coping-
efficacy, illness-acceptance and social-support were associated with resilience and
Factors that associate with resilience in people with IBD

lower levels of depression across domains of life satisfaction, personal growth, and relationship quality. However, this study did not use a specific measure of resilience or incorporate examination of disease activity.

**Study aims**

This study aimed to develop an understanding of resilience in an IBD population based on the key psychological constructs discussed, informed by Carver’s (1998) conceptual resilience framework. This research used a mixed-methods design to elicit qualitative and quantitative evidence to underpin a robust theoretical model. This study aimed to address gaps in current knowledge by examining additional variables in relation to resilience, including IBD subtype, time since diagnosis (TSD), IOU, control-beliefs and understanding of the role of disease activity. The experience of thriving (Carver, 1998) was not incorporated because outcomes of ‘bouncing back’ better reflect the objectives of recovery focused clinical services aiming to foster resilience (pre-illness functioning) in the context of limited fiscal resources.

**Clinical implications**

The new empirically informed, theoretical understanding developed in this study has important clinical implications. NICE (2010, guideline 91) recommend cognitive behaviourial therapy (CBT), for the treatment of depression in those with CI’s. However, there remains a lack of understanding of how psychological processes strengthen resilience (Timmer et al., 2011) as a desired outcome, particularly in IBD populations. These findings will enable the tailoring of intervention strategies so important factors may be nurtured in those with IBD who are in need (Luo et al., 2019).
Factors that associate with resilience in people with IBD

Methods

Design

A sequential mixed methods design was employed (Creswell et al., 2003), whereby the personal, lived accounts of resilience experience, elicited via interviews (phase A), confirmed, and extended findings in the existing literature and informed additional constructs to be examined statistically in an online survey (phase B). Interviewed participants also commented on the usability of the survey (Appendix A). The survey contained self-report measures enabling statistical examination of the associations between the variables and resilience. A mixed-methods approach draws on the strengths of each data type (Halcomb & Hickman, 2015), by foregrounding both participant’s voice and statistical examination of associations between constructs.

Epistemological position

The researcher and study approach were oriented towards critical realism as a philosophical and methodological framework (Fletcher, 2017). Aligning with the mixed-methods design, critical realism combines components of positivist and constructionist paradigms but deviates from both in its position that ontology (the nature of reality) is not reducible to epistemology (knowledge of reality) (Fletcher, 2017). Empirically, events can be measured and observed but only understood through the filter of human experience, thus, the researcher’s interpretation was influenced by her own unique experiences, beliefs, and values. Therefore, subjective interpretations can differ according to individual data-analysts (Madill et al., 2000).

The researcher arrived at this positioning from her previous experiences of training in the Clinical Psychology field and learning to deliver Cognitive Analytic
Factors that associate with resilience in people with IBD

Therapy (CAT, Ryle, 1999) which is underpinned by attachment and cognitive, behavioural theories (Beck, 1976; Bowlby, 1969; Freud, 1900; Kernberg, 1975; Watson, 1913; Winnicott, 1960). CAT focuses on how emotional and relational patterns underlie one’s current experiences or difficulties. The researcher was concurrently immersed in other psychological theories relevant to resilience and related constructs which underpinned the analysis (Bandura, 1977; Carver, 1998; Duckworth et al., 2009; Rotter, 1987). Indeed, the researcher understood theoretical and evidence informed knowledge of IBD but had no lived experience of it. Combined, these experiences exerted an influence on the data being interpreted through a relational lens and with preconceived ideals related to positive psychological processes and outcomes.

Ethics

The study was designed in accordance with the British Psychological Society Ethical Guidelines (2018) and the British Psychological Association Code of Human Research Ethics (2014). Ethical approval for the study was obtained from the Sheffield University Ethics Committee who provided research governance sponsorship (Appendix B).

Phase A: Qualitative enquiry

Recruitment

Purposive sampling methods were employed intending to recruit enough participants that met specified inclusion criteria, to attend a focus-group. A group size of 4-8 has been argued to be suitable for exploring a range of participant experiences (Krueger & Casey, 2015). Advertisements were disseminated electronically via social media platforms, Twitter and Facebook and a database containing email addresses from volunteer research participants held by the University of Sheffield. Only two
Factors that associate with resilience in people with IBD

Participants attended a joint interview due to participant constraints and logistical challenges thus a design amendment was subsequently developed to elicit participant views via individual interviews; a methodology that enabled study aims to be achieved. The amendment was ethically approved. Three participants who had expressed interest in participation in the focus group but who could not attend were invited to participate in individual interviews. One was face-to-face and two via telephone interviews.

**Participants**

To be eligible to participate, participants needed to be over 18 years with a confirmed diagnosis of IBD, including IBD indeterminate.

**Procedure**

Participants who agreed to be interviewed were electronically sent an information sheet (Appendix C) and consent form (Appendix D). Signed consent forms were collated prior to the interviews. Three participants were interviewed on University of Sheffield premises, conducted by the main researcher. A semi-structured interview schedule was developed by the researcher, guided by thematic analysis (TA) and qualitative IBD literature (Braun & Clarke, 2013; Luo et al., 2019). Questions were designed to be flexible, with suggested prompts including questions like “are there any psychological factors that you feel have affected your resilience?” (see Appendix E for interview schedule).

Those who opted for telephone interviews provided audio-recorded verbal consent and consent forms were electronically signed by participants. Interviews lasted 37-64 minutes (average 54.7 minutes) and were conducted in August/September 2019. Participants were offered a £10 voucher for their participation. Another clinical psychology doctoral trainee observed the focus group and took notes to aid accurate
Factors that associate with resilience in people with IBD

transcription and offer additional insights. All interviews were audio-recorded and anonymously transcribed (using pseudonyms) verbatim by the researcher.

**Qualitative analytic method**

TA was employed and data were analysed in an inductive way, enabling themes to emerge from the data (Braun & Clark, 2006; Patton, 1990). TA is a flexible approach to data-analysis and can be conducted within both realist/essentialist and constructionist paradigms, conducive with the critical realist epistemological position (Braun & Clarke, 2006). Indeed, the researcher supports the realist idea that some forms of “truth” exist and interview data offered opportunity for participants to share part of their perceptual reality. However, it was acknowledged that one’s understanding of others’ realities cannot be fully achieved (Willig, 2008). Braun and Clarke’s (2006) 6-step process was undertaken and revisited in a recursive process (see Appendix F), leading to the culmination of themes.

**Reflexivity**

The researcher recognised herself as an active part of the research process. To bring to conscious awareness the influence of the researcher’s assumptions on the interpretation of data (Brocki & Wearden, 2006), the transcripts were repeatedly revisited to ensure the codes and themes were rooted in the data. Input was also derived from another researcher who had observed and given her interpretations of the focus group data. Furthermore, research supervisors (who are also Clinical Psychologists) were involved in theme generation and the researcher’s reflections were discussed to facilitate consideration of her influence on the interpretation.
Factors that associate with resilience in people with IBD

Results

An analysis and interpretation of data is presented. All participants identified as white British females and considered themselves in remission. Their ages ranged from 22-49 years (mean 34) and disease duration ranged from 2-28 years (mean 10.8). They reported diagnoses of CD (n=2) and UC (n=3). They discussed times that their condition caused distress and felt difficult to endure. Remission was frequently associated with reduced distress and a sense of increased resilience. The perception of themselves as resilient was evident, however it was a dynamic state.

Two superordinate themes emerged, each comprising three subordinate themes (Table 1). Themes are discussed and accompanied by illustrative quotes (see Appendix G for further supporting quotes). Resilience was characterised by ambivalent states; defined as simultaneously holding conflicting feelings or reactions (Schneider & Swartz, 2017). Themes comprised intrapersonal (within the mind) and interpersonal processes (occurring relationally). How participants managed the inherent tensions either positively or negatively affected their sense of resilience.
Factors that associate with resilience in people with IBD

Table 1

Summary of superordinate and subordinate themes

<table>
<thead>
<tr>
<th>Superordinate themes</th>
<th>Subordinate themes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Intrapersonal ambivalence: Grit</td>
<td>1.1 “I quite like the control”</td>
</tr>
<tr>
<td></td>
<td>1.2 “An invisible illness”</td>
</tr>
<tr>
<td></td>
<td>1.3 Carry on regardless”</td>
</tr>
<tr>
<td>2. Interpersonal ambivalence: Social support</td>
<td>2.1 “The support really helps”</td>
</tr>
<tr>
<td></td>
<td>2.2 “Nobody really understood”</td>
</tr>
<tr>
<td></td>
<td>2.3 “brave face”</td>
</tr>
</tbody>
</table>

Themes

1. Superordinate theme: Intrapersonal ambivalence, grit

‘Grit’ permeated the discourse; namely the need for diligent engagement with long-term goals (social and occupational) to maintain resilience. Participants reclaimed control by coping independently which boosted resilience, but a conflict occurred when this led to the legitimacy of the condition and its severity being questioned. Endurance, a regulatory strength, persisting diligently when presented with difficulty (Hamby et al., 2013) was adopted. This created mixed emotions and either positively or negatively impacted resilience.
Factors that associate with resilience in people with IBD

1.1 “I quite like the control” For all participants, IBD challenges were buffered through reclaiming perceived control. This was achieved by managing the condition autonomously in variable ways. This prevented a potential deterioration in their mental state which boosted resilience. One way of regaining control was through positive risk-taking and making disparate decisions to medical professionals to stay on track with valued goals. The ability to manage independently and work towards goals (social and occupational) generated feelings of satisfaction and pride:

“If I had no way of helping me control it myself I would feel a bit hopeless, I quite like the control………..I think without being able to manage it for myself I would struggle to be okay about it.” (Harriet)

the satisfaction that I’m managing it myself and actually its working really well.” (Annie)

1.2 “An invisible illness” The internal conflict around autonomous management was that the legitimacy of the condition and its severity came under question. One participant discussed relief at the point of diagnosis as it validated the legitimacy of her symptoms. The perception that others might think the symptoms to be spurious or exaggerated threatened identity, causing difficult emotions, negatively impacting resilience.

Grit encompassed personal goals related to maintaining integrity, and a premorbid identity as a fully functioning, able-bodied, genuine individual. This conflict was variably managed. Most of the participants subscribed to the non-disclosure view due to anxieties about looking weak or burdening others. While this temporarily boosted resilience, the lack of openness about the impact of the condition meant that participants endured their symptoms alone, lessening resilience. Conversely, one participant opted
Factors that associate with resilience in people with IBD

for full public disclosure, motivated by anger. She self-preserved by attempting to prove or demonstrate teleological evidence of the severity of the experience.

“The frustration......that some people are questioning whether it’s as bad as you’re making out.” (Annie)

“I was pissed off at people, when you’ve got an invisible illness, you tend to get people thinking she’s making it up or exaggerating......that was horrendous and I genuinely think that was the worst part” (Sarah)

“No one’s asking me if I’m alright but I’m just thinking none of these people around me understand what I’m going through right now and that can be hard.” (Claire)

1.3 “Carry on regardless”. Endurance was illuminated by phrases such as “not let it beat me” and “bouncing back you’ve just got to”. These participants strived towards an imagined life trajectory prior to their IBD diagnosis, demonstrating commitment to activities valued by them and wider society. This was underpinned by a fear of loss in some cases. Differing internal coping strategies were employed to achieve endurance, including “ignorance”, and following a period of loss and grief; “acceptance”.

“I made myself do everything and I still went to work everyday......mentally really didn’t wanna be there but, I force myself.... I’m ignorant because I’m like no I’m fine, just gotta carry on” (Claire)

“If I’m having a flare up it’s not going to stop me from going out there, doing my socialising, having plans that I’ve already made.........I just keep pushing through.” (Harriet)
Factors that associate with resilience in people with IBD

“When you reach the acceptance you have to look at how you live your life from now on…..keep looking forward so, you might end up in a better place than you thought you were headed anyways.” (Sarah)

2. **Superordinate theme: Interpersonal ambivalence, social support**

Actual or perceived social support impacted resilience. Participants desired support that was empathic and boundaried, which enhanced resilience. However, a conflict arose from the fear or reality of receiving negative reactions, being misunderstood, judged, or stigmatised. To avoid this eventuality, participants put on a “brave face” which simultaneously benefited and disadvantaged resilience. This was interpreted as stoicism; “silent endurance, lack of emotion……a ‘stiff upper lip” (Moore et al., 2012, p.159-160).

All participants described parents, family, and close friends as their main sources of support. In line with autonomous management of the condition, there were mixed feelings towards medical professionals who were viewed as either helpful or a hindrance, contingent on their availability and expertise.

2.1 **“The support really helps”** All participants desired support in the form of an inherent understanding, thus others who had a realistic understanding and ability to provide empathic care were valued. This enabled frank conversations about their experiences and reciprocal support. This enhanced resilience by helping emotional management of the condition. However, it was important that the care received had limits so that it was not a threat to their identity. When participants felt “pandered too” (Claire) or wrapped “in cotton wool” (Harriet) this undermined their perceived competence. Empathy was desired but an encouraging approach that honoured their self-efficacy was imperative.
Factors that associate with resilience in people with IBD

“I think the support really helps me being able to manage...the negative emotional effects the disease can have and that’s the importance of support.” (Harriet)

“I feel like I handle it quite well, I don’t want someone to pander to me..........they’re supportive, they’re not feeling sorry for me because that’s not what you want.” (Claire)

2.2 “Nobody really understood”. Their need for closeness was accompanied by a fear of being misunderstood or dismissed. Others lacked understanding or knowledge or there was a felt stigma about being ill and a taboo around IBD. The impact of enduring an experience misunderstood by others had profound effects on the ways in which participants related to others. The perceived or real experience of others misunderstanding created difficult emotions which led to a reduced sense of resilience. Anger that one participant felt at experiencing severe pain and fatigue that was not acknowledged by those around her, led her to develop an online support forum. However, participants also managed this by dismissing others in varying ways. This included choosing to not “let them in”; to initiate intimacy with new people or share experiences. Creating this ‘safe’ distance temporarily supported resilience, however in the long-term this compromised intimacy and restricted a social network of supportive individuals, hindering resilience. For others, an intolerance of others’ lack of understanding was manifest or a minimisation of others’ experiences of suffering. A self-perception as being comparatively ‘strong’ temporarily boosted resilience as it defended against the perception of themselves as vulnerable. However, this perpetuated a sense of distance from others which depleted their sense of resilience.

“Nobody was listening, or nobody really understood what I was going through and that really pissed me off.” (Sarah)
Factors that associate with resilience in people with IBD

“Brought out a less tolerant side of me..........others might say, you know, my goldfish died (laughs) and that’s where I have less empathy with that situation.” (Sally)

“Some people wallow in being a victim of something.” (Annie)

2.3 “Brave face”. The interpersonal conflict was resolved through the concealment of their struggles, stoicism. This enabled resilience as it facilitated self-preservation, however, it brought about conflicted feelings. An underlying anxiety and guilt about letting others down led to avoidance of self-care such as taking time off sick from work (linking to endurance). Participants engaged with stoicism with resentment and frustration that perpetuated their aloneness. This reinforced the lack of acknowledgement from others, which negatively impacted resilience in the long term. There was recognition that stoicism was unsustainable and when expected by others it brought about anger, lessening a sense of resilience.

“I’d be fine on the outside to most people then internally it’d be really shit....” (Claire)

“Tend to just brush it off and go with I’m fine.” (Sarah)

“I had a fury and said I’ve got a life-long life changing chronic condition you might be allowed to feel a bit sorry for yourself.” (Annie)

Data analysis summary

The data revealed key factors that have been previously associated with resilience in those with CI’s and IBD. Central tenets of resilience pertained to coping independently, perceived control and social support. There was also reference to uncertainty, acceptance, and the influences of disease activity; higher disease activity
Factors that associate with resilience in people with IBD

was associated with reduced resilience. TSD evoked mixed feelings. The construct of ‘grit’ also emerged.

**Phase B: Quantitative enquiry**

**Recruitment and Procedure**

The recruitment methods were the same as phase A. This phase was additionally advertised through Crohn’s and Colitis UK’s website (see Appendix H). Participants from Phase A or expressed interest but could not participate for logistical reasons were emailed a weblink to the Qualtrics online survey. The information sheet and consent were contained within the weblink (Appendix I). Data were collected from 30th January until 15th March 2020. Data collated after this was deemed to be influenced by Covid-19 circumstances and was thus excluded from the analysis. Participants were able to enter a £25 vouchers prize draw.

**Quantitative measures**

*Screening and demographics information.*

The online survey contained screening questions pertaining to age and confirmation of IBD diagnosis. The survey contained demographic and IBD-related questions (including age of diagnosis, subtype, relapse/remission status) and the following self-report measures (see Appendix J). For all measures higher scores indicate greater levels of the constructs. A full-scale, total score was analysed for all measures except the Illness Cognition Questionnaire (ICQ; Evers et al., 2001). The internal consistency scores (α) for each measure in the current study ranged from acceptable to excellent (.78 - 93, see Table 4).

*Connor-Davidson Resilience Scale (CD-RISC, Connor & Davidson, 2003).*
Factors that associate with resilience in people with IBD

The 25-item CD-RISC was designed to assess the personal characteristics that embody resilience, including self-efficacy, patience, optimism, faith, personal competence, trust/tolerance/strengthening effects of stress, acceptance of change and secure relationships and evaluates items on a 5-point Likert scale from 0 “not true at all” to 4 “true nearly all of the time” (scoring 0-100). The internal consistency was found to be good (α =0.89) in a sample of individuals with generalised anxiety disorder and post-traumatic stress disorder (Connor & Davidson, 2003).

**Short Health Scale (SHS, Hjortswang et al., 2006, in Mcdermott et al., 2013).**

The 4-item SHS is a proxy measure of disease activity capturing health-related QOL. The SHS comprises 4x100mm analogue scales assessing symptom burden, activities of daily life, disease related worry and general well-being. The scale was previously validated in a Swedish and Norwegian population (Hjortswang et al., 2006) and later in an English IBD population, with test-retest reliabilities revealing correlations from 0.70-0.89 (Mcdermott et al., 2013).

**Illness Cognitions Questionnaire**

The ICQ comprises the subscales, helplessness, acceptance, and perceived benefits. The 6-item acceptance subscale was used in this study which assesses acceptance of one’s CI and uses a 1-4 Likert scale from 1 “not at all” to 4 “completely” (scoring 6-24). The acceptance subscale has demonstrated good internal consistency (α = 0.91, Evers et al., 2001) and α=.92, .89 at two time points (Sirois & Hirsh, 2017).

**Coping Efficacy Scale (CES, Gignac et al., 2000).**

The 3-item CES assesses the extent that individuals feel that they are coping effectively with symptoms, emotional aspects and daily challenges of their
Factors that associate with resilience in people with IBD

condition measured on a Likert scale from 1 “strongly disagree” to 5 “strongly agree”. As in previous research (Sirois & Hirsch, 2017) ‘IBD’ replaced the term ‘illness’. The scale was created in error for this study and thus was scored on a 7-point Likert scale with the additional scale items “somewhat-disagree” and “strongly-agree” (scoring 1-21). The CES has demonstrated good internal consistency in arthritis (α = .80; Sirois & Hirsch, 2013), and IBD sample (α = .90) (Sirois & Hirsch, 2017).


The 8-item FSSQ measured perceived social support, covering receipt of emotional and practical support, on a 5-point Likert scale ranging from 1 “much less than I would like” to 5 “as much as I would like”. The measure is scored by averaging all items, resulting in scores ranging from 1-5. It has demonstrated good internal consistency at two time points (alphas= .91 and .93) (Sirois & Hirsch, 2017).

Control Beliefs Inventory (CBI, Sirois, 2002).

The 26-item CBI measures four specific health related control beliefs: General control, chance control, symptom control and mastery/health self-efficacy. The CBI was designed for use with CI populations and each subscale has demonstrated acceptable or good internal consistency (α= 0.70-0.91, Sirois, 2003). The original scale assessed items on a 6-point Likert scale, from 1 “strongly disagree” to 6, “strongly agree”. The scale was created in error for this study and thus was scored on a 1-7 Likert scale with “neither agree nor disagree” (scoring 7-182).

The Intolerance of Uncertainty Scale-Short Form (IU-SF, Carleton et al., 2007).

The 12-item IU-SF assesses prospective anxiety and inhibitory anxiety through assessing reactions to uncertainty, ambiguous situations, and the future. It demonstrated
Factors that associate with resilience in people with IBD

excellent internal consistency (α = .91) in a sample of American undergraduate students (Carleton et al., 2010), large community sample (α = .92) (Carleton et al., 2010, cited in Hale et al., 2016) and demonstrated good reliability and validity in a general population Chinese sample (α = .86).

The Short Grit Scale (SGS, Duckworth & Quinn, 2009).

The 8-item SGS measures trait-level perseverance and passion for long-term goals. It includes elements of diligence, enduring, being hard-working and not discouraged by setbacks, assessed on a 5-point Likert scale, 1 “not like me at all” to 5, “very much like me”. The measure is scored by averaging all items, resulting in a grit score ranging from 1 to 5. The SGS has demonstrated good internal reliability, test-retest reliability, and criterion reliability in studies of adolescents and young adults (Duckworth & Quinn, 2009; Sharkey et al., 2017). In Traino et al.’s (2019) study on college students with CI’s the reliability was good (α = 0.81).

Sample characteristics

Eighty-five participants completed the survey. Most of the participants were female, in remission and UK based (see Table 3). A priori power analysis determined the sample size needed to prevent type II errors when conducting regressions analyses. Applying a cautious assumption that all nine predictor variables correlated with resilience, a sample size of 135 was required to achieve 0.80 power at a p-value of 0.05 (Field, 2009). A post-hoc analysis based on the six variables that significantly correlated with resilience and entered into the hierarchical regression analysis was conducted. The rule of thumb that between 10-15 participants per predictor were needed to achieve 0.80 power at the 0.05 level was used (Field, 2009), hence, 60-90 participants were required.
Factors that associate with resilience in people with IBD

**Results**

**Data analytic plan**

Statistical Package for Social Sciences (SPSS) version 23 was used to analyse the data. Correlation analyses enabled examination of the associations between the continuous variables and the outcome. Categorical variables were examined via comparison of mean resilience scores and independent t-tests. A hierarchical regression analysis examined the amount of variance in resilience that could be explained by illness-acceptance, coping-efficacy, social support, control-beliefs, and intolerance of uncertainty (Field, 2009). Disease activity was entered into block 1 as a covariate; at block 2 illness-acceptance, coping-efficacy and social support were grouped together as coping resources. At block 3, control-beliefs and intolerance of uncertainty were grouped together as beliefs related to controllability.

The data were examined to check for assumptions of multivariate analyses which involved examination of missing data, outliers, and parametric assumptions of normality (Tabachnik, & Fidell, 2014). Histograms, Q-Q plots, skewness, and kurtosis values were assessed and checked against values demonstrating normal distribution (see Appendix K, Stevens, 2002). The Shapiro-Wilks test (Shapiro & Wilk, 1965) was used because it has more power to detect differences than alternate tests (Field, 2009). Pearson correlation and Spearman’s rho coefficients were interpreted for normally distributed and non-normally distributed data, respectively. No outliers were identified from visual inspection of scatterplots. Finally, the absence of multicollinearity was assumed because the correlation coefficients for all independent variables were not too highly correlated (r < .90) (Field, 2013).

**Missing data**
Factors that associate with resilience in people with IBD

There was a small amount of missing data values (n=15). A statistical test indicated that data were missing completely at random (Little, 1988; p = 1.00). Thus, it was appropriate to use case mean substitution (Hanna, & Dempster, 2012); reported in previous research (Downey & King, 1998; Eekhout et al., 2012; FoxWasylyshyn & El-Masri, 2005; Raymond, 1986; Roth et al., 1999).

**Descriptive data**

Table 2 summarises participant and disease-related characteristics. The majority were female, UK based and considered themselves to be in remission.
Factors that associate with resilience in people with IBD

Table 2

Participant and disease characteristics

| Participant characteristics |  
|-----------------------------|--------------------------------------------------|
| Gender % (n) (female)       | 72.94 (62)                                       |
| Age (mean, SD)              | 39.49 (11.45)                                    |
| Country:                    |                                                  |
| United Kingdom % (n)        | 87.1(74)                                         |
| Europe % (n)                | 3.5(3)                                           |
| Canada % (n)                | 2.4(2)                                           |
| USA % (n)                   | 4.7(4)                                           |
| Australia % (n)             | 1.2(1)                                           |
| Other % (n)                 | 1.2(1)                                           |

| Disease characteristics |  
|-------------------------|--------------------------------------------------|
| Age of diagnosis (mean, SD) | 26.53 (11.1)                                     |
| Illness duration (mean, SD)  | 13.04 (10.99)                                    |
| Diagnostic subtype:        |                                                  |
| Crohn’s disease % (n)      | 49.4(42)                                         |
| Ulcerative Colitis % (n)   | 44.70(38)                                        |
| Other: % (n)               | 5.9(5)                                           |
| Disease activity status:   |                                                  |
| Relapse (n, %)             | 35.29(30)                                        |
| Remission (n, %)           | 64.71(55)                                        |

Note. SD = standard deviation
Factors that associate with resilience in people with IBD

Descriptive scoring data from all measures are presented in Table 3. None of the scales had categorical cut-offs, but for all, greater scores indicated a greater presence of each construct.

Table 3
Cronbach’s alphas, and descriptive statistics for all measures

<table>
<thead>
<tr>
<th>Variables</th>
<th>A</th>
<th>Possible range</th>
<th>Minimum in sample</th>
<th>Maximum in sample</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSD (years)</td>
<td>.84</td>
<td>0-400</td>
<td>38</td>
<td>400</td>
<td>201.4</td>
<td>90.87</td>
</tr>
<tr>
<td>Disease activity</td>
<td>.88</td>
<td>1-5</td>
<td>1.38</td>
<td>5.00</td>
<td>3.87</td>
<td>0.88</td>
</tr>
<tr>
<td>Social support</td>
<td>.86</td>
<td>6-24</td>
<td>6</td>
<td>24</td>
<td>16.41</td>
<td>4.18</td>
</tr>
<tr>
<td>Acceptance</td>
<td>.78</td>
<td>1-5</td>
<td>1.25</td>
<td>3</td>
<td>2.24</td>
<td>0.37</td>
</tr>
<tr>
<td>Grit</td>
<td>.87</td>
<td>26-182</td>
<td>65</td>
<td>153</td>
<td>116.60</td>
<td>18.71</td>
</tr>
<tr>
<td>Control beliefs</td>
<td>.88</td>
<td>3-21</td>
<td>3</td>
<td>21</td>
<td>15.32</td>
<td>4.23</td>
</tr>
<tr>
<td>Coping-efficacy</td>
<td>.89</td>
<td>12-60</td>
<td>15</td>
<td>60</td>
<td>32.47</td>
<td>9.3</td>
</tr>
<tr>
<td>Intolerance of uncertainty</td>
<td>.93</td>
<td>0-100</td>
<td>29</td>
<td>96</td>
<td>66.07</td>
<td>15.30</td>
</tr>
</tbody>
</table>

Note. TSD=Time since diagnosis.
Factors that associate with resilience in people with IBD

Descriptive analyses

Independent t-tests assessed differences between categorical variables and resilience. There was no significant effect for gender, \( t(83) = -0.11, p = 0.917 \), despite females (\( M = 66.2, \ SD = 15.2 \)) scoring greater than males (\( M = 65.8, \ SD = 15.9 \)). There was no significant effect for disease activity status (relapse/remission), \( t(83) = -1.8, p = 0.917 \), despite those reporting to be in remission scoring greater (\( M = 68.3, \ SD = 14.6 \)) than those in relapse (\( M = 62.1, \ SD = 15.9 \)). There was no significant effect for disease subtype, \( t(78) = 0.84, p = 0.622 \), despite those with CD reporting greater resilience scores (\( M = 67.6, \ SD = 14.9 \)) than those with UC (\( M = 64.7, \ SD = 16.3 \)). The “other” subtype was omitted from this analysis due to the small number in this subgroup (\( N = 4 \)). Finally, correlational analysis revealed that age and resilience were not significantly correlated, \( r(-0.54), p = 0.63 \).

Correlational analyses

All variables except grit and TSD were significantly correlated with resilience (\( p<0.001 \)). Therefore, grit and TSD were not entered into the hierarchical regression analysis. As expected, negative correlations were found between disease activity and IOU and resilience (see Table 4).
Factors that associate with resilience in people with IBD

Table 4

Bivariate analyses of the relationship between independent variables and resilience.

<table>
<thead>
<tr>
<th></th>
<th>TSD</th>
<th>Disease activity</th>
<th>Acceptance</th>
<th>Coping-efficacy</th>
<th>Social support</th>
<th>Control beliefs</th>
<th>IOU</th>
<th>Grit</th>
<th>Resilience</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSD</td>
<td>1</td>
<td>-.123</td>
<td>.323**</td>
<td>.188</td>
<td>.181</td>
<td>-.021</td>
<td>.030</td>
<td>.101</td>
<td>.197</td>
</tr>
<tr>
<td>Disease activity</td>
<td>1</td>
<td>-.518**</td>
<td>- .558**</td>
<td>-.285**</td>
<td>-.390**</td>
<td>.429**</td>
<td>.123</td>
<td>-.391**</td>
<td></td>
</tr>
<tr>
<td>Acceptance</td>
<td>1</td>
<td>.736**</td>
<td>.400**</td>
<td>.492**</td>
<td>-.330**</td>
<td>-.234*</td>
<td>.705**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coping-efficacy</td>
<td>1</td>
<td>.408**</td>
<td>.348**</td>
<td>-.400**</td>
<td>-.082</td>
<td>.625**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social support</td>
<td>1</td>
<td>.028</td>
<td>-.204</td>
<td>.111</td>
<td>.456**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control beliefs</td>
<td>1</td>
<td>-.221*</td>
<td>-.270*</td>
<td>.494**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IOU</td>
<td>1</td>
<td>.028</td>
<td>-.474**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grit</td>
<td>1</td>
<td></td>
<td>.176</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resilience</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note. TSD=Time since diagnosis. Greater scores on all scales equate to higher amount of that construct. Pearson Product-moment correlations coefficients are presented for disease activity, acceptance, control-beliefs, IOU, grit and resilience. Spearman’s Rho correlation coefficients are presented for TSD, social-support and coping-efficacy. *p<0.05 **p<0.01.
Factors that associate with resilience in people with IBD

**Regression analyses**

A hierarchical regression analysis was conducted to analyse the data. The model explained 67.1% of the variance and disease activity, social-support, coping-efficacy, illness-acceptance, IOU and control-beliefs were significant predictors, $R^2 = .671$, $R^2_{\text{adjusted}} = .646$, $F(2,78)=12.874$, $p<0.001$. Table 5 reports the regression analysis. In step 1, disease activity explained 15.7% of the variance in resilience, $R^2 = .157$, $R^2_{\text{Adjusted}} = .147$, $F (1, 83) = 15.434$, $p = < .001$. The addition of illness-acceptance, coping-efficacy and social support explained a further 40.6% of the variance in resilience, $\Delta R^2 = .563$, $R^2_{\text{Adjusted}} = .541$, $F (3, 80) = 24.783$, $p < .001$, with only social support and illness acceptance making a significant contribution to the model. The addition of control-beliefs and IOU at step 3 explained a further 10.8% of the variance in resilience, $\Delta R^2 = 0.671$, $R^2_{\text{Adjusted}} = .646$, $F (2, 78) = 12.874$, $p < .001$, making a significant contribution to the model.
Factors that associate with resilience in people with IBD

Table 5

Summary of regression analyses predicting resilience

<table>
<thead>
<tr>
<th>Block</th>
<th>Variables</th>
<th>Unstandardised Coefficients</th>
<th>Standardised Coefficients</th>
<th>95.0% Confidence interval for $\beta$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>B</td>
<td>Std. Error</td>
<td>B</td>
</tr>
<tr>
<td>1</td>
<td>Disease activity</td>
<td>-.067</td>
<td>.017</td>
<td>-.396***</td>
</tr>
<tr>
<td>2</td>
<td>Disease activity</td>
<td>.008</td>
<td>.015</td>
<td>.048</td>
</tr>
<tr>
<td></td>
<td>Social support</td>
<td>3.099</td>
<td>1.429</td>
<td>.177*</td>
</tr>
<tr>
<td></td>
<td>Coping efficacy</td>
<td>.906</td>
<td>.419</td>
<td>.251*</td>
</tr>
<tr>
<td></td>
<td>Acceptance</td>
<td>1.764</td>
<td>.413</td>
<td>.482***</td>
</tr>
<tr>
<td>3</td>
<td>Disease activity</td>
<td>.036</td>
<td>.15</td>
<td>.215*</td>
</tr>
<tr>
<td></td>
<td>Social support</td>
<td>4.147</td>
<td>1.29</td>
<td>.237**</td>
</tr>
<tr>
<td></td>
<td>Coping efficacy</td>
<td>.568</td>
<td>.376</td>
<td>.157</td>
</tr>
<tr>
<td></td>
<td>Acceptance</td>
<td>1.478</td>
<td>.378</td>
<td>.404***</td>
</tr>
<tr>
<td></td>
<td>Control-beliefs</td>
<td>.218</td>
<td>.063</td>
<td>.267**</td>
</tr>
<tr>
<td></td>
<td>IOU</td>
<td>-.458</td>
<td>.123</td>
<td>.278***</td>
</tr>
</tbody>
</table>

Note. N=85. Note. $N = 85$. Block 1 $\Delta R^2 = .147***$, Block 2 $\Delta R^2 = .541***$, Block 3 $\Delta R^2 = .646***$

*p < .05, **p < .01, *** p < .001

Discussion

This exploratory study, informed by Carver’s (1998) conceptual resilience framework, developed a nuanced understanding of resilience in IBD populations, by extending existing research exploring social support, coping-efficacy and illness-acceptance. Grit was interpreted as a feature of resilience from the qualitative data. The study then conducted the first statistical examination of grit, IOU, control-beliefs, and resilience in an IBD population, with consideration of disease activity.
Factors that associate with resilience in people with IBD

Resilience was not differentiated according to gender, age, or disease subtype. The regression lends support to existing studies finding that social-support, coping-efficacy and illness-acceptance associate with resilience in IBD populations (Sirois & Hirsch, 2017). Sirois and Hirsch (2017) found that coping-efficacy distinguished thriving from resilience cross-sectionally. In the current study coping-efficacy was less predictive of resilience than other factors, however the measure’s validity was affected and thus comparison with other studies is compromised.

These findings are in line with the supposition that an individual’s perceived capability to perform an action (coping-efficacy) influences emotional well-being, linked to agency to exert control over events (Bandura, 1977, 1997). The modified social learning theory (Wallston, 1992) argues that coping behaviour is contingent on one’s perceptions of control over health outcomes. These findings indicate resilience is one such outcome. Confirming the association between control-beliefs and positive outcomes in other CI populations (Lenze et al., 2008; Panagiotou et al., 2014), control-beliefs predicted resilience in those with IBD.

Uncertainty is linked to how in control one feels (McCormick, 2002). IOU was negatively correlated with resilience; an anticipated finding because it is predictive of psychopathology in CI and emotional disorder populations (Gentes & Ruscio, 2011; Kurita et al., 2013; Mcevoy & Maloney, 2012). Combined, IOU and control-beliefs contributed 10.7% of the variance in resilience over and above other factors. In this study, IOU also held negative correlations with control-beliefs, coping-efficacy and illness-acceptance. Hence these positive appraisals (which predict resilience) may
Factors that associate with resilience in people with IBD

indirectly influence the association between IOU and resilience. However, future research could investigate how these cognitions mediate the IOU/resilience association.

Grit, the perseverance towards long-term goals (Duckworth et al., 2007) was found not to significantly correlate with resilience. This was unanticipated given previous findings on grit’s positive correlation with HRQOL, psychological wellbeing and life satisfaction (Duckworth et al., 2007; Sharkey et al., 2017; Singh & Jha, 2008; Vainio & Daukantaite, 2016). It might be that what participants voiced in this study was a daily form of endurance, persisting diligently when presented with difficulty (Hamby et al., 2013), supported by Carver (2010) who argued the struggle to prevail is a likely associate of resilience. This study suggests that in those with IBD, if one is unable to envisage long-term goals due to limitations imposed by unpredictable disease activity, the character trait of persistence; the tendency to continue striving on a daily basis, may be more apt and has been found to correlate with resilience in a non-clinical sample (Kim et al., 2013). Research examining endurance and resilience in relation to IBD is warranted. Furthermore, those with IBD worry about their education or occupation being affected (Luo et al., 2019). Hence the negative correlation between grit and resilience generated in this study suggests that grit triggers the threat system (LeDoux, 1998) within a sociocultural context whereby value is placed on productivity and occupational success. Acceptance of illness-related limitations may therefore be more pertinent.

Like previous findings with IBD populations, illness-acceptance predicted resilience (Kiebles et al., 2010; Sirois & Hirsch, 2017); perhaps because it positivises IBD’s meaning, aiding tolerance of its unpredictable, uncontrollable nature (Evers et al., 2001). Those with greater acceptance also possessed greater coping-efficacy, so it may
Factors that associate with resilience in people with IBD

be that the implementation of effective coping strategies enables acceptance and resilience (Carver, 1998). It is possible that a reciprocal and mutually reinforcing relationship exist between these variables and resilience, however future longitudinal research would be needed to elucidate causal pathways. Finally, the positive correlation between social support and illness-acceptance mirrors previous findings (Janowski et al., 2012). The qualitative analysis indicated complexities within the relationship between social support and resilience, thus while it was found to predict resilience, the FSSQ (Broadhead et al, 1988) did not capture these complexities, limiting the findings.

Resilience and disease variables

Disease-activity negatively predicted resilience explaining 15.7% of the variance in the model (prior to controlling for the other variables). This was unsurprising because higher disease-activity associates with distress (Graff et al., 2006) depression and anxiety (Tribbick et al., 2017) and lower QOL (Vander-Have, 2014). (Dorrian et al., 2009; Knowles et al., 2011; Knowles et al., 2013; Zhang et al., 2016). These findings suggested that once social support, acceptance, and coping-efficacy were controlled for, combined, they reduced the negative effect on resilience of disease activity, turning it into a small positive effect. This indicates interrelationships between the variables and disease activity and that their effects are not in isolation.

Prior research has elucidated that disease-activity can directly impact perceptions of one’s illness influencing a negative mindset and that they mediate the association between disease-activity and negative outcomes (Tribbick et al., 2017). The negative appraisals in these existing studies pertain to chronicity and lack of controllability. The findings in this study indicate a complex relationship between disease activity, the variables under examination in this study and resilience. Thus,
Factors that associate with resilience in people with IBD

Further research could extend these findings by conducting moderator or mediator analyses to diversify the types of illness perceptions under examination and further elucidate the role of disease activity and these variables in relation to resilience.

Acceptance was positively and significantly correlated with TSD. This suggests acceptance may evolve with experience, perhaps because a process of desensitisation to aversive IBD experiences occurs over time (Carver, 2010). Resilience is a dynamic process (Skrastins & Fletcher, 2016; Werner, 1994) and longitudinal research that collects data from the point of diagnosis over the disease course would further understanding of the temporal relations between variables and resilience.

**Study limitations**

The study limitations should be acknowledged when interpreting the findings. Phase A yielded a small sample size (Braun & Clarke, 2013; Fugard & Potts, 2014). However, the data were deemed adequate to meet the study aims. Selection bias may have influenced who volunteered (Khazaal et al., 2014) towards those perceiving themselves as resilient. The sample was a homogenous population of white, British, educated females in remission. Thus, findings are less transferable to others, particularly those experiencing active disease. Reflective diary keeping would have aided reflection on the researcher’s contributions to the interpretation of data (Ortlipp, 2008).

Due to the cross-sectional design, causal inferences could not be determined (Sedgwick, 2014). Furthermore, the design did not enable exploration of the influence of confounding factors including personality traits or emotional disorders which may impact on resilience (Kim et al., 2013). Additionally, self-report measures bear the risk of recall bias and shared method variance; meaning the results could have been artificially inflated (Podsakoff et al., 2003). The measures used were psychometrically
Factors that associate with resilience in people with IBD

sound, however the Likert scales for the CES and CBI were entered erroneously, thus findings for those measures should be interpreted with caution. Finally, the study relied upon self-reported diagnoses and disease-activity. While recruitment from clinical settings may have improved the accuracy of this data, arguably, capturing perceived disease severity holds more value and self-reports are comparable to medical reports (Randell et al., 2014).

The complexities of defining resilience are widely recognised (Windle, 2010). Within this study, resilience was measured as resilience-related traits (Connor & Davidson, 2010) and as a dependent variable which is fluid in nature but was captured cross-sectionally. While this research was exploratory and aimed to develop a better conceptual understanding of resilience in those with IBD, these conceptual, measurement and design issues, mean that caution should be applied when interpreting the findings and when comparing these findings with other studies.

The current sample were only partially representative of the general population. Those known to have the highest diagnostic incidence fall within the age-bracket of 20-29 years (Johnston & Logan, 2008) and in this study the mean diagnostic age was 26.53 years. However, approximately three quarters were female and epidemiological studies suggest there is a 1:3 incidence ratio of males to females (Bernstein et al., 2006; Brant & Nguyen, 2008, GDB collaborators 2019).

Nevertheless, the post-hoc analysis indicated that the sample size was adequate to avoid type I or II errors. The bivariate correlations between variables and resilience were at the .01 alpha level which reduces the risk of type 1 errors. Finally, this exploratory research adds to a burgeoning body of literature on resilience in IBD populations.
Factors that associate with resilience in people with IBD

Implications for clinical practice

These findings indicate that across the illness trajectory fostering one’s ILOC, coping-efficacy and illness-acceptance may improve resilience. In line with current guidance (NICE, 2010), CBT enables practitioners to foster these psychological resources and challenge negative appraisals. However, acceptance is more specifically addressed through the application of third-wave therapies, such as Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), Compassion Focused Therapy (Gilbert, 2009) or Acceptance and Commitment Therapy (ACT, Hayes, 2004), which aim to enable one’s ability to embrace the present moment and difficult emotions (Khoury et al., 2013). A review of ACT revealed promising findings for those with long-term conditions (Graham et al., 2016). Additionally, targeting IOU as a transdiagnostic factor in line with CBT for Generalised Anxiety Disorder (NICE, 2011) might foster resilience. Future research could examine the effectiveness of third-wave therapies for those with IBD.

Fostering the aforementioned factors may be particularly important when disease-activity is high. Higher disease activity also leads to a lower perception of social support; thus, practitioners should encourage engagement with health-care services at these times. It may be that professional support is creatively adapted such as utilising phone or video contacts so that it is accessible to individuals where disease activity imposes physical restrictions.
Factors that associate with resilience in people with IBD

Conclusions

The current study found that illness cognitions pertaining to coping resources and beliefs about controllability predict resilience over and above the negative predictive influence of disease activity. Rather than perseverance to long-term goals, daily persistence or endurance might be more important to resilience in an IBD population. Future research should examine endurance, causal pathways between illness cognitions and resilience, and the mediating influences of these illness cognitions between disease activity and resilience. Finally, research could examine the application and effectiveness of third-wave therapies in those with IBD.
Factors that associate with resilience in people with IBD

References


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


https://doi.org/10.1080/00223890802634290.


https://doi.org/10.1023/A:1021890322153.


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Kabat-Zinn, J. (1990). *Full Catastrophe Living: the program of the Stress Reduction Clinic at the University of Massachusetts Medical Centre*. Dell.
Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


https://doi:10.1007/s11892-012-0317-0.


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD


Factors that associate with resilience in people with IBD

Factors that associate with resilience in people with IBD

Appendix A

Participant survey comments

*Participants were asked to consider practical aspects of the preliminary online survey (e.g. length of survey and ease of completion) and to identify if any potential emotional issues might arise.

It took them approximately 15 minutes to complete the survey

The feedback was largely positive about the length and utility of the survey; however, they gave their views on the order of the measures within the survey.

The length felt “okay” but advised to consider order of scales so that it alternates short and long scales to keep effort up and willingness to complete until the end;

Some items felt repetitive.

The layout is important, to have the Likert scale visible where each item is;

Comments regarding the wording of the resilience scale (this was because the preliminary scale contained the version of the CD-RISC that was online prior to purchasing). Once purchased the full accurate wording of the scale was amended.
Factors that associate with resilience in people with IBD

Appendix B

Ethics approval and research governance sponsor letter

Downloaded: 25/04/2019
Approved: 08/04/2019

Katie Boden
Registration number: 170149396
Psychology
Programme: Doctorate Clinical Psychology

Dear Katie

PROJECT TITLE: An exploration of the factors that associate with resilience in individuals with IBD: A mixed methods study
APPLICATION: Reference Number 023134

On behalf of the University ethics reviewers who reviewed your project, I am pleased to inform you that on 08/04/2019 the above-named project was approved on ethics grounds, on the basis that you will adhere to the following documentation that you submitted for ethics review:

- University research ethics application form 023134 (dated 05/04/2019).
- Participant information sheet 1055099 version 2 (26/03/2019).
- Participant information sheet 1055100 version 2 (26/03/2019).
- Participant consent form 1055101 version 2 (26/03/2019).

The following optional amendments were suggested:

* Amend the Head of Psychology Department to Glenn Waller and be consistent about the DClin Psy. In addition, Crohn's Disease is sometimes written without the apostrophe in the information and consent form—please amend.

If during the course of the project you need to deviate significantly from the above-approved documentation please inform me since written approval will be required.

Yours sincerely

Jilly Gibson-Miller
Ethics Administrator
Psychology
Factors that associate with resilience in people with IBD

Department Of Psychology.
Clinical Psychology Unit.
Department of Clinical Psychology (DClIn Psy) Programme
Clinical supervision training and NHS research training & consultancy.

Dr. A R Thompson, Clinical Training Research Director
Please address any correspondence to Amrit Sinha
Research Support Officer
Telephone: 0114 2226650
Email: a.sinha@sheffield.ac.uk

24th September 2018

To: Research Governance Office

Dear Sir/Madam,

RE: Confirmation of Scientific Approval and indemnity of enclosed Research Project

Project title: An exploration of the factors that associate with resilience in individuals with IBD. A mixed methods study

Investigators: Katie Boden (DClIn Psy Trainee, University of Sheffield); Georgina Rawes; Fuschia Sirio; Rebecca Yeates. Academic Supervisors (University of Sheffield)

I write to confirm that the enclosed proposal forms part of the educational requirements for the Doctorate Clinical Psychology Qualification (DClIn Psy) run by the Clinical Psychology Unit, University of Sheffield.

Three independent scientific reviewers usually drawn from academic staff within the Psychology Department have reviewed the proposal. Review includes appraisal of the proposed statistical analysis conducted by a statistical expert based in the School of Health and Related Research (ScHARR). Where appropriate an expert in qualitative methods is also appointed to review proposals.

I can confirm that approval of a proposal is dependent upon all necessary amendments having been made to the satisfaction of the reviewers and I can confirm that in this case the reviewers are content that the above study is of sound scientific quality. Consequently, the University will if necessary indemnify the study and act as sponsor.

Given the above, I would remind you that the Department already has an agreement with your office to exempt this proposal from further scientific review. However, if you require any further information, please do not hesitate to contact me.

Yours sincerely

[Signature]

Dr. Andrew Thompson
Director of Research Training

Ccs: Katie Boden; Georgina Rawes; Fuschia Sirio; Rebecca Yeates
Factors that associate with resilience in people with IBD

Appendix C

Information sheets (focus group and interviews)

Information sheet

An exploration of factors associated with resilience in those with IBD: A focus group

Department of Psychology.
Clinical Psychology Unit
Doctor of Clinical Psychology (DClin Psy) programme

Telephone: 0114 222 6574
Email: kboden@sheffield.ac.uk

You are invited....

To participate in a research study conducted at the University of Sheffield. Before you decide to take part it is important that you understand the research that is being done and what it will involve, so that you can give informed consent. Please take the time to read the following information carefully and discuss it with others if you wish. You are welcome to ask any questions to Katie Boden (lead researcher) if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

*If you are interested in participating, please ensure you could be available on Friday 31st May or Friday 7th June 2019. The focus group will last approximately 1 hour to 1 and a half hours and a specific time will be agreed when enough participants have expressed an interest.

The project and aims

The overall aim of the research is to explore the factors that influence resilience in individuals with IBD. The first element (which you are being invited to participate in) is a group interview to discuss what factors are felt to be important in influencing resilience from those with lived experience of IBD. This will contribute to the development of the research question and second part of the study.

Why have I been invited to participate in the study?

You have been invited to participate because you have been given a medical diagnosis of IBD (either Crohn’s Disease or Ulcerative Colitis). Approximately seven other people will also be recruited to take part in the group interview for this study.
Factors that associate with resilience in people with IBD

Do I have to take part?

It is up to you to decide whether or not you would like to take part and you are under no obligation to participate. If you decide to take part you will be given this information sheet to read and keep and you can withdraw from the study at any time during the focus group and up until 4 weeks after. You do not need to give a reason.

What will happen once I agree to participate in the study?

You will be asked to attend a group interview at a time that is convenient. You will be asked questions about what you think the important factors are that influence resilience in living with IBD. This will take approximately 60 minutes and it is your choice whether you feel comfortable answering any of the questions. The group interview will be audio-recorded and the files transferred to a password protected computer that is secure and regularly backed up. Data will be destroyed on successful publication of the research.

Will my taking part in this project be kept confidential?

All the information that we collect about you during the course of the research will be kept strictly confidential and will only be accessible to members of the research team. An alternative name (a pseudonym) will be assigned to you on completion of the group interview (you can choose this yourself if you wish) and so you will not be identifiable in any reports or publications.

What are the benefits of taking part?

Whilst there are no immediate benefits to participating in the project, it is hoped that this work will add to our knowledge base around the factors that influence resilience so that it can inform the help individuals receive around managing their condition. It is also hoped that it will stimulate further research in this area.

What are the possible disadvantages and risks of taking part?

Some of the questions will likely prompt thought around how you have managed your condition, which may make you feel uncomfortable in some way. If you feel distressed at any stage, you can leave the interview or withdraw from the project completely.

What if something goes wrong or if I become distressed as a result of taking part in the study?

If after participating, you decide that you would like to withdraw your data from the study please email kboden@sheffield.ac.uk, quoting the pseudonym allocated to you at the end of the study. You do not need to provide a reason for withdrawing from the study.

If you feel distressed after participating, you can contact your GP or a non-statutory organisation such as Crohn’s and Colitis UK.

If, after participating in the study, you wish to raise a complaint, you can do this by contacting Dr Glenn Waller (Head of Psychology Department) on 0114 222 6571 or by email on g.waller@sheffield.ac.uk.

What type of information will be sought from me and why is the collection of this information relevant for achieving the research project’s objectives?

Information about your age, gender, ethnicity and your diagnosis or IBD will be collated because this will help the researcher see whether these factors impact on levels of resilience.
Factors that associate with resilience in people with IBD

What will happen to the results of the research project?
The study results will be written up and submitted as a doctoral thesis. You will not be identifiable in any report or publication of these results. The results of this study may be published in a peer-reviewed scientific journal in the future.

Will I receive any reimbursement of expenses for taking part in this research?
You will receive reimbursement on any travel costs you have incurred so please keep any receipts for public transport travel. You will also be given a £10 gift voucher as a gesture of thanks for your participation.

Who is organising and funding the research?
The University of Sheffield is organising and funding this research

Who has ethically reviewed the project?
The ethics of this research has been reviewed and approved by The University of Sheffield’s Research Ethics Committee.

Who is the data controller?
The University of Sheffield will act as the Data Controller for this study. This means that the University is responsible for looking after your information and using it properly.

What is the legal basis for processing my personal data?
According to data protection legislation, we are required to inform you that the legal basis we are applying in order to process your personal data is that ‘processing is necessary for the performance of a task carried out in the public interest’ (Article 6(1)(e)). Further information can be found in the University’s Privacy Notice

https://www.sheffield.ac.uk/govern/data-protection/privacy/general

Contact for further information
If you would like any further information you can contact Katie Boden (lead researcher) by email kboden1@Sheffield.ac.uk

Thank-you for taking part in the project.
Information sheet

An exploration of factors associated with resilience in those with IBD: An interview

Department of Psychology,
Clinical Psychology Unit
Doctor of Clinical Psychology (DClin Psy) programme

Telephone: 0114 222 6574
Email: kboden1@sheffield.ac.uk

You are invited….

To participate in a research study conducted at the University of Sheffield. Before you decide to take part it is important that you understand the research that is being done and what it will involve, so that you can give informed consent. Please take the time to read the following information carefully and discuss it with others if you wish. You are welcome to ask any questions to Katie Boden (lead researcher) if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

*The date and time of the interview will be negotiated between you and the researcher. This can take place face to face or via telephone or skype. It is intended to last approximately 1 hour.

The project and aims

The overall aim of the research is to explore the factors that influence resilience in individuals with IBD. The first element (which you are being invited to participate in) is an interview to discuss what factors are felt to be important in influencing resilience from those with lived experience of IBD. This will contribute to the development of the research question and second part of the study.

Why have I been invited to participate in the study?

You have been invited to participate because you have been given a medical diagnosis of IBD (either Crohn’s Disease or Ulcerative Colitis).

Do I have to take part?

It is up to you to decide whether or not you would like to take part and you are under no obligation to participate. If you decide to take part you will be given this information sheet to read and keep and you can withdraw from the study at any time during the interview and up until 4 weeks after. You do not need to give a reason.

What will happen once I agree to participate in the study?
Factors that associate with resilience in people with IBD

You will be asked to attend an interview at a time that is convenient. You will be asked questions about what you think the important factors are that influence resilience in living with IBD. This will take approximately 45 to 60 minutes and it is your choice whether you feel comfortable answering any of the questions. The interview will be audio-recorded and the files transferred to a password protected computer that is secure and regularly backed up. Data will be destroyed on successful publication of the research.

Will my taking part in this project be kept confidential?

All the information that we collect about you during the course of the research will be kept strictly confidential and will only be accessible to members of the research team. An alternative name (a pseudonym) will be assigned to you on completion of the interview (you can choose this yourself if you wish) and so you will not be identifiable in any reports or publications.

What are the benefits of taking part?

Whilst there are no immediate benefits to participating in the project, it is hoped that this work will add to our knowledge base around the factors that influence resilience so that it can inform the help individuals receive around managing their condition. It is also hoped that it will stimulate further research in this area.

What are the possible disadvantages and risks of taking part?

Some of the questions will likely prompt thought around how you have managed your condition, which may make you feel uncomfortable in some way. If you feel distressed at any stage, you can terminate the interview or withdraw from the project completely.

What if something goes wrong or if I become distressed as a result of taking part in the study?

If after participating, you decide that you would like to withdraw your data from the study please email kboden1@sheffield.ac.uk, quoting the pseudonym allocated to you at the end of the study.

You do not need to provide a reason for withdrawing from the study.

If you feel distressed after participating, you can contact your GP or a non-statutory organisation such as Crohn’s and Colitis UK.

If, after participating in the study, you wish to raise a complaint, you can do this by contacting Dr Glenn Waller (Head of Psychology Department) on 0114 222 6571 or by email on g.waller@sheffield.ac.uk.

What type of information will be sought from me and why is the collection of this information relevant for achieving the research project’s objectives?

Information about your age, gender, ethnicity and your diagnosis or IBD will be collated because this will help the researcher see whether these factors impact on levels of resilience

What will happen to the results of the research project?

The study results will be written up and submitted as a doctoral thesis. You will not be identifiable in any report or publication of these results. The results of this study may be published in a peer-reviewed scientific journal in the future.

Will I receive any reimbursement of expenses for taking part in this research?
Factors that associate with resilience in people with IBD

You will receive reimbursement on any travel costs you have incurred (if relevant) so please keep any receipts for public transport travel. You will also be given a £10 gift voucher as a gesture of thanks for your participation.

Who is organising and funding the research?
The University of Sheffield is organising and funding this research.

Who has ethically reviewed the project?
The ethics of this research has been reviewed and approved by The University of Sheffield’s Research Ethics Committee.

Who is the data controller?
The University of Sheffield will act as the Data Controller for this study. This means that the University is responsible for looking after your information and using it properly.

What is the legal basis for processing my personal data?
According to data protection legislation, we are required to inform you that the legal basis we are applying in order to process your personal data is that ‘processing is necessary for the performance of a task carried out in the public interest’ (Article 6(1)(e)). Further information can be found in the University’s Privacy Notice

https://www.sheffield.ac.uk/govern/data-protection/privacy/general

Contact for further information
If you would like any further information you can contact Katie Boden (lead researcher) by email kboden1@Sheffield.ac.uk

Thank-you for taking part in the project.
Appendix D

Consent form (focus group)

Exploring resilience factors in individuals with Inflammatory Bowel Disease

<table>
<thead>
<tr>
<th>Please tick the appropriate boxes</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Taking Part in the Project</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I have read and understood the project information sheet or the project has been fully explained to me. (If you will answer No to this question please do not proceed with this consent form until you are fully aware of what your participation in the project will mean.)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>I have been given the opportunity to ask questions about the project.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>I agree to take part in the project. I understand that taking part in the project will include participating in a focus-group/interview and that this will be audio-recorded. I understand that audio data will be destroyed once the research has been successfully published.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>I understand that my taking part is voluntary and that I can withdraw from the study up until 4 weeks after the focus group. I do not have to give any reasons for why I no longer want to take part and there will be no adverse consequences if I choose to withdraw. I understand that if I do not wish to answer any particular questions, I am free to decline. I am aware I can contact the researcher Katie Boden on <a href="mailto:kboden1@sheffield.ac.uk">kboden1@sheffield.ac.uk</a> to discuss this further if I wish.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td><strong>How my information will be used during and after the project</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I understand my personal details such as name, phone number, address and email address etc. will not be revealed to people outside the project.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>I understand and agree that my words may be quoted in publications, reports, web pages, and other research outputs. I understand that I will not be named in these outputs unless I specifically request this.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>I understand and agree that other authorised researchers will have access to this data only if they agree to preserve the confidentiality of the information as requested in this form.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>I understand and agree that other authorised researchers may use my data in publications, reports, web pages, and other research outputs, only if they agree to preserve the confidentiality of the information as requested in this form.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>I give permission for the focus-group data that I provide to be given to the Research Support Officer at the Clinical Psychology Unit University of Sheffield so it can be used for future research and learning.</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td><strong>So that the information you provide can be used legally by the researchers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I agree to assign the copyright I hold in any materials generated as part of this project to The University of Sheffield.</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Name of participant [printed]          Signature          Date
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD

Appendix E

Interview schedule used for focus group and individual interviews

<table>
<thead>
<tr>
<th>Core question</th>
<th>Prompts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ask everyone’s name (focus group), how long you have lived with IBD for and (if comfortable to answer) which subtype it is?</td>
<td>N/A</td>
</tr>
<tr>
<td>Do you feel this definition of resilience is relevant to your experience of your condition?</td>
<td>Definition given to participants “resilience as the ability to bounce back from adversity or challenges” Clarify many definitions of resilience but for the purpose of the research this one has been chosen. Clarify definition if required</td>
</tr>
<tr>
<td>Are there any disease-specific factors that you think have influenced your resilience?</td>
<td>Prompts: Does anything come to mind? e.g. Has the time since diagnosis influenced resilience? Has disease subtype (CD, UC) influenced resilience? Has the level of disease-activity influenced resilience?</td>
</tr>
<tr>
<td>Are there any psychological factors that you feel have affected your resilience levels?</td>
<td>Prompts: Explain psychological processes include what is in your mind and may include coping strategies. Does anything come to mind? Do thought processes influence or relate to your resilience? Do your beliefs influence or relate to your resilience? Do your feelings influence or relate to your resilience?</td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD

Do your views on your condition influence or relate to your resilience?

<table>
<thead>
<tr>
<th>Core question</th>
<th>Prompts</th>
</tr>
</thead>
<tbody>
<tr>
<td>What areas of your life do you feel your condition has impacted on?</td>
<td>Prompts: Does anything come to mind? Does it impact on your employment?</td>
</tr>
<tr>
<td>Do you feel as though your ability to be resilient has changed since you started experiencing IBD symptoms?</td>
<td>Does it impact on your intimate relationships? Does it impact on your social life?</td>
</tr>
<tr>
<td>What are your views on the important factors that enable you to manage your condition?</td>
<td>Prompt: How might coping with challenges have changed before or after your IBD diagnosis? How have your coping styles or resilience changed over course of the condition? Prompt: Are there obstacles to managing your condition? Do you think if those factors were taken away it would affect your ability to be resilient?</td>
</tr>
<tr>
<td>Have there been times during your condition that you have felt more resilient than others?</td>
<td>Prompt: Can you recall a time when your felt your resilience was low? Can you recall a time when you felt your resilience was high?</td>
</tr>
<tr>
<td>What are your main sources of support?</td>
<td>Prompt: Is this support the most important factor to being resilient or are other factors more important?</td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD

Appendix F

Braun and Clarke (2006) thematic analysis steps

1. **Familiarisation of data.**

   The main researcher undertook the role of interviewer, transcriber and data-analyst which facilitated immersion in the data and familiarisation. The transcript was checked against the recordings for accuracy. Time was taken to repeatedly read the transcripts and elements of the data that were deemed meaningful were highlighted.

2. **Generating initial codes**

   Line-by-line coding was conducted by electronic notetaking (see line by line coding example below). The researcher was mindful of the surrounding text so that context was not lost. Braun and Clarke (2006) recommend coding multiple times in order to uncover potential multiple meanings, thus the transcripts and codes were read repeatedly, and additional notes made that were based on semantic meaning. The research question and aims were kept in mind throughout. Attention was paid to word choices, repetitions, how experiences were described and use of metaphor. The data-analyst was mindful to give equal attention to each line. Further, all relevant extracts for each theme were collated and either utilised as illustrative quotes in the final report or as part of a separate document (see Appendix G). Some codes considered less relevant to the research question and aims were excluded (e.g. discussion about medication use).
Factors that associate with resilience in people with IBD

Line-by-line coding examples:

<table>
<thead>
<tr>
<th>Data extracts from transcripts</th>
<th>Coding (descriptive and semantic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sally: Other things that happen in life, if you can get through how bad having IBD is that actually you can cope with a lot more and I think it becomes a bit of a reference that you might say, I’m in real pain, oh but it’s not as bad as the pain I might feel, if I had a flare up</td>
<td>Comparing IBD challenges to other adverse events desensitisation</td>
</tr>
<tr>
<td>Harriet: yeh I agree with that totally and on my shorter term scale when you are having the flare ups, erm, kind of, I’ve got to a point now where I can’t stop this kind of letting me do everything that I still want to do, if I’m having a flare up its not going to stop me from going out there, doing my socialising, having loads of plans that I’ve already made, so it’s kind of learning how to kind of function around the IBD diagnosis and erm still, kind of, because when I was diagnosed I was only 15 and my friends wouldn’t have really understood, like what was going on, erm , so it was kind of like learning to just carry on and staying as I was at that age to like, maintain like, my social life</td>
<td>Sharing experience with peer, Making note of disease activity and effects of time on mindset Determination to function as well as desires Meeting goals, enduring despite symptoms, perseverance-grit Social goals important - grit Adaptation to maintain functioning Age, young friends not understanding-invisible struggle Act normal, brave face to stay connected to friends-stoicism</td>
</tr>
<tr>
<td>Researcher: that sounds quite lonely Harriet: yeh its hard, yeh, yeh I just didn’t really, well it’s not something I’d ever like come across, erm</td>
<td>Emotionally demanding to keep functioning despite IBD challenges and others not understanding New experience for her</td>
</tr>
<tr>
<td>Sally: cos you were very young, that’s a.. Harriet: yeh, teenage years, I say luckily, that’s probably the wrong word, but my brother had it or was diagnosed it’s a couple of year before so me and the family sort of understood it so it wasn’t as lonely as it could have been but more in terms of my friends being at school and my social life it was kind of trying to maintain where I was at in that part of my life whilst still having the diagnosis, er, yeh</td>
<td>Suggestion of age as an influencing factor Family/other with lived experience understanding helping combat aloneness, aiding resilience Brave face, endure symptoms to maintain social identity Concealing illness</td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD

<table>
<thead>
<tr>
<th>Disease activity as affecting resilience and mind frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>In agreement regarding disease activity</td>
</tr>
<tr>
<td>Adapting to functioning around disease activity</td>
</tr>
<tr>
<td>Intolerance of others, dismissiveness of others struggles</td>
</tr>
<tr>
<td>Questioning legitimacy of others difficulties</td>
</tr>
<tr>
<td>Comparison of IBD challenges to others, disruption to functioning</td>
</tr>
</tbody>
</table>

| Others not understanding the struggle |
| Struggle invisible |
| Others diminishing the extent of the challenges |
| Helping resilience as its invisible, a pretence to self and others, stoicism |
| Not showing emotions, “brave face” for others- stoicism |
| “brave face” transcending to her |
| Close social circle understanding but felt stigma |
| Fear of being labelled, identity as poorly person |
| Fear of being different, being treated different |
| Avoiding intimacy, dismissing others |

Researcher: Yeh, and it sounds like for you (looking at Sally) if I can deal with that then I can deal with other stuff that comes along, like it sounds like a really positive mind frame to have
Sally: yeh I think it’s really easy to have a positive mind frame when you’re in remission
Harriet: yes definitely (laughs)
Sally: and it’s hard when you have a relapse, I think that’s the, but I mean I would agree in terms of you adapt your life accordingly and [pause] but definitely and in some ways if I’m honest it’s made me less tolerant of other people at times probably brought out a less tolerant side of me because erm [pause] because the excuses that other people might come up with, and you think really? actually that doesn’t register on the, erm, on the list of things that might disrupt your life

Claire: erm yeh in a way I think that people still don’t understand it and people don’t appreciate quite how bad it is so it actually I think helps your resilience cos you feel like you can’t show it so you almost have to go the other way that you’ve gotta put the brave face on for other people but then it becomes normal for you because you’re acting it, it becomes normal, erm but because people don’t quite understand it, or it feels, I think like with my close friends, good friends they get it, but you do still feel a bit of stigma for it, like I don’t want to be labelled as the person who’s poorly cos of this, how people treat you for it or don’t treat you for it cos you don’t let them in that much, it’s just like when you’re tired and people are like why you tired you know like just family say you shouldn’t be tired you’re young, it’s things like that and they don’t really know what they’re saying and they obviously they
Factors that associate with resilience in people with IBD

<table>
<thead>
<tr>
<th>Know what I’ve got but they just haven’t thought about what they’re saying to you so when someone says something like that to you and you’re like [pause]</th>
<th>Others as dismissive and not understanding Dismissive comments, lack of “knowing” from others, insensitivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Researcher: yeh what’s it like hearing comments like that Claire: Well it’s not very nice but I don’t sort of respond to them cos I just think, especially with older family members it’s not gonna make any difference, they won’t get it</td>
<td>Unpleasant feeling being misunderstood Choosing not to clarify and explain condition, withholding due to expectation others won’t understand</td>
</tr>
</tbody>
</table>

3. **Searching for themes**

The codes were reviewed for comparisons, similarities, and contrasts. Similar codes enabled identification of broader themes and subthemes and diagrams/maps were constructed to organise the themes. The conceptual maps evolved (below are three examples of maps constructed in chronological order). The research team also read the transcripts and themes/constructs that were apparent within the data were discussed in research supervision.

Conceptual maps examples:
Factors that associate with resilience in people with IBD
4. **Reviewing themes**

Research supervision was used to review the thematic maps and alternative possibilities and perspectives on the data were discussed. Diagrams and supporting quotes
Factors that associate with resilience in people with IBD

facilitated decision-making and repeatedly reading transcripts ensured that themes reflected the dataset as a whole and represented all participants discourse.

5. Defining and naming themes

Braun and Clarke (2006) recommend describing the central organising features of themes in a succinct and coherent manner, accompanied by quotes to illustrate themes. Research supervision was utilised to discuss the various constructs (and their accompanying definitions) that may be present in the analysis and this aided clarity over themes.

6. Producing the report

The report aimed to provide a clear, concise narrative of the themes and interpretation of the data, giving relatively equal attention to each theme. Braun and Clarke’s (2006) checklist of criteria for undertaking a good quality TA was followed.

<table>
<thead>
<tr>
<th>Process</th>
<th>No.</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcription</td>
<td>1</td>
<td>The data have been transcribed to an appropriate level of detail, and the transcripts have been checked against the tapes for 'accuracy'.</td>
</tr>
<tr>
<td>Coding</td>
<td>2</td>
<td>Each data item has been given equal attention in the coding process.</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Themes have not been generated from a few vivid examples (an anecdotal approach), but instead the coding process has been thorough, inclusive and comprehensive.</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>All relevant extracts for each theme have been collated.</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Themes have been checked against each other and back to the original data set.</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Themes are internally coherent, consistent, and distinctive.</td>
</tr>
<tr>
<td>Analysis</td>
<td>7</td>
<td>Data have been analysed – interpreted, made sense of – rather than just paraphrased or described.</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Analysis and data match each other – the extracts illustrate the analytic claims.</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Analysis tells a convincing and well-organized story about the data and topic.</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>A good balance between analytic narrative and illustrative extracts is provided.</td>
</tr>
<tr>
<td>Overall</td>
<td>11</td>
<td>Enough time has been allocated to complete all phases of the analysis adequately, without rushing a phase or giving it a once-over-lightly.</td>
</tr>
<tr>
<td>Written report</td>
<td>12</td>
<td>The assumptions about, and specific approach to, thematic analysis are clearly explicated.</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>There is a good fit between what you claim you do, and what you show you have done – ie, described method and reported analysis are consistent.</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>The language and concepts used in the report are consistent with the epistemological position of the analysis.</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>The researcher is positioned as active in the research process; themes do not just 'emerge'.</td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD

Appendix G

Illustrative quotes for each theme (pseudonyms used)

**Superordinate theme: Grit**

**Subordinate theme: Reclaiming control through autonomous coping**

“If there’s a problem, I’m proactive and other people have sort of said that to me, like I admire so much how you’re dealing with it and then how I talk about it so there is a psychological satisfaction to be had from that knowing I’m not gonna let it beat me.” (Annie)

“You adapt your life accordingly.” (Sally)

“For me it’s about understanding myself, like I had to be very aware of what I was eating, what I was drinking, making sure that I understood my condition, I couldn’t expect other people to understand if I didn’t know what’s going on.” (Harriet)

“Quite a positive person and I’m very erm I don’t just let things just happen to me I will go and sort things out.” (Annie)

“I’d rather deal with it myself erm unless its, I’ve not felt like I really needed to go.” (Claire) (referring to consideration of professional help)

“I’ll try and eat food that’s a bit more carbs, potato based bread cos its thicker and it helps, its heavy and helps everything come out, stay away from veg or anything high fibre, I’ll stay away from things that I know are gonna bother it if it’s really inflamed in there.” (Claire)
Factors that associate with resilience in people with IBD

“And I think cos I feel like I handle it quite well I don’t want someone to panda to me, I don’t want to be pandered too.” (Claire)

“You feel like you literally have no control, you have no control when you want to go to the toilet, you have no control over whether your tummy’s going to hurt today and how that’ll feel you literally it feels like you lost control of anything.” (Sarah) (before feeling in control and developing self-efficacy)

“I think a lot of the time it’s our reaction to stuff we have the control over how we react to something, we don’t have the control over what’s happening to us, we just have to decide how we’re going to deal with that.” (Sarah) (self-efficacy of emotions)

“Kind of recognise what symptoms are telling you that a flare is coming and stuff so to me I think it’s always essential to have a plan,” (Sarah)

**Subordinate theme: Legitimacy under question, maintaining identity through self-preservation:**

“Like straight away was really helpful cos I couldn’t believe that someone actually believed me straight.” (Claire) (point of diagnosis)

“Like I’ll go on course and stuff in London and I just keep it to myself cos then you don’t have to explain it to anybody.” (Claire)

“People are like why you tired you know like just family say you shouldn’t be tired you’re young, it’s things like that and they don’t really know what they’re saying and they obviously they know what I’ve got but they just haven’t thought about what they’re saying.” (Claire)
Factors that associate with resilience in people with IBD

“I threw the book across the room and I thought I’m going to deal with it how I want to deal with it.” (Annie)

“The frustration from it being an invisible illness where erm you know that some people are questioning whether it’s as bad as you’re making out or erm then with us you’re paranoid if they might be but you’re not sure kind of thing.” (Annie)

“You either lie to them and tell them you’re alright or you can actually tell them how you are and you can literally see their eyes glaze over when you’re telling them that you’re still sick.” (Sarah)

“It’s sometimes just easier not to tell people in the first place but then they’re not watching you and asking these questions.” (Harriet)

“It’s like it’s not so much of a focus for myself in my own life, so it doesn’t have to be something you associate me with, you don’t have to look at me and ask me all these questions just like let that happen in the background.” (Harriet)

“To explain the whole, whole diagnosis and what’s wrong with me, people don’t actually wanna know that realistically.” (Harriet)

“Well my manager knows and people I think people I’m close with at work know but not everybody.” (Claire) (limited disclosure)

Subordinate theme: Endurance (an invisible struggle)

“Yeh helpful, just don’t even go there, I wonder at times if having IBD has made me more independent.” (Sally)

“Trying to still do all the things you need to do.” (Annie)
Factors that associate with resilience in people with IBD

“I’ve got to a point now where I can’t stop this kind of letting me do everything that I still want to do.” (Harriet)

“I’m going to carry on and do my thing and not let it stop me.” (Harriet)

“It was kind of like learning to just carry on and staying as I was at that age to like, maintain like, my social life.” (Harriet)

“Not letting it stop me into doing what I need to do, and for me that’s really important.” (Harriet)

“If I’m having a flare up it’s not going to stop me from going out there, doing my socialising, having loads of plans that I’ve already made.” (Harriet)

“I don’t mind now, the challenge, I kind of don’t mind challenges in my life, whatever the challenges are, I quite like fighting them (all laugh), I quite like seeing a challenge and acknowledging that challenge, how am I gonna beat that.” (Harriet)

“I just keep pushing through, and ensure it doesn’t stop me doing my uni work and doesn’t stop me doing or achieve what I want to achieve” (Harriet)

“Times when I could of shouldn’t have been there, you know times like that when I force myself to do things.” (Claire)

“Sit at home and you’re not at work and you feel really guilty for not being at work like the guilt always kicks in and I think cos you’ve been brought up with the whole you work for a living.” (Claire) (social pressure to endure)

“I think it’s just that but people just get on with things don’t they.’ (Claire)
Factors that associate with resilience in people with IBD

“I’m a bit ignorant to it, so I kind of think well I’ll put it to the back of my mind that I’ve got anything wrong with me because it’s just easier just to, get on with things.”
(Claire)

“If someone else was saying that to me then I’d feel awful for them but when I’m saying it, it’s just everyday life.” (Claire)

“When the symptoms are bad it’s hard to get yourself out of a mental state of I just don’t wanna do anything I don’t wanna see anybody it’s that kind.” (Claire) (endurance hard when symptoms more severe)

“I think just it’s doing the things you like to do that make a massive difference and even though sometimes going out is hard cos you’re scared to do it, it helps a hell of a lot cos you’re doing stuff that you enjoy.” (Claire)

“I have a reference point when I’m ill or when anything’s happened, and I’ll say well actually it’s not as bad as that.” (Sally) (desensitisation - allows endurance)

“I think your brothers got the right attitude, for me, I think he’s got the right attitude, to carry on regardless.” (Sally)

“Students that I’ve had with IBD, I have to say they are not necessarily the ones who have asked for exceptional circumstances……maybe that’s resilience.” (Sally)

“There was never a question that you wouldn’t get up and go to school or work or anything like that so that carries on that stays with you throughout your life.” (Sally)

“Trying to still do all the things you need to do.” (Annie)

“You either don’t do life or you deal with life on or own terms and take that control back and I think that’s when the resilience comes in.” (Sarah)
Factors that associate with resilience in people with IBD

**Superordinate theme: Social support**

**Subordinate theme: Supportive, understanding others**

“Even my friends who understand a lot about it now, but sometimes they’re too nice, like if I’m having a flare up like they wrap me up in cotton wool, which I find a bit patronising like I always when I’m ill I hate people treating me like I’m ill whereas my parents like I’ve mentioned before are very much tough love.” (Harriet)

“I think it’s just easier when people understand what you’re going through cos you don’t have to explain everything, it’s like an unsaid communication between the two of you, you don’t have to say it it’s difficult to put into words how IBD can make you feel sometimes.” (Harriet)

“Well works has been amasing I have to say my boss I told him straight away and erm he said have as much time off as is needed.” (Annie)

“Just having emotional support and having someone to talk to, knowing those nurses are at the end of the line.” (Annie)

“The sheer number of women who came to me and emailed me or sent me a card saying its amasing how you’re dealing with this.” (Annie)

“Yeh sort of friends and family my mum always asks me how I am and she’ll’ send little cards and presents through the post and obviously my husband has been great but I’d have to say work really cos they’ve just been utterly supportive.” (Annie)

“They were just as flexible as I needed them to be.” (Annie) (about employers)
Factors that associate with resilience in people with IBD

“I feel like I need to support people as well because it gives my entire journey of crapness a purpose if I use it positive ways and me being able to offer people advice or support makes me feel better.” (Sarah)

“I mean it was nice to be able to talk to people who understood anyway so that was helpful.” (Sarah)

“My MD actually had Crohn’s disease which helped monumentally.” (Sarah)

“He’s [husband] probably the only person he actually kind of gets it and he’s very patient with it, to be fair my mum and dad are aswell, my family my close family are and friends.” (Claire)

“Like if I’m on a night out and I don’t feel good and I’ll say to a friend I’m gonna have to go home now and they understand it and things like that I think it must just be the people that you are around.” (Claire)

“And I think cos I feel like I handle it quite well I don’t want someone to panda to me, I don’t want to be pandered too.” (Claire)

“Husband yes, yeh I would say, I mean of course he’s only ever known me with Crohn’s, erm so it’s just not an issue for him.” (Sally)

“I had a very understanding flatmate who I would still consider to be my closest friend and I think she put up with a lot.” (Sally)

Subordinate theme: Misunderstanding/dismissive others:

“When I was really poorly my social life as well and people didn’t understand it, so that had quite a big impact on going out and seeing friends and then friends didn’t necessarily understand it so they’d get frustrated at you.” (Claire)
Factors that associate with resilience in people with IBD

“You can explain it as much as you, whereas it’s not always good enough for some people, because they don’t know what it’s like to be in your shoes.” (Claire)

“It’s just like when you’re tired and people are like why you tired you know like just family say you shouldn’t be tired you’re young, it’s things like that and they don’t really know what they’re saying and they obviously they know what I’ve got but they just haven’t thought about what they’re saying to you.” (Claire)

“I was only 15 so a lot of my friends wouldn’t have really understood.” (Harriet)

“If I did have a flare up initially if I was at uni I’d feel a little like alone, so it kind of made me feel a bit more negative about the whole thing.” (Harriet)

“Part of that independence, because like you’re very aware of what you need to do and how you can manage it, the people who don’t understand it are the barriers.” (Harriet)

“Especially as when you’re younger you can get labels like a flake.” (Harriet)

“It’s sometimes just easier not to tell people in the first place but then they’re not watching you and asking these questions.” (Harriet)

“I think that was out of anger and frustration more than anything else because nobody was listening or nobody really understood what I was going through and that really pissed me off.” (about developing an online support forum) (Sarah)

“A lot of people find it difficult to understand anyway, it was a taboo subject.” (Sarah)

“Like it doesn’t make sense to them and people stop inviting you out to things because you don’t turn up very often because you’re not very well and its very painful and its exhausting to keep having to tell people that you’re still not well and you figure out who actually cares.” (Sarah)
Factors that associate with resilience in people with IBD

“They don’t understand and a lot of the time it upsets people when you’re not very well, like my mum if I actually tell her when I’m ill, how I feel and in what way she gets upset about that and I don’t think it’s worth upsetting her.” (Sarah)

“I don’t have friends that are very dramatic and have a lot of issues that aren’t real issues because that stresses me out as well.” (Sarah)

“We were sort of sat at the dinner table eating and I was just kind of I was just so upset about the whole thing and this daunting thing ahead of me and he just sort of said no no we’re not doing that don’t let your chin drop.” (Annie)

“Partly because I had a very tough boss that would not have been allowed almost.” (Sally)

“Those who have the condition, yes, those who don’t have the condition, not necessarily and there’s a sort of spectrum of how supportive they can be.” (Sally)

“Because the excuses that other people might come up with, and you think really? actually that doesn’t register on the, erm, on the list of things that might disrupt your life.” (Sally)

“I purposely avoided forums because they just, I think not to be mean but just some people wallow in being a victim of something.” (Annie)

Subordinate theme: Stoicism/brave face

“I don’t think I’ve ever taken time off for IBD.” (Sally)

“They try their very best but because I know they don’t really get where I’m coming from I tend to just brush it off and go with I’m fine.” (Sarah)
Factors that associate with resilience in people with IBD

“I don’t really tell a lot of people not a lot of people really know, only some of my close friends know some of them didn’t really get it so I don’t think there’s any need for people who aren’t that close to me to know, because it shouldn’t be impacting them.” (Claire)

“There’s chairs and you can sit down but you want people to stand up because it’s better for people to think when they’re stood up and sometimes I’ve got to sit down when I should be the one who’s kind of, practicing what you preach and then you’re sat down and you’re like urgh I shouldn’t be doing this.” (Claire)

“I suppose there’s that thing of sometimes when you are feeling pretty shit about it you don’t feel like there’s that many people to talk to about it and the ones you do speak to you feel like they’ve heard it all before and you don’t want to bog them down so you feel like you don’t want to sound like you’re being pathetic.” (Claire)

“I can get into work every day and I manage to do these things so it’s kind of I shouldn’t really complain with how I am cos of what other people.” (Claire)

“Probably times when I could of shouldn’t have been there, you know times like that when I force myself to do things.” (Claire)

“I think people know there’s something, but they don’t know what it is.” (Claire)

“You don’t have to look at me and ask me all these questions just like let that happen in the background, I do, just don’t worry about it.” (Harriet)

“You just have to like push through it like still when I’m going through that I’m not gonna let anyone else in my life that doesn’t need to know that I’m going through that.” (Harriet)

“Hate letting people down, but I wouldn’t want to take time off work because I’m yeh it’s not I don’t know I’d feel guilt as well.” (Harriet)
Factors that associate with resilience in people with IBD

“It’s sometimes just easier not to tell people in the first place but then they’re not watching you and asking these questions.” (Harriet)
Factors that associate with resilience in people with IBD

Appendix H

All online advertisements

Crohn’s and Colitis UK advertisement:

**Project title:** Resilience in individuals with Inflammatory Bowel Disease.

**What the researchers will look at:**

The challenges of living with IBD can generate significant stress which can be difficult to cope with. As a result, many individuals experience periods of low mood, anxiety and low self-esteem. We are interested in identifying what helps individuals adapt to the challenges of living with IBD and reduce distress. Resilience is defined as the ability to “bounce back” from adversity and has been well researched in individuals with other physical health conditions. However, there is very little research and understanding about what factors enhance or hinder resilience in people living with IBD. Further knowledge could enable healthcare professionals to help those with IBD adapt and develop resilience in the face of IBD challenges. Factors that influence resilience could include the severity of the disease, the amount of social support one feels they have, how one copes with the condition or how in control one feels.

Researchers at the University of Sheffield are looking for people aged 18 or over who have a confirmed diagnosis of IBD (this might include Crohn’s Disease, Ulcerative...
Factors that associate with resilience in people with IBD

Colitis or Indeterminate IBD) to take part in a survey which aims to identify what factors help people feel resilient when living with IBD.

The first part of this study has already been conducted. This was an interview study and identified traits, coping skills and experiences people with IBD thought may influence their own resilience. These findings have informed the development of the second part of the study; this online survey. The survey aims to identify what factors have the most influence on resilience across a wider population of individuals with IBD. Approximately 135 people are needed to complete this online survey so that the relationships between the identified factors and resilience can be statistically analysed.

What do the researchers think this could mean for people with IBD?

This research aims to understand what factors are most likely to enhance resilience in individuals with IBD. An improved understanding and evidence base means that psychological interventions (such as talking therapies) offered to individuals with IBD who are struggling with their mental and emotional health can be tailored to strengthen resilience in this population.

If you are interested and would like more information about the study, please click on this link:

https://sheffieldpsychology.eu.qualtrics.com/jfe/form/SV_af1OR152RMOMwLj

Social media advertisement:

"Do you have IBD? Looking for adults over 18 with IBD to participate in my online research study on resilience in people with IBD. To take part, please follow this link: https://sheffieldpsychology.eu.qualtrics.com/jfe/form/SV_af1OR152RMOMwLj"
Factors that associate with resilience in people with IBD

University volunteer database:

Email title:
Do you have IBD? Take part in research on resilience.

Dear Colleague,
> I am researching resilience in people with IBD, as part of a study at the University of Sheffield.
> If you are over 18, have IBD and are interested please click on this link which will take you to an online survey:
> [https://sheffieldpsychology.eu.qualtrics.com/jfe/form/SV_af1OR152RMOMwLj](https://sheffieldpsychology.eu.qualtrics.com/jfe/form/SV_af1OR152RMOMwLj)
> The research has been approved by the Research Ethics Committee in the Department of Psychology at the University of Sheffield.
> Thank you very much,
> Katie Boden
> Trainee Clinical Psychologist
> Information related to this message is available at [https://sheffieldpsychology.eu.qualtrics.com/jfe/form/SV_af1OR152RMOMwLj](https://sheffieldpsychology.eu.qualtrics.com/jfe/form/SV_af1OR152RMOMwLj).
Factors that associate with resilience in people with IBD

Appendix I

Online survey information and consent

Q5
You are invited to participate in a research study conducted at the University of Sheffield. Before you decide to take part it is important that you understand the research that is being done and what it will involve, so that you can give informed consent. Please take the time to read the following information carefully and discuss it with others if you wish. You are welcome to ask any questions of Katie Boden (lead researcher) if there is anything that is not clear or if you would like more information. Please take time to decide whether or not you wish to take part.

The project
This is an exploratory study of the factors that influence resilience in individuals with IBD.

What is the purpose of the research?
This study aims to explore what factors associate with resilience in people managing IBD.

Why have I been invited to participate in the study?
You have been invited to participate because you have been given a medical diagnosis of IBD (either Crohn’s Disease or Ulcerative Colitis). Approximately 130 other people will also be recruited to take part in the online survey.

Do I have to take part?
It is up to you to decide whether or not you would like to take part and you are under no obligation to participate. If you decide to take part, you can withdraw from the study up until 4 weeks after completion of the online survey. You do not need to give a reason. You can also withdraw during completion of the survey by closing the browser.

Do I have to take part?
It is up to you to decide whether or not you would like to take part and you are under no obligation to participate. If you decide to take part, you can withdraw from the study up until 4 weeks after completion of the online survey. You do not need to give a reason. You can also withdraw during completion of the survey by closing the browser.

What will happen once I agree to participate in the study?
You will be asked to complete an online survey which will take approximately 15-20 minutes to complete. In the survey you will be asked questions about psychological factors such as dealing with uncertainty, how in control you feel, how accepting of your illness you are, and questions related to resilience. Following completion of the online survey you will be entered into a prize draw with a chance to receive £25 in Amazon gift vouchers.

What are the benefits of taking part?
Whilst there are no immediate benefits to participating in the project, it is hoped that this work will add to our knowledge base around the factors that influence resilience so that it can inform the help individuals receive around managing their condition. It is also hoped that it will stimulate further research in this area.

What are the possible disadvantages and risks of taking part?
Some of the questions in the survey will ask about how you manage uncertainty and feelings in control, which may make you feel uncomfortable in some way. If you feel distressed at any stage, you can pause the survey or withdraw from the project completely.

What if something goes wrong or if I become distressed as a result of taking part in the study?
If after participating, you decide that you would like to withdraw your data from the study please email kboden1@sheffield.ac.uk, quoting the unique survey number allocated to you at the end of the study. You do not need to provide a reason for withdrawing from the study.
Factors that associate with resilience in people with IBD

If you feel distressed after participating, you can contact your GP or a non-statutory organisation such as Crohn’s and Colitis UK.

If, after participating in the study, you wish to raise a complaint, you can do this by contacting Dr Glenn Waller (Head of Psychology Department) on 0114 222 6568 or by email on g.waller@sheffield.ac.uk.

Protecting your identity
All the information that we collect about you during the course of the research will be kept strictly confidential. You will not be identifiable in any reports or publications.

What type of information will be sought from me and why is the collection of this information relevant for achieving the research project’s objectives?
Information about your age, gender, ethnicity and your diagnosis or IBD will be collated because this will help the researcher to understand whether these factors impact on levels of resilience.

What will happen to the results of the research project?
The study results will be written up and submitted as a doctoral thesis. You will not be identifiable in any report or publication of these results. The results of this study may be published in a peer-reviewed scientific journal in the future.

Who is organising and funding the research?
The University of Sheffield is organising and funding this research.

Who has ethically reviewed the project?
This project has been ethically approved via Sheffield ethics committee.

Contact for further information
If you would like any further information you can contact Katie Boden (lead researcher) by email kboden1@Sheffield.ac.uk

Online consent:

Please Select the appropriate response.
Taking part in the project

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

I have read and understood the project information sheet dated $(date://CurrentDate/SL) (if you will answer No to this question please do not proceed with this consent form until you are fully aware of what your participation in the project will mean.)

I have been given the opportunity to ask questions about the project.

I agree to take part in the project. I understand that taking part in the project will include completing a questionnaire.

I understand that my taking part is voluntary and that I can withdraw from the study anytime up to the point that I submit my survey. I do not have to give any reasons for why I no longer want to take part and there will be no adverse consequences if I choose to withdraw.
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD

Appendix J
Copy of all measures

Demographics questions (including questions regarding TSD, relapse/remission status)

<table>
<thead>
<tr>
<th>Q12</th>
<th>What is your gender?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
</tr>
<tr>
<td></td>
<td>Female</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q8</th>
<th>What is your current age?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q10</th>
<th>In what country/continent do you currently live?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Europe</td>
</tr>
<tr>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td></td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>Australia</td>
</tr>
<tr>
<td></td>
<td>South America</td>
</tr>
<tr>
<td></td>
<td>Other (please list below)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q34</th>
<th>What is your diagnosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Crohn’s disease</td>
</tr>
<tr>
<td></td>
<td>Ulcerative colitis</td>
</tr>
<tr>
<td></td>
<td>Other, please list below</td>
</tr>
</tbody>
</table>

| Q38 | Please list other IBD below. |
Factors that associate with resilience in people with IBD

Connor-Davidson Resilience Scale (CD-RISC, Connor & Davidson, 2003).

Removed for copyright reasons
Appendix K

Normality tests

SPSS screenshots of tests of normality demonstrating Shapiro-Wilks tests. The Shapiro-Wilk test has more power to detect differences, therefore the significance level from this test was interpreted (Field, 2009). If the value of this was greater than 0.05 (p>0.05), the data were deemed to be normally distributed. Therefore, disease activity, FSSQ data (social support), SGS (grit), CES (coping-efficacy), TSD and acceptance were deemed to be not normally distributed. The dependent variable of resilience was normally distributed.

SPSS screenshot of Shapiro-Wilk tests:

<table>
<thead>
<tr>
<th>Tests of Normality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kolmogorov-Smirnov</td>
</tr>
<tr>
<td>Statistic</td>
</tr>
<tr>
<td>Total disease activity</td>
</tr>
<tr>
<td>Total FSS Qfinal</td>
</tr>
<tr>
<td>Total GRIT</td>
</tr>
<tr>
<td>Total CBI</td>
</tr>
<tr>
<td>Total coping eff</td>
</tr>
<tr>
<td>Total RISC</td>
</tr>
<tr>
<td>Total IU</td>
</tr>
<tr>
<td>TSD</td>
</tr>
<tr>
<td>ICOACC subscale</td>
</tr>
</tbody>
</table>

* This is a lower bound of the true significance.

*a Lilliefors Significance Correction
Factors that associate with resilience in people with IBD

SPSS output screenshots demonstrating kurtosis and skewness values, histograms and Q-Q plots for each variable:

<table>
<thead>
<tr>
<th>Total Disease Activity</th>
<th>Mean</th>
<th>95% Confidence Interval for Mean</th>
<th>Lower Bound</th>
<th>Upper Bound</th>
<th>5% Trimmed Mean</th>
<th>Median</th>
<th>Variance</th>
<th>Std. Deviation</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Range</th>
<th>Interquartile Range</th>
<th>Skewness</th>
<th>Kurtosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>201.3901</td>
<td>9.85562</td>
<td></td>
<td></td>
<td>200.8391</td>
<td>197.0000</td>
<td>8256.325</td>
<td>90.86432</td>
<td>38.00</td>
<td>400.00</td>
<td>362.00</td>
<td>157.50</td>
<td>-0.92</td>
<td>0.261</td>
</tr>
<tr>
<td>Total FSSQfinal</td>
<td>3.8733</td>
<td>.09495</td>
<td></td>
<td></td>
<td>3.9238</td>
<td>4.0000</td>
<td>0.766</td>
<td>0.87535</td>
<td>1.38</td>
<td>5.00</td>
<td>3.63</td>
<td>1.25</td>
<td>-0.746</td>
<td>0.261</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD

<table>
<thead>
<tr>
<th>TotalGRIT</th>
<th>Mean</th>
<th>2.2408</th>
<th>0.03964</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>95% Confidence Interval for Mean</td>
<td>Lower Bound</td>
<td>2.1619</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upper Bound</td>
<td>2.3196</td>
</tr>
<tr>
<td></td>
<td>5% Trimmed Mean</td>
<td></td>
<td>2.2516</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td></td>
<td>2.2500</td>
</tr>
<tr>
<td></td>
<td>Variance</td>
<td></td>
<td>0.134</td>
</tr>
<tr>
<td></td>
<td>Std. Deviation</td>
<td></td>
<td>0.36543</td>
</tr>
<tr>
<td></td>
<td>Minimum</td>
<td></td>
<td>1.25</td>
</tr>
<tr>
<td></td>
<td>Maximum</td>
<td></td>
<td>3.00</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td></td>
<td>1.75</td>
</tr>
<tr>
<td></td>
<td>Interquartile Range</td>
<td></td>
<td>0.50</td>
</tr>
<tr>
<td></td>
<td>Skewness</td>
<td>-0.530</td>
<td>0.261</td>
</tr>
<tr>
<td></td>
<td>Kurtosis</td>
<td>-0.161</td>
<td>0.517</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICQAC subscale</th>
<th>Mean</th>
<th>16.4118</th>
<th>0.45322</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>95% Confidence Interval for Mean</td>
<td>Lower Bound</td>
<td>15.5105</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upper Bound</td>
<td>17.3130</td>
</tr>
<tr>
<td></td>
<td>5% Trimmed Mean</td>
<td></td>
<td>16.4248</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td></td>
<td>16.0000</td>
</tr>
<tr>
<td></td>
<td>Variance</td>
<td></td>
<td>17.459</td>
</tr>
<tr>
<td></td>
<td>Std. Deviation</td>
<td></td>
<td>4.17844</td>
</tr>
<tr>
<td></td>
<td>Minimum</td>
<td></td>
<td>6.00</td>
</tr>
<tr>
<td></td>
<td>Maximum</td>
<td></td>
<td>24.00</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td></td>
<td>18.00</td>
</tr>
<tr>
<td></td>
<td>Interquartile Range</td>
<td></td>
<td>7.00</td>
</tr>
<tr>
<td></td>
<td>Skewness</td>
<td>0.019</td>
<td>0.261</td>
</tr>
<tr>
<td></td>
<td>Kurtosis</td>
<td>-0.765</td>
<td>0.517</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TotalICBI</th>
<th>Mean</th>
<th>116.6042</th>
<th>2.02984</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>95% Confidence Interval for Mean</td>
<td>Lower Bound</td>
<td>112.5576</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upper Bound</td>
<td>120.6408</td>
</tr>
<tr>
<td></td>
<td>5% Trimmed Mean</td>
<td></td>
<td>116.8772</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td></td>
<td>119.0000</td>
</tr>
<tr>
<td></td>
<td>Variance</td>
<td></td>
<td>360.223</td>
</tr>
<tr>
<td></td>
<td>Std. Deviation</td>
<td></td>
<td>18.71424</td>
</tr>
<tr>
<td></td>
<td>Minimum</td>
<td></td>
<td>65.00</td>
</tr>
<tr>
<td></td>
<td>Maximum</td>
<td></td>
<td>153.00</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td></td>
<td>88.00</td>
</tr>
<tr>
<td></td>
<td>Interquartile Range</td>
<td></td>
<td>27.91</td>
</tr>
<tr>
<td></td>
<td>Skewness</td>
<td>-0.351</td>
<td>0.261</td>
</tr>
<tr>
<td></td>
<td>Kurtosis</td>
<td>-0.408</td>
<td>0.517</td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD

<table>
<thead>
<tr>
<th>Totalcopeff</th>
<th>Mean</th>
<th>15.3213</th>
<th>.45894</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>95% Confidence Interval for Mean</td>
<td>Lower Bound</td>
<td>14.4086</td>
</tr>
<tr>
<td></td>
<td>5% Trimmed Mean</td>
<td>15.5727</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>15.0000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Variance</td>
<td>17.903</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Std. Deviation</td>
<td>4.23118</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Minimum</td>
<td>3.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum</td>
<td>21.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>18.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interquartile Range</td>
<td>5.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Skewness</td>
<td>-.667</td>
<td>.261</td>
</tr>
<tr>
<td></td>
<td>Kurtosis</td>
<td>.082</td>
<td>.517</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TotalRISC</th>
<th>Mean</th>
<th>66.0706</th>
<th>1.65969</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>95% Confidence Interval for Mean</td>
<td>Lower Bound</td>
<td>62.7701</td>
</tr>
<tr>
<td></td>
<td>5% Trimmed Mean</td>
<td>66.3693</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>67.0000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Variance</td>
<td>234.138</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Std. Deviation</td>
<td>15.30156</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Minimum</td>
<td>29.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum</td>
<td>96.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>67.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interquartile Range</td>
<td>25.50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Skewness</td>
<td>-.217</td>
<td>.261</td>
</tr>
<tr>
<td></td>
<td>Kurtosis</td>
<td>-.554</td>
<td>.517</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TotalIU</th>
<th>Mean</th>
<th>32.4706</th>
<th>1.00845</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>95% Confidence Interval for Mean</td>
<td>Lower Bound</td>
<td>30.4652</td>
</tr>
<tr>
<td></td>
<td>5% Trimmed Mean</td>
<td>32.0948</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>32.0000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Variance</td>
<td>86.443</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Std. Deviation</td>
<td>9.29745</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Minimum</td>
<td>15.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum</td>
<td>60.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>45.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interquartile Range</td>
<td>11.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Skewness</td>
<td>.559</td>
<td>.261</td>
</tr>
<tr>
<td></td>
<td>Kurtosis</td>
<td>.353</td>
<td>.517</td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD

<table>
<thead>
<tr>
<th>TSD</th>
<th>Mean</th>
<th>12.9647</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>95% Confidence Interval for Mean</td>
<td>10.5887</td>
</tr>
<tr>
<td></td>
<td>Lower Bound</td>
<td>15.3407</td>
</tr>
<tr>
<td></td>
<td>Upper Bound</td>
<td>12.1046</td>
</tr>
<tr>
<td></td>
<td>5% Trimmed Mean</td>
<td>9.0000</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>121.344</td>
</tr>
<tr>
<td></td>
<td>Variance</td>
<td>11.01562</td>
</tr>
<tr>
<td></td>
<td>Std. Deviation</td>
<td>.00</td>
</tr>
<tr>
<td></td>
<td>Minimum</td>
<td>45.00</td>
</tr>
<tr>
<td></td>
<td>Maximum</td>
<td>45.00</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>18.00</td>
</tr>
<tr>
<td></td>
<td>Interquartile Range</td>
<td>.959</td>
</tr>
<tr>
<td></td>
<td>Skewness</td>
<td>.253</td>
</tr>
<tr>
<td></td>
<td>Kurtosis</td>
<td>.517</td>
</tr>
</tbody>
</table>
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD

![Normal Q-Q Plot of TotalFSSQfinal](image1)

![Histogram](image2)

- Mean = 16.41
- Std. Dev. = 4.178
- N = 65
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD
Factors that associate with resilience in people with IBD